<?xml version="1.0" encoding="UTF-8"?><search-results xmlns="http://www.w3.org/2005/Atom" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:opensearch="http://a9.com/-/spec/opensearch/1.1/" xmlns:dc="http://purl.org/dc/elements/1.1/"><opensearch:totalResults>2992343</opensearch:totalResults><opensearch:startIndex>600</opensearch:startIndex><opensearch:itemsPerPage>100</opensearch:itemsPerPage><opensearch:Query role="request" searchTerms="heart" startPage="600"/><link ref="self" href="http://api.elsevier.com:80/content/search/index:scopus?start=600&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="first" href="http://api.elsevier.com:80/content/search/index:scopus?start=0&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="prev" href="http://api.elsevier.com:80/content/search/index:scopus?start=500&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="next" href="http://api.elsevier.com:80/content/search/index:scopus?start=700&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><link ref="last" href="http://api.elsevier.com:80/content/search/index:scopus?start=4900&amp;count=100&amp;query=heart&amp;view=COMPLETE&amp;httpAccept=application/xml&amp;apiKey=b50e60b193e884e6d78948e916d816a0" type="application/xml"/><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929471664"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929471664?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929471664&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929471664&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091743515001176"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929471664</prism:url><dc:identifier>SCOPUS_ID:84929471664</dc:identifier><eid>2-s2.0-84929471664</eid><dc:title>Association between exposure to household cigarette smoking behavior and cigarette smoking in Hispanic adults: Findings from the Hispanic Community Health Study/Study of Latinos</dc:title><dc:creator>Navas-Nacher E.</dc:creator><prism:publicationName>Preventive Medicine</prism:publicationName><prism:issn>00917435</prism:issn><prism:eIssn>10960260</prism:eIssn><prism:volume>77</prism:volume><prism:pageRange>35-40</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ypmed.2015.04.011</prism:doi><pii>S0091743515001176</pii><dc:description>Â© 2015 Elsevier Inc. Background: Cigarette smoking behavior is highly determined by social influences during childhood and adolescence. This phenomenon has not been fully evaluated in the Hispanic/Latino population. Purpose: To examine the association between exposure to household cigarette smoking behavior (HCSB) and adult cigarette smoking among a diverse Hispanic/Latino population living in four US urban centers. The effect of acculturation on cigarette smoking was also evaluated. Methods: Data from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) (n. = 13,231, ages 18-74. years, collected between March 2008 and June 2011) were analyzed using logistic regression. Results: HCSB exposure was an independent risk factor for adult current cigarette smoking in Hispanic/Latinos (OR 1.7; 95% CI 1.4, 2.1) after controlling for relevant confounders including socio-demographic and cultural factors. Cubans and Puerto Ricans had the highest prevalence of HCSB exposure (59% and 47% respectively) and highest prevalence of current cigarette smoking (26% and 32%) compared with other Hispanic/Latino groups, (p &lt; .01). Conclusions: Our data suggest that exposure to HCSB in Hispanics/Latinos living in the US is an independent predictor of adult cigarette smoking, and this association appears to be strongest in Cubans and Puerto Ricans.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027561</affiliation-url><afid>60027561</afid><affilname>University of Illinois at Chicago</affilname><name-variant>University of Illinois at Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027561</affiliation-url><afid>60027561</afid><affilname>University of Illinois at Chicago</affilname><name-variant>University of Illinois at Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029251</affiliation-url><afid>60029251</afid><affilname>University of Miami</affilname><name-variant>University of Miami</name-variant><affiliation-city>Coral Gables</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018926</affiliation-url><afid>60018926</afid><affilname>San Diego State University</affilname><name-variant>San Diego State University</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007363</affiliation-url><afid>60007363</afid><affilname>Northwestern University</affilname><name-variant>Northwestern University</name-variant><affiliation-city>Evanston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002388</affiliation-url><afid>60002388</afid><affilname>Albert Einstein College of Medicine of Yeshiva University</affilname><name-variant>Albert Einstein College of Medicine</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029251</affiliation-url><afid>60029251</afid><affilname>University of Miami</affilname><name-variant>University of Miami</name-variant><affiliation-city>Coral Gables</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032211</affiliation-url><afid>60032211</afid><affilname>University of Texas System</affilname><name-variant>University of Texas</name-variant><affiliation-city>Austin</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025111</affiliation-url><afid>60025111</afid><affilname>The University of North Carolina at Chapel Hill</affilname><name-variant>University of North Carolina at Chapel Hill</name-variant><affiliation-city>Chapel Hill</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027565</affiliation-url><afid>60027565</afid><affilname>Columbia University Medical Center</affilname><name-variant>Columbia University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507482777</author-url><authid>6507482777</authid><authname>Navas-Nacher E.</authname><surname>Navas-Nacher</surname><given-name>E. L.</given-name><initials>E.L.</initials><afid>60027561</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56506346700</author-url><authid>56506346700</authid><authname>Kelley M.</authname><surname>Kelley</surname><given-name>M. A.</given-name><initials>M.A.</initials><afid>60027561</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55965915500</author-url><authid>55965915500</authid><authname>Birnbaum-Weitzman O.</authname><surname>Birnbaum-Weitzman</surname><given-name>O.</given-name><initials>O.</initials><afid>60029251</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25721911500</author-url><authid>25721911500</authid><authname>Gonzalez P.</authname><surname>Gonzalez</surname><given-name>P.</given-name><initials>P.</initials><afid>60018926</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56648134100</author-url><authid>56648134100</authid><authname>Ghiachello A.</authname><surname>Ghiachello</surname><given-name>A. L.</given-name><initials>A.L.</initials><afid>60007363</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7403163090</author-url><authid>7403163090</authid><authname>Kaplan R.</authname><surname>Kaplan</surname><given-name>R. C.</given-name><initials>R.C.</initials><afid>60002388</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56590722000</author-url><authid>56590722000</authid><authname>Lee D.</authname><surname>Lee</surname><given-name>D. J.</given-name><initials>D.J.</initials><afid>60029251</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56651188200</author-url><authid>56651188200</authid><authname>Bandiera F.</authname><surname>Bandiera</surname><given-name>F. C.</given-name><initials>F.C.</initials><afid>60032211</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56553250900</author-url><authid>56553250900</authid><authname>Bangdiwala S.</authname><surname>Bangdiwala</surname><given-name>S. I.</given-name><initials>S.I.</initials><afid>60025111</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56647540400</author-url><authid>56647540400</authid><authname>Barr R.</authname><surname>Barr</surname><given-name>R. G.</given-name><initials>R.G.</initials><afid>60027565</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56637065300</author-url><authid>56637065300</authid><authname>Daviglus M.</authname><surname>Daviglus</surname><given-name>M. L.</given-name><initials>M.L.</initials><afid>60027561</afid></author><authkeywords>Cigarette smoking | Ethnocultural groups | Hispanics | Household | Latinos | Social influences | Tobacco use</authkeywords><intid>1785964470</intid><source-id>17665</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929358991"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929358991?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929358991&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929358991&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315006622"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929358991</prism:url><dc:identifier>SCOPUS_ID:84929358991</dc:identifier><eid>2-s2.0-84929358991</eid><dc:title>Cytokine storm after cessation of tocilizumab in a patient with refractory Takayasu arteritis</dc:title><dc:creator>Arita Y.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>187</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>319-321</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>1 August 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.03.399</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013829</affiliation-url><afid>60013829</afid><affilname>Osaka University Faculty of Medicine</affilname><name-variant>Osaka University Medical School</name-variant><affiliation-city>Suita</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013829</affiliation-url><afid>60013829</afid><affilname>Osaka University Faculty of Medicine</affilname><name-variant>Osaka University Medical School</name-variant><affiliation-city>Suita</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024322</affiliation-url><afid>60024322</afid><affilname>Osaka University</affilname><name-variant>Osaka University</name-variant><affiliation-city>Suita</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002354</affiliation-url><afid>60002354</afid><affilname>University of Tokyo Faculty of Medicine</affilname><name-variant>University of Tokyo</name-variant><affiliation-city>Tokyo</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015682</affiliation-url><afid>60015682</afid><affilname>Japan Science and Technology Agency</affilname><name-variant>CREST</name-variant><affiliation-city>Kawaguchi</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26029723100</author-url><authid>26029723100</authid><authname>Arita Y.</authname><surname>Arita</surname><given-name>Yoh</given-name><initials>Y.</initials><afid>60013829</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7007175990</author-url><authid>7007175990</authid><authname>Nakaoka Y.</authname><surname>Nakaoka</surname><given-name>Yoshikazu</given-name><initials>Y.</initials><afid>60013829</afid><afid>60015682</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7007175990</author-url><authid>7007175990</authid><authname>Nakaoka Y.</authname><surname>Nakaoka</surname><given-name>Yoshikazu</given-name><initials>Y.</initials><afid>60013829</afid><afid>60015682</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7202018048</author-url><authid>7202018048</authid><authname>Otsuki M.</authname><surname>Otsuki</surname><given-name>Michio</given-name><initials>M.</initials><afid>60013829</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56643960200</author-url><authid>56643960200</authid><authname>Higuchi K.</authname><surname>Higuchi</surname><given-name>Kaori</given-name><initials>K.</initials><afid>60013829</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55947939100</author-url><authid>55947939100</authid><authname>Hashimoto-Kataoka T.</authname><surname>Hashimoto-Kataoka</surname><given-name>Takahiro</given-name><initials>T.</initials><afid>60013829</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55323250400</author-url><authid>55323250400</authid><authname>Yasui T.</authname><surname>Yasui</surname><given-name>Taku</given-name><initials>T.</initials><afid>60013829</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56303454900</author-url><authid>56303454900</authid><authname>Masaki T.</authname><surname>Masaki</surname><given-name>Takeshi</given-name><initials>T.</initials><afid>60013829</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56644135200</author-url><authid>56644135200</authid><authname>Ohtani T.</authname><surname>Ohtani</surname><given-name>Tomohito</given-name><initials>T.</initials><afid>60013829</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55649016500</author-url><authid>55649016500</authid><authname>Kishimoto T.</authname><surname>Kishimoto</surname><given-name>Tadamitsu</given-name><initials>T.</initials><afid>60024322</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003624108</author-url><authid>7003624108</authid><authname>Yamauchi-Takihara K.</authname><surname>Yamauchi-Takihara</surname><given-name>Keiko</given-name><initials>K.</initials><afid>60013829</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56496412900</author-url><authid>56496412900</authid><authname>Komuro I.</authname><surname>Komuro</surname><given-name>Issei</given-name><initials>I.</initials><afid>60002354</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:56504623700</author-url><authid>56504623700</authid><authname>Sakata Y.</authname><surname>Sakata</surname><given-name>Yasushi</given-name><initials>Y.</initials><afid>60013829</afid></author><authkeywords>Cytokine storm | Interleukin-6 | Recurrence | Takayasu arteritis (tak) | Tocilizumab</authkeywords><intid>1535944688</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928988438"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928988438?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928988438&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928988438&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S8756328215001386"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928988438</prism:url><dc:identifier>SCOPUS_ID:84928988438</dc:identifier><eid>2-s2.0-84928988438</eid><dc:title>Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2</dc:title><dc:creator>Takeno A.</dc:creator><prism:publicationName>Bone</prism:publicationName><prism:issn>87563282</prism:issn><prism:volume>77</prism:volume><prism:pageRange>135-141</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bone.2015.04.025</prism:doi><pii>S8756328215001386</pii><dc:description>Â© 2015 Elsevier Inc. Background: Elevated plasma homocysteine (Hcy) level is associated with the risk of osteoporotic fracture. While Hcy increases oxidative stress, AMP-activated protein kinase (AMPK) activation ameliorates it. This study aimed to investigate whether Hcy induces apoptosis of osteocytic MLO-Y4 cells through regulating expressions of oxidant and anti-oxidant enzymes and determine the effects of AMPK activation by 5-aminoimidazole-4-carboxamide-1-Î²- d-ribofuranoside (AICAR) and metformin on the Hcy-induced apoptosis of the cells. Results: DNA fragment ELISA and TUNEL staining assays showed that Hcy treatments (0.1-5.0. mM) induced apoptosis of MLO-Y4 cells in a dose-dependent manner. The detrimental effect of Hcy was partly but significantly reversed by an antioxidant (N-acetylcysteine) and NADPH oxidase (Nox) inhibitors (apocynin and diphenyleneiodonium). In addition, treatment with AICAR (0.05-0.1. mM) and metformin (10-100. Î¼M) ameliorated Hcy-induced apoptosis of the cells. The favorable effect of metformin on Hcy-induced apoptosis was completely canceled by an AMPK inhibitor Ara-A. Hcy increased the expression levels of Nox1 and Nox2, while it had no effects on the expressions of Nox4 or the anti-oxidant enzymes, superoxide dismutase 1 and 2. Hcy-induced increases in the expressions of Nox1 and Nox2 decreased significantly by treatments with AICAR. Conclusion: These findings suggest that Hcy induces apoptosis of osteocytes by increasing the expressions of Nox1 and Nox2, and AMPK activation by AICAR and metformin effectively prevents the detrimental reactions. Thus, AMPK activation may be a potent therapeutic candidate for preventing Hcy-induced osteocyte apoptosis and the resulting bone fragility.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026275</affiliation-url><afid>60026275</afid><affilname>Shimane University</affilname><name-variant>Shimane University</name-variant><affiliation-city>Matsue</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56625730900</author-url><authid>56625730900</authid><authname>Takeno A.</authname><surname>Takeno</surname><given-name>Ayumu</given-name><initials>A.</initials><afid>60026275</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7202193728</author-url><authid>7202193728</authid><authname>Kanazawa I.</authname><surname>Kanazawa</surname><given-name>Ippei</given-name><initials>I.</initials><afid>60026275</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55624472373</author-url><authid>55624472373</authid><authname>Tanaka K.</authname><surname>Tanaka</surname><given-name>Ken ichiro</given-name><initials>K.i.</initials><afid>60026275</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55986398900</author-url><authid>55986398900</authid><authname>Notsu M.</authname><surname>Notsu</surname><given-name>Masakazu</given-name><initials>M.</initials><afid>60026275</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56582186800</author-url><authid>56582186800</authid><authname>Yokomoto M.</authname><surname>Yokomoto</surname><given-name>Maki</given-name><initials>M.</initials><afid>60026275</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:34878091200</author-url><authid>34878091200</authid><authname>Yamaguchi T.</authname><surname>Yamaguchi</surname><given-name>Toru</given-name><initials>T.</initials><afid>60026275</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7403670899</author-url><authid>7403670899</authid><authname>Sugimoto T.</authname><surname>Sugimoto</surname><given-name>Toshitsugu</given-name><initials>T.</initials><afid>60026275</afid></author><authkeywords>AMP-activated protein kinase | Homocysteine | NADPH oxidase | Osteocyte | Oxidative stress</authkeywords><intid>2035878694</intid><source-id>29551</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924629394"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924629394?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924629394&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924629394&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0889157515000332"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924629394</prism:url><dc:identifier>SCOPUS_ID:84924629394</dc:identifier><eid>2-s2.0-84924629394</eid><dc:title>Changes in donkey milk lipids in relation to season and lactation</dc:title><dc:creator>Martini M.</dc:creator><prism:publicationName>Journal of Food Composition and Analysis</prism:publicationName><prism:issn>08891575</prism:issn><prism:volume>41</prism:volume><prism:pageRange>30-34</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jfca.2014.12.019</prism:doi><pii>S0889157515000332</pii><dc:description>Â© 2015 Elsevier Inc. In this study the fatty acid profile and morphometric characteristics of fat globules in Amiata donkey milk in relation to the lactation phase and production season have been evaluated. Individual donkey milk samplings were carried out monthly starting from day 30 of lactation until day 300. The amount of fat and the diameter of the milk fat globules were fairly stable during lactation, whereas the number of globules/mL of milk decreased significantly only in the last phase of lactation. The fatty acid composition showed only few changes during lactation, which consisted in a progressive decrease in the short chain fatty acids and an increasing trend in the monounsaturated fatty acids. Winter milk showed a significantly larger average diameter, a lower number of fat globules/mL, lower (P&lt;. 0.01) percentages of short-chain saturated fatty acids and more (P&lt;. 0.01) long-chain and monounsaturated fatty acids. In addition, significantly lower percentages of C18:0 and higher of palmitoleic, oleic and vaccenic acids were detected in the cooler season. In conclusion the lipid fraction of donkey milk did not show notable changes during lactation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028868</affiliation-url><afid>60028868</afid><affilname>Universita di Pisa</affilname><name-variant>University of Pisa</name-variant><affiliation-city>Pisa</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113544190</affiliation-url><afid>113544190</afid><affilname>Centro di Ricerche Agro-Ambientali Enrico Avanzi</affilname><name-variant>Centro interdipartimentale di ricerche E. Avanzi</name-variant><affiliation-city>San Piero a Grado</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112949566</affiliation-url><afid>112949566</afid><affilname>Instituto Federal de EducaÃ§Ã£o</affilname><name-variant>Instituto Federal de EducaÃ§Ã£o</name-variant><affiliation-city>Natal</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115049073</affiliation-url><afid>115049073</afid><affilname>Centro Interdipartimentale di Ricerca Nutraceutica e Alimentazione per la Salute</affilname><name-variant>Centro Interdipartimentale di Ricerca Nutraceutica e Alimentazione per la Salute</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202428041</author-url><authid>7202428041</authid><authname>Martini M.</authname><surname>Martini</surname><given-name>Mina</given-name><initials>M.</initials><afid>60028868</afid><afid>115049073</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202428041</author-url><authid>7202428041</authid><authname>Martini M.</authname><surname>Martini</surname><given-name>Mina</given-name><initials>M.</initials><afid>60028868</afid><afid>115049073</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:37025524400</author-url><authid>37025524400</authid><authname>Altomonte I.</authname><surname>Altomonte</surname><given-name>Iolanda</given-name><initials>I.</initials><afid>113544190</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56545603400</author-url><authid>56545603400</authid><authname>Manica E.</authname><surname>Manica</surname><given-name>Emanuel</given-name><initials>E.</initials><afid>112949566</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:12806841500</author-url><authid>12806841500</authid><authname>Salari F.</authname><surname>Salari</surname><given-name>Federica</given-name><initials>F.</initials><afid>113544190</afid></author><authkeywords>Amiata donkey | Donkey milk nutritional quality | Fatty acids | Food analysis | Food composition | Lactation | Milk fat globules | Seasonal changes in milk</authkeywords><intid>35169273</intid><source-id>20582</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930211888"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930211888?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930211888&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930211888&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S016726811500133X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930211888</prism:url><dc:identifier>SCOPUS_ID:84930211888</dc:identifier><eid>2-s2.0-84930211888</eid><dc:title>Why do households forego high returns from technology adoption? Evidence from improved cooking stoves in Burkina Faso</dc:title><dc:creator>Bensch G.</dc:creator><prism:publicationName>Journal of Economic Behavior and Organization</prism:publicationName><prism:issn>01672681</prism:issn><prism:volume>116</prism:volume><prism:pageRange>187-205</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jebo.2015.04.023</prism:doi><pii>S016726811500133X</pii><dc:description>Â© 2015 Elsevier B.V. Around 3 billion people in developing countries rely on woodfuels for their daily cooking needs with profound negative implications for their workload, health, and budget as well as the environment. Improved cooking stove (ICS) technologies appear to be an obvious solution in many cases. Indeed we find that users of a very simple ICS in urban Burkina Faso need between 20 and 30 percent less firewood compared to traditional stoves, making the investment highly profitable. In spite of these high returns and great efforts made by the international community to disseminate ICSs, take-up rates are - similar to many other high-return innovations - strikingly low; in our case a mere 10 percent. When exploring adoption decisions of households, we find suggestive evidence that a major deterrent to adoption is the upfront investment costs. They seem to be much more important than access to information, taste preferences, or the woman's role in the household. These findings suggest that perhaps more direct promotion strategies such as subsidies would help households to overcome liquidity constraints, and would hence improve adoption rates.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112713043</affiliation-url><afid>112713043</afid><affilname>Rheinisch-WestfÃ¤lisches Institut fÃ¼r Wirtschaftsforschung (RWI)</affilname><name-variant>Rheinisch-WestfÃ¤lisches Institut fÃ¼r Wirtschaftsforschung (RWI)</name-variant><affiliation-city>Essen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014151</affiliation-url><afid>60014151</afid><affilname>Universitat Passau</affilname><name-variant>University of Passau</name-variant><affiliation-city>Passau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022265</affiliation-url><afid>60022265</afid><affilname>Erasmus University Rotterdam</affilname><name-variant>Erasmus University</name-variant><affiliation-city>Rotterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007893</affiliation-url><afid>60007893</afid><affilname>Institut Zur Zukunft Der Arbeit</affilname><name-variant>IZA</name-variant><affiliation-city>Bonn</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016218</affiliation-url><afid>60016218</afid><affilname>University of Witwatersrand</affilname><name-variant>University of the Witwatersrand</name-variant><affiliation-city>Johannesburg</affiliation-city><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:53982494000</author-url><authid>53982494000</authid><authname>Bensch G.</authname><surname>Bensch</surname><given-name>Gunther</given-name><initials>G.</initials><afid>112713043</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35952524300</author-url><authid>35952524300</authid><authname>Grimm M.</authname><surname>Grimm</surname><given-name>Michael</given-name><initials>M.</initials><afid>60014151</afid><afid>60022265</afid><afid>60007893</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35952524300</author-url><authid>35952524300</authid><authname>Grimm M.</authname><surname>Grimm</surname><given-name>Michael</given-name><initials>M.</initials><afid>60014151</afid><afid>60022265</afid><afid>60007893</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35952524300</author-url><authid>35952524300</authid><authname>Grimm M.</authname><surname>Grimm</surname><given-name>Michael</given-name><initials>M.</initials><afid>60014151</afid><afid>60022265</afid><afid>60007893</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55705328900</author-url><authid>55705328900</authid><authname>Peters J.</authname><surname>Peters</surname><given-name>JÃ¶rg</given-name><initials>J.</initials><afid>112713043</afid><afid>60016218</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55705328900</author-url><authid>55705328900</authid><authname>Peters J.</authname><surname>Peters</surname><given-name>JÃ¶rg</given-name><initials>J.</initials><afid>112713043</afid><afid>60016218</afid></author><authkeywords>Energy access | Household technology adoption | Liquidity constraints | Sub-Saharan Africa | Traditions | Weak beliefs</authkeywords><intid>1536087828</intid><source-id>23865</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927649449"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927649449?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927649449&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927649449&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S092585741500155X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927649449</prism:url><dc:identifier>SCOPUS_ID:84927649449</dc:identifier><eid>2-s2.0-84927649449</eid><dc:title>Antioxidant and behavior responses of earthworms after introduction to a simulated vermifilter environment</dc:title><dc:creator>Li Y.</dc:creator><prism:publicationName>Ecological Engineering</prism:publicationName><prism:issn>09258574</prism:issn><prism:volume>81</prism:volume><prism:pageRange>218-227</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ecoleng.2015.04.045</prism:doi><pii>S092585741500155X</pii><dc:description>Â© 2015 Elsevier B.V. Vermifiltration is a new technology for treating wastewater with a high organic loading, but there is almost no published information on the biochemical and behavioral response of earthworms in a vermifilter environment. This study measured antioxidase enzyme (AOE) activities and reactive oxygen species (ROS) and malondialdehyde (MDA) levels in tissues of earthworms for a period of 56 d after transfer into simulated vermifilters. Three vermifilter media were tested. In general AOE activities, ROS and MDA were elevated for the first 3-5 d after transfer, variable for approximately the next 7 d, and statistically indistinguishable from controls after 15 d. Similarly, earthworm activity as measured by daily burrowing length was initially enhanced but converged with that of controls after 6 d. Removal of chemical oxygen demand (COD) from artificial wastewater was significantly correlated with AOE and ROS in earthworm tissues, and daily burrowing length of earthworms, but none of these parameters was correlated to NH&lt;inf&gt;4&lt;/inf&gt;&lt;sup&gt;+&lt;/sup&gt;-N removal rate, suggesting earthworms do not play a direct role in nitrogen removal in vermifilters. The data provide useful information for vermifilter operators about the biochemical adaptive process earthworms undergo when introduced to a vermifilter environment and the lag time between set up and reliable operation of a vermifilter. The results could potentially lead to development of preconditioning treatments to shorten the settling-down time for newly set up vermifilters. Maximum burrow depth was reduced in simulated vermifilters, suggesting an optimal depth for vermifilter substrates. The three vermifilter media tested differed in performance and possible reasons are briefly discussed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Shanghai Jiao Tong University</affilname><name-variant>School of Agriculture and Biology</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Sol Agronomie Spatialisation</affilname><name-variant>INRA</name-variant><name-variant>Agrocampus Rennes</name-variant><name-variant>UMR 1069</name-variant><affiliation-city>Rennes</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Landcare Research</affilname><affiliation-city>Lincoln</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Massey University</affilname><name-variant>Institute of Agriculture and Environment</name-variant><affiliation-city>Palmerston North</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:39561230300</author-url><authid>39561230300</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yinsheng</given-name><initials>Y.</initials><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55968432000</author-url><authid>55968432000</authid><authname>Zhang F.</authname><surname>Zhang</surname><given-name>Feifei</given-name><initials>F.</initials><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56412444100</author-url><authid>56412444100</authid><authname>Ai X.</authname><surname>Ai</surname><given-name>Xiaojie</given-name><initials>X.</initials><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:44361633500</author-url><authid>44361633500</authid><authname>Wang X.</authname><surname>Wang</surname><given-name>Xiuhong</given-name><initials>X.</initials><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7101627501</author-url><authid>7101627501</authid><authname>Robin P.</authname><surname>Robin</surname><given-name>Paul</given-name><initials>P.</initials><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56591965800</author-url><authid>56591965800</authid><authname>Cavanagh J.</authname><surname>Cavanagh</surname><given-name>Jo</given-name><initials>J.</initials><afid/></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56592337700</author-url><authid>56592337700</authid><authname>Matthew C.</authname><surname>Matthew</surname><given-name>Cory</given-name><initials>C.</initials><afid/></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:17346459100</author-url><authid>17346459100</authid><authname>Qiu J.</authname><surname>Qiu</surname><given-name>Jiangping</given-name><initials>J.</initials><afid/></author><authkeywords>Adaptation | Antioxidase | Burrow | Earthworm | Vermifiltration | Wastewater</authkeywords><intid>1535647456</intid><source-id>20291</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929581224"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929581224?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929581224&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929581224&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S014181301500330X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929581224</prism:url><dc:identifier>SCOPUS_ID:84929581224</dc:identifier><eid>2-s2.0-84929581224</eid><dc:title>Inhibitory effect of quercetin in the formation of advance glycation end products of human serum albumin: An in vitro and molecular interaction study</dc:title><dc:creator>Alam M.</dc:creator><prism:publicationName>International Journal of Biological Macromolecules</prism:publicationName><prism:issn>01418130</prism:issn><prism:eIssn>18790003</prism:eIssn><prism:volume>79</prism:volume><prism:pageRange>336-343</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijbiomac.2015.05.004</prism:doi><pii>S014181301500330X</pii><dc:description>Â© 2015 Elsevier B.V. Non-enzymatic glycation entails the reaction between the carbonyl group of a sugar with the amino group of a protein giving rise to Schiff base and Amadori products. The formation of advanced glycation end products (AGEs) leads to the generation of free radicals, which play an important role in the pathophysiology of ageing and diabetes. Bioavailable dietary antioxidants like quercetin (QC) are thought to inhibit AGEs formation. This study was aimed to investigate the effect of quercetin on AGE formation and features the glycation of human serum albumin (HSA) and its characterization by various spectroscopic techniques. The effect of quercetin, against the formation of AGEs was studied using a glycated human serum albumin product, haemoglobin-Î´-gluconolactone, and aminoguanidine. The results were then corroborated with estimation of protein oxidation, lipid peroxidation and comet assay. On the basis of the experimental data, computational docking studies were then performed to understand the location of the site of quercetin binding and its best bound conformation with respect to human serum albumin. Through this study we have demonstrated the mechanism of formation of AGE and its inhibition by quercetin. We have also suggested that the supplementation with dietary antioxidants like quercetin might protect against free radical toxicity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032269</affiliation-url><afid>60032269</afid><affilname>Aligarh Muslim University</affilname><name-variant>Aligarh Muslim University</name-variant><affiliation-city>Aligarh</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56286233700</author-url><authid>56286233700</authid><authname>Alam M.</authname><surname>Alam</surname><given-name>Md Maroof</given-name><initials>M.M.</initials><afid>60032269</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56366368100</author-url><authid>56366368100</authid><authname>Ahmad I.</authname><surname>Ahmad</surname><given-name>Irshad</given-name><initials>I.</initials><afid>60032269</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602460193</author-url><authid>6602460193</authid><authname>Naseem I.</authname><surname>Naseem</surname><given-name>Imrana</given-name><initials>I.</initials><afid>60032269</afid></author><authkeywords>AGEs | Comet assay | Lipid and protein oxidation | Molecular docking | Quercetin</authkeywords><intid>2035976852</intid><source-id>17544</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923924467"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923924467?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923924467&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923924467&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0045793015000456"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923924467</prism:url><dc:identifier>SCOPUS_ID:84923924467</dc:identifier><eid>2-s2.0-84923924467</eid><dc:title>Numerical simulation of surface acoustic wave actuated enantiomer separation by the finite element immersed boundary method</dc:title><dc:creator>Beleke-Maxwell K.</dc:creator><prism:publicationName>Computers and Fluids</prism:publicationName><prism:issn>00457930</prism:issn><prism:volume>112</prism:volume><prism:pageRange>50-60</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>s016/j.compfluid.2015.02.008</prism:doi><pii>S0045793015000456</pii><dc:description>Â© 2015 Elsevier Ltd. Enantiomers are chiral objects such as chemical molecules that can be distinguished by their handedness. They typically occur as racemic compounds of left- and right-handed species which may have completely different properties. Therefore, in applications such as drug design in pharmacology, enantiomer separation is an important issue. Here, we present a new technology for enantiomer separation by surface acoustic wave generated vorticity patterns consisting of pairwise counter-rotating vortices in a carrier fluid. The enantiomers are injected onto the surface of the fluid between two counter-rotating vortices such that right-handed (left-handed) enantiomers get attracted by left-rotating (right-rotating) vortices. In particular, we are concerned with the numerical simulation of this separation process by an application of the finite element immersed boundary method which relies on the solution of a coupled system consisting of the incompressible Navier-Stokes equations and the equations of motion of the immersed enantiomers described with respect to an Eulerian and a Lagrangian coordinate system. For a model system of deformable, initially L-shaped enantiomers the results of the numerical simulations reveal a perfect separation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004923</affiliation-url><afid>60004923</afid><affilname>North Carolina State University</affilname><name-variant>North Carolina State University</name-variant><affiliation-city>Raleigh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016060</affiliation-url><afid>60016060</afid><affilname>Universitat Augsburg</affilname><name-variant>University of Augsburg</name-variant><affiliation-city>Augsburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016060</affiliation-url><afid>60016060</afid><affilname>Universitat Augsburg</affilname><name-variant>University of Augsburg</name-variant><affiliation-city>Augsburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005837</affiliation-url><afid>60005837</afid><affilname>University of Houston</affilname><name-variant>University of Houston</name-variant><affiliation-city>Houston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56534095800</author-url><authid>56534095800</authid><authname>Beleke-Maxwell K.</authname><surname>Beleke-Maxwell</surname><given-name>K.</given-name><initials>K.</initials><afid>60004923</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006357702</author-url><authid>7006357702</authid><authname>Franke T.</authname><surname>Franke</surname><given-name>T.</given-name><initials>T.</initials><afid>60016060</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56250944900</author-url><authid>56250944900</authid><authname>Hoppe R.</authname><surname>Hoppe</surname><given-name>R. H W</given-name><initials>R.H.W.</initials><afid>60016060</afid><afid>60005837</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56250944900</author-url><authid>56250944900</authid><authname>Hoppe R.</authname><surname>Hoppe</surname><given-name>R. H W</given-name><initials>R.H.W.</initials><afid>60016060</afid><afid>60005837</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14043571400</author-url><authid>14043571400</authid><authname>Linsenmann C.</authname><surname>Linsenmann</surname><given-name>C.</given-name><initials>C.</initials><afid>60016060</afid></author><authkeywords>Enantiomer separation | Finite element immersed boundary method | Surface acoustic waves</authkeywords><intid>35078136</intid><source-id>18160</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929581135"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929581135?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929581135&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929581135&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S003193841500267X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929581135</prism:url><dc:identifier>SCOPUS_ID:84929581135</dc:identifier><eid>2-s2.0-84929581135</eid><dc:title>Homer1a-dependent recovery from depression-like behavior by photic stimulation in mice</dc:title><dc:creator>Sun P.</dc:creator><prism:publicationName>Physiology and Behavior</prism:publicationName><prism:issn>00319384</prism:issn><prism:eIssn>1873507X</prism:eIssn><prism:volume>147</prism:volume><prism:pageRange>334-341</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.physbeh.2015.05.007</prism:doi><pii>S003193841500267X</pii><dc:description>Â© 2015 Elsevier Inc. A significant number of depressed people are resistant to drug therapy. Promising alternative therapy may be brain stimulation achievable by diverse methods. In a mouse model of depression, we previously investigated the mechanisms by which repetitive transcranial magnetic stimulation (rTMS) reverses depression-like behavior, and found an essential involvement of the immediate early gene product Homer1a. Home1a is known to be expressed not just by rTMS but also by photic stimulation (PS) via activation of the retino-geniculo-cortical pathway, suggesting that PS may have an antidepressant effect. This was tested by using a two-phase version of forced swimming (FS), in which the first phase consists of a 10-min swimming for 5 consecutive days and the second phase takes place at a 4-week interval for testing behavior. During the 4-week period, PS was applied everyday (300. lx, 2. Hz for 6. h daily). After the last swimming, the brains were removed and subjected to quantitative RT-PCR and electrophysiological analysis. The 4-week-long PS alleviated depression-like behavior to the extent comparable to that obtained with rTMS previously. Homer1a expression was drastically reduced by FS and recovered by PS. Consistently with our previous studies, activity of the large conductance calcium-activated potassium (BK) channel was facilitated by PS in a Homer1a-dependent manner. PS may thus have a potential utility for depression therapy. Furthermore, given that Homer1a is implicated in various neuropsychiatric disorders, brain stimulations that induce Homer1a expression, such as rTMS or PS, may have a wider applicability than currently thought.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008727</affiliation-url><afid>60008727</afid><affilname>Kanazawa Medical University</affilname><name-variant>Kanazawa Medical University</name-variant><affiliation-city>Kahoku District</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025761</affiliation-url><afid>60025761</afid><affilname>Huazhong University of Science and Technology</affilname><name-variant>Huazhong Univ. of Sci. and Technol.</name-variant><affiliation-city>Wuhan</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023133</affiliation-url><afid>60023133</afid><affilname>Qinghai University</affilname><name-variant>Qinghai University</name-variant><affiliation-city>Xining</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202976159</author-url><authid>7202976159</authid><authname>Sun P.</authname><surname>Sun</surname><given-name>Peng</given-name><initials>P.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202976159</author-url><authid>7202976159</authid><authname>Sun P.</authname><surname>Sun</surname><given-name>Peng</given-name><initials>P.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56447240100</author-url><authid>56447240100</authid><authname>Zhang Q.</authname><surname>Zhang</surname><given-name>Qing</given-name><initials>Q.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56447240100</author-url><authid>56447240100</authid><authname>Zhang Q.</authname><surname>Zhang</surname><given-name>Qing</given-name><initials>Q.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56448711000</author-url><authid>56448711000</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yu</given-name><initials>Y.</initials><afid>60008727</afid><afid>60023133</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56448711000</author-url><authid>56448711000</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yu</given-name><initials>Y.</initials><afid>60008727</afid><afid>60023133</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56447436000</author-url><authid>56447436000</authid><authname>Wang F.</authname><surname>Wang</surname><given-name>Furong</given-name><initials>F.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56447436000</author-url><authid>56447436000</authid><authname>Wang F.</authname><surname>Wang</surname><given-name>Furong</given-name><initials>F.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56650364100</author-url><authid>56650364100</authid><authname>Chen R.</authname><surname>Chen</surname><given-name>Rui</given-name><initials>R.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56650364100</author-url><authid>56650364100</authid><authname>Chen R.</authname><surname>Chen</surname><given-name>Rui</given-name><initials>R.</initials><afid>60008727</afid><afid>60025761</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35239353500</author-url><authid>35239353500</authid><authname>Yamamoto R.</authname><surname>Yamamoto</surname><given-name>Ryo</given-name><initials>R.</initials><afid>60008727</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35431817600</author-url><authid>35431817600</authid><authname>Kato N.</authname><surname>Kato</surname><given-name>Nobuo</given-name><initials>N.</initials><afid>60008727</afid></author><authkeywords>BK channel | Depression | Excitability | Homer | Photic stimulation</authkeywords><intid>1785982412</intid><source-id>24007</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928978788"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928978788?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928978788&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928978788&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0925443915001301"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928978788</prism:url><dc:identifier>SCOPUS_ID:84928978788</dc:identifier><eid>2-s2.0-84928978788</eid><dc:title>Insulin increases glomerular filtration barrier permeability through PKGIÎ±-dependent mobilization of BK&lt;inf&gt;Ca&lt;/inf&gt; channels in cultured rat podocytes</dc:title><dc:creator>Piwkowska A.</dc:creator><prism:publicationName>Biochimica et Biophysica Acta - Molecular Basis of Disease</prism:publicationName><prism:issn>09254439</prism:issn><prism:eIssn>1879260X</prism:eIssn><prism:volume>1852</prism:volume><prism:issueIdentifier>8</prism:issueIdentifier><prism:pageRange>1599-1609</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbadis.2015.04.024</prism:doi><pii>S0925443915001301</pii><dc:description>Â© 2015 Elsevier B.V. Podocytes are highly specialized cells that wrap around glomerular capillaries and comprise a key component of the glomerular filtration barrier. They are uniquely sensitive to insulin; like skeletal muscle and fat cells, they exhibit insulin-stimulated glucose uptake and express glucose transporters. Podocyte insulin signaling is mediated by protein kinase G type I (PKGI), and it leads to changes in glomerular permeability to albumin. Here, we investigated whether large-conductance Ca&lt;sup&gt;2+&lt;/sup&gt;-activated K&lt;sup&gt;+&lt;/sup&gt; channels (BK&lt;inf&gt;Ca&lt;/inf&gt;) were involved in insulin-mediated, PKGIÎ±-dependent filtration barrier permeability.Insulin-induced glomerular permeability was measured in glomeruli isolated from Wistar rats. Transepithelial albumin flux was measured in cultured rat podocyte monolayers. Expression of BK&lt;inf&gt;Ca&lt;/inf&gt; subunits was detected by RT-PCR. BK&lt;inf&gt;Ca&lt;/inf&gt;, PKGIÎ±, and upstream protein expression were examined in podocytes with Western blotting and immunofluorescence. The BK&lt;inf&gt;Ca&lt;/inf&gt;-PKGIÎ± interaction was assessed with co-immunoprecipitation.RT-PCR showed that primary cultured rat podocytes expressed mRNAs that encoded the pore-forming Î± subunit and four accessory Î² subunits of BK&lt;inf&gt;Ca&lt;/inf&gt;. The BK&lt;inf&gt;Ca&lt;/inf&gt; inhibitor, iberiotoxin (ibTX), abolished insulin-dependent glomerular albumin permeability and PKGI-dependent transepithelial albumin flux. Insulin-evoked albumin permeability across podocyte monolayers was also blocked with BK&lt;inf&gt;Ca&lt;/inf&gt; siRNA. Moreover, ibTX blocked insulin-induced disruption of the actin cytoskeleton and changes in the phosphorylation of PKG target proteins, MYPT1 and RhoA.These results indicated that insulin increased filtration barrier permeability through mobilization of BK&lt;inf&gt;Ca&lt;/inf&gt; channels via PKGI in cultured rat podocytes. This molecular mechanism may explain podocyte injury and proteinuria in diabetes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082128</affiliation-url><afid>60082128</afid><affilname>Miroslaw Mossakowski Medical Research Center of the Polish Academy of Sciences</affilname><name-variant>Polish Academy of Sciences</name-variant><affiliation-city>Warsaw</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012383</affiliation-url><afid>60012383</afid><affilname>Akademia Medyczna w Gdansku</affilname><name-variant>Medical University of GdaÅsk</name-variant><affiliation-city>Gdansk</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012383</affiliation-url><afid>60012383</afid><affilname>Akademia Medyczna w Gdansku</affilname><name-variant>Medical University of GdaÅsk</name-variant><affiliation-city>Gdansk</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9044482200</author-url><authid>9044482200</authid><authname>Piwkowska A.</authname><surname>Piwkowska</surname><given-name>Agnieszka</given-name><initials>A.</initials><afid>60082128</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507822910</author-url><authid>6507822910</authid><authname>Rogacka D.</authname><surname>Rogacka</surname><given-name>Dorota</given-name><initials>D.</initials><afid>60082128</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37088046800</author-url><authid>37088046800</authid><authname>Audzeyenka I.</authname><surname>Audzeyenka</surname><given-name>Irena</given-name><initials>I.</initials><afid>60082128</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55633591000</author-url><authid>55633591000</authid><authname>Kasztan M.</authname><surname>Kasztan</surname><given-name>MaÅgorzata</given-name><initials>M.</initials><afid>60012383</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7005564414</author-url><authid>7005564414</authid><authname>Angielski S.</authname><surname>Angielski</surname><given-name>Stefan</given-name><initials>S.</initials><afid>60082128</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005450481</author-url><authid>7005450481</authid><authname>Jankowski M.</authname><surname>Jankowski</surname><given-name>Maciej</given-name><initials>M.</initials><afid>60082128</afid><afid>60012383</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005450481</author-url><authid>7005450481</authid><authname>Jankowski M.</authname><surname>Jankowski</surname><given-name>Maciej</given-name><initials>M.</initials><afid>60082128</afid><afid>60012383</afid></author><authkeywords>Constriction apparatus | Filtration barrier permeability | Insulin | Large-conductance Ca&lt;sup&gt;2+&lt;/sup&gt;-activated K&lt;sup&gt;+&lt;/sup&gt; channels | Podocyte</authkeywords><intid>535878082</intid><source-id>21722</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929471819"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929471819?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929471819&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929471819&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0001457515001414"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929471819</prism:url><dc:identifier>SCOPUS_ID:84929471819</dc:identifier><eid>2-s2.0-84929471819</eid><dc:title>A systematic review of the literature on safety measures to prevent railway suicides and trespassing accidents</dc:title><dc:creator>HavÃ¢rneanu G.</dc:creator><prism:publicationName>Accident Analysis and Prevention</prism:publicationName><prism:issn>00014575</prism:issn><prism:volume>81</prism:volume><prism:pageRange>30-50</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>1 August 2015</prism:coverDisplayDate><prism:doi>10.1016/j.aap.2015.04.012</prism:doi><pii>S0001457515001414</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. Abstract This review covers a central aspect in railway safety which is the prevention of suicides and trespassing accidents. The paper attempts to answer the following research question: 'What measures are available to reduce railway suicide and trespass, and what is the evidence for their effectiveness?' The review is based on 139 relevant publications, ranging from 1978 to 2014. The analysis aimed to identify the past and current trend in the prevention practice by looking both quantitatively and qualitatively at the recommended measures. According to the results, there has been a constant focus on suicide prevention, and only relatively recent interest in trespass countermeasures. The content analysis revealed 19 main preventative categories which include more than 100 specific measures. We identified 16 common categories against railway suicide and trespass, and 3 categories of specific measures to prevent suicide. There are only 22 studies which provide empirical support for the effectiveness of measures. Actual combinations of measures are barely evaluated, but several challenges emerge from the literature. The discussion focuses on the need for a unified approach to suicide and trespass prevention, and on the importance to consider the effect mechanism of the measures in order to design better interventions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115249746</affiliation-url><afid>115249746</afid><affilname>International Union of Railways (UIC)</affilname><name-variant>International Union of Railways (UIC)</name-variant><affiliation-city>Paris</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104916</affiliation-url><afid>60104916</afid><affilname>IFSTTAR - French institute of science and technology for transport, development and networks</affilname><name-variant>IFSTTAR</name-variant><affiliation-city>Marne-la-Vallee</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56648179600</author-url><authid>56648179600</authid><authname>HavÃ¢rneanu G.</authname><surname>HavÃ¢rneanu</surname><given-name>Grigore M.</given-name><initials>G.M.</initials><afid>115249746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56647709600</author-url><authid>56647709600</authid><authname>Burkhardt J.</authname><surname>Burkhardt</surname><given-name>Jean Marie</given-name><initials>J.M.</initials><afid>60104916</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36970710900</author-url><authid>36970710900</authid><authname>Paran F.</authname><surname>Paran</surname><given-name>FranÃ§oise</given-name><initials>F.</initials><afid>60104916</afid></author><authkeywords>Countermeasures | Prevention | Railway suicide | Train-pedestrian fatalities | Trespass</authkeywords><intid>535964392</intid><article-number>3784</article-number><source-id>19532</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927914772"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927914772?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927914772&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927914772&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0160412015000872"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927914772</prism:url><dc:identifier>SCOPUS_ID:84927914772</dc:identifier><eid>2-s2.0-84927914772</eid><dc:title>Inflammatory markers in relation to long-term air pollution</dc:title><dc:creator>Mostafavi N.</dc:creator><prism:publicationName>Environment International</prism:publicationName><prism:issn>01604120</prism:issn><prism:eIssn>18736750</prism:eIssn><prism:volume>81</prism:volume><prism:pageRange>1-7</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.envint.2015.04.003</prism:doi><pii>S0160412015000872</pii><dc:description>Â© 2015 Elsevier Ltd. Long-term exposure to ambient air pollution can lead to chronic health effects such as cancer, cardiovascular and respiratory disease. Systemic inflammation has been hypothesized as a putative biological mechanism contributing to these adverse health effects. We evaluated the effect of long-term exposure to air pollution on blood markers of systemic inflammation.We measured a panel of 28 inflammatory markers in peripheral blood samples from 587 individuals that were biobanked as part of a prospective study. Participants were from Varese and Turin (Italy) and Umea (Sweden). Long-term air pollution estimates of nitrogen oxides (NO&lt;inf&gt;x&lt;/inf&gt;) were available from the European Study of Cohorts for Air Pollution Effects (ESCAPE). Linear mixed models adjusted for potential confounders were applied to assess the association between NO&lt;inf&gt;x&lt;/inf&gt; and the markers of inflammation.Long-term exposure to NO&lt;inf&gt;x&lt;/inf&gt; was associated with decreased levels of interleukin (IL)-2, IL-8, IL-10 and tumor necrosis factor-Î± in Italy, but not in Sweden. NO&lt;inf&gt;x&lt;/inf&gt; exposure levels were considerably lower in Sweden than in Italy (Sweden: median (5th, 95th percentiles) 6.65Î¼g/m&lt;sup&gt;3&lt;/sup&gt; (4.8, 19.7); Italy: median (5th, 95th percentiles) 94.2Î¼g/m&lt;sup&gt;3&lt;/sup&gt; (7.8, 124.5)). Combining data from Italy and Sweden we only observed a significant association between long-term exposure to NO&lt;inf&gt;x&lt;/inf&gt; and decreased levels of circulating IL-8.We observed some indication for perturbations in the inflammatory markers due to long-term exposure to NO&lt;inf&gt;x&lt;/inf&gt;. Effects were stronger in Italy than in Sweden, potentially reflecting the difference in air pollution levels between the two cohorts.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007989</affiliation-url><afid>60007989</afid><affilname>Utrecht University</affilname><name-variant>University of Utrecht</name-variant><affiliation-city>Utrecht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015150</affiliation-url><afid>60015150</afid><affilname>Imperial College London</affilname><name-variant>Imperial College</name-variant><affiliation-city>London</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031040</affiliation-url><afid>60031040</afid><affilname>Umea universitet</affilname><name-variant>UmeÃ¥ University</name-variant><affiliation-city>Umea</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112576790</affiliation-url><afid>112576790</afid><affilname>Cancer Prevention and Research Institute (ISPO)</affilname><name-variant>ISPO Cancer Prevention and Research Institute</name-variant><affiliation-city>Florence</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112576371</affiliation-url><afid>112576371</afid><affilname>HuGeF Foundation</affilname><name-variant>HuGeF Foundation</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031687</affiliation-url><afid>60031687</afid><affilname>National Hellenic Research Foundation</affilname><name-variant>National Hellenic Research Foundation</name-variant><affiliation-city>Athens</affiliation-city><affiliation-country>Greece</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031040</affiliation-url><afid>60031040</afid><affilname>Umea universitet</affilname><name-variant>UmeÃ¥ University</name-variant><affiliation-city>Umea</affiliation-city><affiliation-country>Sweden</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56596683500</author-url><authid>56596683500</authid><authname>Mostafavi N.</authname><surname>Mostafavi</surname><given-name>Nahid</given-name><initials>N.</initials><afid>60007989</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:14521738400</author-url><authid>14521738400</authid><authname>Vlaanderen J.</authname><surname>Vlaanderen</surname><given-name>Jelle</given-name><initials>J.</initials><afid>60007989</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23090009700</author-url><authid>23090009700</authid><authname>Chadeau-Hyam M.</authname><surname>Chadeau-Hyam</surname><given-name>Marc</given-name><initials>M.</initials><afid>60015150</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:15829316600</author-url><authid>15829316600</authid><authname>Beelen R.</authname><surname>Beelen</surname><given-name>Rob</given-name><initials>R.</initials><afid>60007989</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6507236174</author-url><authid>6507236174</authid><authname>Modig L.</authname><surname>Modig</surname><given-name>Lars</given-name><initials>L.</initials><afid>60031040</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35381532600</author-url><authid>35381532600</authid><authname>Palli D.</authname><surname>Palli</surname><given-name>Domenico</given-name><initials>D.</initials><afid>112576790</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004247529</author-url><authid>7004247529</authid><authname>Bergdahl I.</authname><surname>Bergdahl</surname><given-name>Ingvar A.</given-name><initials>I.A.</initials><afid>60031040</afid><afid>60031040</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7004247529</author-url><authid>7004247529</authid><authname>Bergdahl I.</authname><surname>Bergdahl</surname><given-name>Ingvar A.</given-name><initials>I.A.</initials><afid>60031040</afid><afid>60031040</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7103293037</author-url><authid>7103293037</authid><authname>Vineis P.</authname><surname>Vineis</surname><given-name>Paolo</given-name><initials>P.</initials><afid>60015150</afid><afid>112576371</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7103293037</author-url><authid>7103293037</authid><authname>Vineis P.</authname><surname>Vineis</surname><given-name>Paolo</given-name><initials>P.</initials><afid>60015150</afid><afid>112576371</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004818581</author-url><authid>7004818581</authid><authname>Hoek G.</authname><surname>Hoek</surname><given-name>Gerard</given-name><initials>G.</initials><afid>60007989</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:35433793900</author-url><authid>35433793900</authid><authname>Kyrtopoulos S.</authname><surname>Kyrtopoulos</surname><given-name>Soterios A.</given-name><initials>S.A.</initials><afid>60031687</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7006012910</author-url><authid>7006012910</authid><authname>Vermeulen R.</authname><surname>Vermeulen</surname><given-name>Roel</given-name><initials>R.</initials><afid>60007989</afid></author><authkeywords>Air pollution | Chronic health effects | Gene expression | Inflammatory markers</authkeywords><intid>2035696454</intid><source-id>20912</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928777148"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928777148?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928777148&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928777148&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0963996915001969"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928777148</prism:url><dc:identifier>SCOPUS_ID:84928777148</dc:identifier><eid>2-s2.0-84928777148</eid><dc:title>How do brazilian consumers perceive a non-traditional and innovative fruit juice? An approach looking at the packaging</dc:title><dc:creator>Romano K.</dc:creator><prism:publicationName>Food Research International</prism:publicationName><prism:issn>09639969</prism:issn><prism:volume>74</prism:volume><prism:pageRange>123-130</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodres.2015.04.033</prism:doi><pii>S0963996915001969</pii><dc:description>Â© 2015 Elsevier Ltd. Consumer interest in nutritious and innovative foods encourages the development of products based on raw materials with nutraceutical potential. The health benefits provided by pomegranate have been recognized; therefore, the development of pomegranate juice may match consumer expectations regarding this goal. However, the concept has to first be accepted by the consumer. The aim of the study was to utilize a rating based conjoint analysis to investigate how Brazilian consumers perceive pomegranate juice by identifying the role of packaging attributes relevant to the consumer's intention to purchase. Five factors were considered in the study: technology used in the juice production (high hydrostatic pressure - HHP - a technology that preserves nutritional and sensory properties), antioxidants, price, preservatives, and colorant. Eight hypothetical pomegranate juice packages were created following an incomplete block design and evaluated by 150 fruit juice consumers. Three clusters were identified. The average results revealed that antioxidants were the attribute of greatest relative importance to cluster 1 (RI: 36%), followed by HHP (RI: 25%) and colorants (14%). Consumers in cluster 2 considered price as the most important attribute (RI: 41%), followed by antioxidants (RI: 21%) and HHP (RI: 18%). Cluster 3, as well as cluster 2, considered price the most important attribute (RI: 28%), followed by antioxidants (RI: 26%) and HHP (RI: 22%). The results showed that consumers valued information on the health benefits of antioxidants as well as on the technology, suggesting that both types of information may be relevant tools to increase the intention to purchase the product. The application of HHP for pomegranate juice processing was positively perceived by consumers, suggesting a potential commercial application in the Brazilian industry.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027947</affiliation-url><afid>60027947</afid><affilname>Universidade Federal Rural do Rio de Janeiro</affilname><name-variant>Universidade Federal Rural do Rio de Janeiro</name-variant><affiliation-city>Seropedica</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100349451</affiliation-url><afid>100349451</afid><affilname>Embrapa Food Technology</affilname><name-variant>EMBRAPA Food Technology</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56613240300</author-url><authid>56613240300</authid><authname>Romano K.</authname><surname>Romano</surname><given-name>Karen R.</given-name><initials>K.R.</initials><afid>60027947</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7203080044</author-url><authid>7203080044</authid><authname>Rosenthal A.</authname><surname>Rosenthal</surname><given-name>Amauri</given-name><initials>A.</initials><afid>100349451</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6604033389</author-url><authid>6604033389</authid><authname>Deliza R.</authname><surname>Deliza</surname><given-name>Rosires</given-name><initials>R.</initials><afid>100349451</afid></author><authkeywords>Conjoint analysis | Consumer perception | Package | Pomegranate juice</authkeywords><intid>1535851107</intid><source-id>23180</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929331836"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929331836?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929331836&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929331836&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0197397515000715"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929331836</prism:url><dc:identifier>SCOPUS_ID:84929331836</dc:identifier><eid>2-s2.0-84929331836</eid><dc:title>(Re) making trajectories: Eviction, control and power</dc:title><dc:creator>Selim G.</dc:creator><prism:publicationName>Habitat International</prism:publicationName><prism:issn>01973975</prism:issn><prism:volume>48</prism:volume><prism:pageRange>219-226</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.habitatint.2015.04.001</prism:doi><pii>S0197397515000715</pii><dc:description>Â© 2015 Elsevier Ltd. The City of Cairo's experienced a major shift in its urban planning attitude and practice since the mid 1970s which mostly validated elements of economic planning while neutralizing its social aspects. This ad hoc approach escalated conflict in planning politics over the control of space between tiers of the planning institution and the locals leading to rigorous planning actions among major stakeholders such as eviction and control of spaces. The article examines how institutional claims over space reassembled alternative definitions of quality of life in one of Cairo's oldest quarters, and how ambitious planning schemes were mostly driven by entrepreneurial rather than societal. Based on first-hand interviews and visuals, the article aims to reveal the local's struggle to survive such interventions with attention to their daily negotiations in place.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029738</affiliation-url><afid>60029738</afid><affilname>Queen's University Belfast</affilname><name-variant>Queen's University of Belfast</name-variant><affiliation-city>Belfast</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55603029500</author-url><authid>55603029500</authid><authname>Selim G.</authname><surname>Selim</surname><given-name>Gehan</given-name><initials>G.</initials><afid>60029738</afid></author><authkeywords>Bulaq Abul Ela | Eviction and control | Public space | Spatial quality</authkeywords><intid>2035940948</intid><source-id>13760</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84907545906"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84907545906?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84907545906&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84907545906&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0955067414001069"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84907545906</prism:url><dc:identifier>SCOPUS_ID:84907545906</dc:identifier><eid>2-s2.0-84907545906</eid><dc:title>AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis</dc:title><dc:creator>Hardie D.</dc:creator><prism:publicationName>Current Opinion in Cell Biology</prism:publicationName><prism:issn>09550674</prism:issn><prism:eIssn>18790410</prism:eIssn><prism:volume>33</prism:volume><prism:pageRange>1-7</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ceb.2014.09.004</prism:doi><pii>S0955067414001069</pii><dc:description>Â© 2014. The AMP-activated protein kinase (AMPK) is a sensor of energy status that, when activated by metabolic stress, maintains cellular energy homeostasis by switching on catabolic pathways and switching off ATP-consuming processes. Recent results suggest that activation of AMPK by the upstream kinase LKB1 in response to nutrient lack occurs at the surface of the lysosome. AMPK is also crucial in regulation of whole body energy balance, particularly by mediating effects of hormones acting on the hypothalamus. Recent crystal structures of complete AMPK heterotrimers have illuminated its complex mechanisms of activation, involving both allosteric activation and increased net phosphorylation mediated by effects on phosphorylation and dephosphorylation. Finally, AMPK is negatively regulated by phosphorylation of the 'ST loop' within the catalytic subunit.</dc:description><citedby-count>7</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008877</affiliation-url><afid>60008877</afid><affilname>University of Dundee</affilname><name-variant>University of Dundee</name-variant><affiliation-city>Dundee</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24373207900</author-url><authid>24373207900</authid><authname>Hardie D.</authname><surname>Hardie</surname><given-name>D. Grahame</given-name><initials>D.G.</initials><afid>60008877</afid></author><intid>1532324579</intid><source-id>18503</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928578104"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928578104?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928578104&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928578104&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306456515300115"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928578104</prism:url><dc:identifier>SCOPUS_ID:84928578104</dc:identifier><eid>2-s2.0-84928578104</eid><dc:title>Seasonal metabolic variation over two years in an Afrotropical passerine bird</dc:title><dc:creator>Thompson L.</dc:creator><prism:publicationName>Journal of Thermal Biology</prism:publicationName><prism:issn>03064565</prism:issn><prism:eIssn>18790992</prism:eIssn><prism:volume>52</prism:volume><prism:pageRange>58-66</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jtherbio.2015.05.003</prism:doi><pii>S0306456515300115</pii><dc:description>Â© 2015 Elsevier Ltd. Seasonal trends in metabolic parameters are well established in avian populations from highly seasonal environments, however, seasonal trends in metabolism of birds from lower latitudes (and of Afrotropical birds in particular) are not well understood. We investigated seasonal trends in metabolism for a small (10-12 g) Afrotropical bird, the Cape White-eye (Zosterops virens), using flow-through respirometry in two summers and two winters. There was no seasonal difference in body mass between consecutive seasons. The lower critical limit of thermoneutrality was lower in winter (23 Â°C) than in summer (28 Â°C), as expected for a small Afrotropical bird. In the first year of the study, mean whole animal basal metabolic rate (BMR) of Cape White-eyes was significantly lower in winter than in summer, while in the second year of the study this trend was reversed, and in the middle two seasons there was no significant difference in BMR. Differences in mean temperature and mean rainfall between seasons could not account for the seasonal trends in BMR. We conclude that seasonal trends in avian BMR may vary between years, within a population.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010499</affiliation-url><afid>60010499</afid><affilname>University of KwaZulu-Natal</affilname><name-variant>University of KwaZulu-Natal</name-variant><affiliation-city/><affiliation-country>South Africa</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55899213900</author-url><authid>55899213900</authid><authname>Thompson L.</authname><surname>Thompson</surname><given-name>Lindy J.</given-name><initials>L.J.</initials><afid>60010499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55722067100</author-url><authid>55722067100</authid><authname>Brown M.</authname><surname>Brown</surname><given-name>Mark</given-name><initials>M.</initials><afid>60010499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005341100</author-url><authid>7005341100</authid><authname>Downs C.</authname><surname>Downs</surname><given-name>Colleen T.</given-name><initials>C.T.</initials><afid>60010499</afid></author><authkeywords>Afrotropical | Basal metabolic rate | Cape White-eye | Seasonal variation | Zosterops virens</authkeywords><intid>1785811665</intid><source-id>14901</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928943956"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928943956?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928943956&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928943956&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0268401215000407"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928943956</prism:url><dc:identifier>SCOPUS_ID:84928943956</dc:identifier><eid>2-s2.0-84928943956</eid><dc:title>Antecedents of social presence and gratification of social connection needs in SNS: A study of Twitter users and their mobile and non-mobile usage</dc:title><dc:creator>Han S.</dc:creator><prism:publicationName>International Journal of Information Management</prism:publicationName><prism:issn>02684012</prism:issn><prism:volume>35</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:pageRange>459-471</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>1 August 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijinfomgt.2015.04.004</prism:doi><pii>S0268401215000407</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. As the use of social network sites (SNS) proliferates, more people than ever are becoming connected to one another. Nonetheless, we have little knowledge about how certain characteristics of SNS fulfill their users' need for social connection and enhance this connectivity. Building on uses and gratification theory, this study of Twitter users posits that users are drawn to SNS to fulfill their social connection needs and that the sense of social presence SNS engender plays a significant role in fulfilling these needs. We argue that this sense of social presence is formed by immediacy-related characteristics (represented as immediate feedback) and intimacy-related characteristics (represented as feelings of privacy and responsiveness) of SNS in Twitter. We further investigate how those characteristics operate differently on mobile and non-mobile users. To test our hypotheses, we conducted a cross-sectional survey of 798 Twitter users and analyzed their responses using a structural equation model. The results support our research model. Furthermore, analysis of the responses of 367 primarily mobile users and 161 primarily desktop users indicates that the linkage between immediacy-related characteristics and social presence is stronger and the linkage between intimacy-related characteristics and social presence is weaker among mobile users than desktop users of Twitter.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009950</affiliation-url><afid>60009950</afid><affilname>Chosun University</affilname><name-variant>Chosun University</name-variant><affiliation-city>Gwangju</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032144</affiliation-url><afid>60032144</afid><affilname>Korea Advanced Institute of Science &amp; Technology</affilname><name-variant>KAIST</name-variant><affiliation-city>Yusong</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56623621100</author-url><authid>56623621100</authid><authname>Han S.</authname><surname>Han</surname><given-name>Sehee</given-name><initials>S.</initials><afid>60016912</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56202063200</author-url><authid>56202063200</authid><authname>Min J.</authname><surname>Min</surname><given-name>Jinyoung</given-name><initials>J.</initials><afid>60009950</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:26643147500</author-url><authid>26643147500</authid><authname>Lee H.</authname><surname>Lee</surname><given-name>Heeseok</given-name><initials>H.</initials><afid>60032144</afid></author><authkeywords>Gratification of social connection need | Immediacy | Intimacy | Mobile SNS | Social presence</authkeywords><intid>2035871554</intid><source-id>15631</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929322386"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929322386?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929322386&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929322386&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315007895"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929322386</prism:url><dc:identifier>SCOPUS_ID:84929322386</dc:identifier><eid>2-s2.0-84929322386</eid><dc:title>Two young women with severe coronary arterial ostial narrowing: A potential subtype of Takayasu arteritis</dc:title><dc:creator>Yang M.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>189</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>94-95</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>1 August 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.070</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008706</affiliation-url><afid>60008706</afid><affilname>Peking Union Medical College</affilname><name-variant>Peking Union Medical College Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008706</affiliation-url><afid>60008706</afid><affilname>Peking Union Medical College</affilname><name-variant>Peking Union Medical College Hospital</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56229584300</author-url><authid>56229584300</authid><authname>Yang M.</authname><surname>Yang</surname><given-name>Ming</given-name><initials>M.</initials><afid>60008706</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56577140200</author-url><authid>56577140200</authid><authname>Bai X.</authname><surname>Bai</surname><given-name>Xiaoyin</given-name><initials>X.</initials><afid>60008706</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56576630700</author-url><authid>56576630700</authid><authname>Xu J.</authname><surname>Xu</surname><given-name>Jiachen</given-name><initials>J.</initials><afid>60008706</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56577120000</author-url><authid>56577120000</authid><authname>Ni J.</authname><surname>Ni</surname><given-name>Jianjiao</given-name><initials>J.</initials><afid>60008706</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56576732600</author-url><authid>56576732600</authid><authname>Tang J.</authname><surname>Tang</surname><given-name>Jieying</given-name><initials>J.</initials><afid>60008706</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56576906800</author-url><authid>56576906800</authid><authname>Zeng Y.</authname><surname>Zeng</surname><given-name>Yong</given-name><initials>Y.</initials><afid>60008706</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56577189400</author-url><authid>56577189400</authid><authname>Fang Q.</authname><surname>Fang</surname><given-name>Quan</given-name><initials>Q.</initials><afid>60008706</afid></author><authkeywords>Acute coronary syndrome | Disease management | Takayasu arteritis</authkeywords><intid>2035941298</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929352999"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929352999?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929352999&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929352999&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527315007974"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929352999</prism:url><dc:identifier>SCOPUS_ID:84929352999</dc:identifier><eid>2-s2.0-84929352999</eid><dc:title>Percutaneous transapical closure of cardiac apex with an ADO-II device after successful transapical transcatheter prosthetic mitral paravalvular leak closure</dc:title><dc:creator>Iyisoy A.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>189</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>289-292</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>1 August 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2015.04.076</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026716</affiliation-url><afid>60026716</afid><affilname>Gulhane Military Medical Academy</affilname><name-variant>GÃ¼lhane Military Medical Academy</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026716</affiliation-url><afid>60026716</afid><affilname>Gulhane Military Medical Academy</affilname><name-variant>GÃ¼lhane Military Medical Academy</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026661</affiliation-url><afid>60026661</afid><affilname>Mevki Military Hospital</affilname><name-variant>Ankara Mevki Military Hospital</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6701679254</author-url><authid>6701679254</authid><authname>Iyisoy A.</authname><surname>Iyisoy</surname><given-name>Atila</given-name><initials>A.</initials><afid>60026716</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55332922500</author-url><authid>55332922500</authid><authname>Ozturk C.</authname><surname>Ozturk</surname><given-name>Cengiz</given-name><initials>C.</initials><afid>60026716</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7006617047</author-url><authid>7006617047</authid><authname>Celik T.</authname><surname>Celik</surname><given-name>Turgay</given-name><initials>T.</initials><afid>60026716</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8343534000</author-url><authid>8343534000</authid><authname>Demirkol S.</authname><surname>Demirkol</surname><given-name>Sait</given-name><initials>S.</initials><afid>60026661</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6701739555</author-url><authid>6701739555</authid><authname>Cingoz F.</authname><surname>Cingoz</surname><given-name>Faruk</given-name><initials>F.</initials><afid>60026716</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:21935592800</author-url><authid>21935592800</authid><authname>Unlu M.</authname><surname>Unlu</surname><given-name>Murat</given-name><initials>M.</initials><afid>60026716</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:22233891000</author-url><authid>22233891000</authid><authname>Arslan Z.</authname><surname>Arslan</surname><given-name>Zekeriya</given-name><initials>Z.</initials><afid>60026661</afid></author><authkeywords>An ado-ii device | Percutaneous transapical closure of cardiac apex | Prosthetic mitral paravalvular leak closure</authkeywords><intid>535947630</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925944276"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925944276?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925944276&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925944276&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0889157515000587"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925944276</prism:url><dc:identifier>SCOPUS_ID:84925944276</dc:identifier><eid>2-s2.0-84925944276</eid><dc:title>Characterisation of the lipid and protein fraction of fresh camel meat and the associated changes during refrigerated storage</dc:title><dc:creator>Maqsood S.</dc:creator><prism:publicationName>Journal of Food Composition and Analysis</prism:publicationName><prism:issn>08891575</prism:issn><prism:volume>41</prism:volume><prism:pageRange>212-220</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jfca.2014.12.027</prism:doi><pii>S0889157515000587</pii><dc:description>Â© 2015 Elsevier Inc. Characterisation of protein and lipid fractions of fresh camel meat and their associated changes were investigated during 9 days of refrigerated storage. Camel meat lipids contained palmitic acid (C16:0) as dominant fatty acid followed by stearic acid (C18:0) and oleic acid (C18:1 n-9). Content of total saturated fatty acid (SFA) and unsaturated fatty acids were 58.46 and 41.5. mg/100. g, respectively. Total unsaturated fatty acids were reduced at the end of storage. Lipids underwent rapid oxidation as indicated by increase in peroxide value (PV) and thiobarbituric acid reactive substances (TBARS). Decrease in total haem pigment, myoglobin and haemoglobin content with concomitant decrease in redness (a* value) was noticed during the storage. Protein extractability, solubility, TCA-soluble peptides and drip loss increased during storage indicating proteolysis and degradation of structural proteins, which was also evident from SDS-PAGE pattern. This further corroborates with the decrease of textural parameters like hardness, cohesiveness, springiness and gumminess. Thus, the protein and lipid fraction of camel meat underwent considerable changes during refrigerated storage. Therefore, the behaviour of protein and lipid fraction in camel meat during refrigerated storage could provide better understanding of the processing and storage conditions.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008665</affiliation-url><afid>60008665</afid><affilname>United Arab Emirates University</affilname><name-variant>United Arab Emirates University</name-variant><affiliation-city>Al Ain</affiliation-city><affiliation-country>United Arab Emirates</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60071768</affiliation-url><afid>60071768</afid><affilname>Sultan Qaboos University</affilname><name-variant>Sultan Qaboos University</name-variant><affiliation-city>Muscat</affiliation-city><affiliation-country>Oman</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56584790900</author-url><authid>56584790900</authid><authname>Maqsood S.</authname><surname>Maqsood</surname><given-name>Sajid</given-name><initials>S.</initials><afid>60008665</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56584787200</author-url><authid>56584787200</authid><authname>Abushelaibi A.</authname><surname>Abushelaibi</surname><given-name>Aisha</given-name><initials>A.</initials><afid>60008665</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:53878023300</author-url><authid>53878023300</authid><authname>Manheem K.</authname><surname>Manheem</surname><given-name>Kusaimah</given-name><initials>K.</initials><afid>60008665</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6603897991</author-url><authid>6603897991</authid><authname>Kadim I.</authname><surname>Kadim</surname><given-name>Isam Tawfik</given-name><initials>I.T.</initials><afid>60071768</afid></author><authkeywords>Camel meat | Fatty acid analysis | Food analysis | Food composition | Food processing | Lipid oxidation | Protein characterisation | Proteolysis</authkeywords><intid>1035381876</intid><source-id>20582</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928485205"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928485205?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928485205&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928485205&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928493115300151"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928485205</prism:url><dc:identifier>SCOPUS_ID:84928485205</dc:identifier><eid>2-s2.0-84928485205</eid><dc:title>Influence of ceria nanoparticles on chemical structure and properties of segmented polyesters</dc:title><dc:creator>El Fray M.</dc:creator><prism:publicationName>Materials Science and Engineering C</prism:publicationName><prism:issn>09284931</prism:issn><prism:volume>53</prism:volume><prism:pageRange>15-22</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>1 August 2015</prism:coverDisplayDate><prism:doi>10.1016/j.msec.2015.04.010</prism:doi><pii>S0928493115300151</pii><dc:description>Â© 2015 Published by Elsevier B.V. In this work, we present new nanocomposite materials derived from segmented copolyesters, comprising ethylene terephthalate (PET) segments and dimerized linoleic acid (DLA), and nanometric cerium oxide particles (CeO&lt;inf&gt;2&lt;/inf&gt;). Nanoparticles were incorporated in situ during polycondensation in various concentrations, from 0.1 up to 0.6 wt.%. It was found that preparation of nanocomposites in situ, during polycondensation, had no significant influence on changes in segmental composition as determined from &lt;sup&gt;1&lt;/sup&gt;H and &lt;sup&gt;13&lt;/sup&gt;C, as well as 2D NMR. Thermal analysis and calculated degree of crystallinity showed that increasing concentration of ceria nanoparticles lead to an increase in mass content of PET crystallites in hard segments. The XRD investigations also showed an increased intensity of characteristic signals with increasing ceria concentration. Simultaneously, the incorporation of CeO&lt;inf&gt;2&lt;/inf&gt; led to an increase in tensile strength and elongation at break, indicating a reinforcing and plasticizing effect of ceria nanoparticles. However, the modulus at 10% strain decreased with increasing amount of nanoparticles. The in vitro culture of human cardiac progenitor cells (hCPCs) on the new materials indicated a homogenous cell displacement across the samples after 5 days with no signs of cytotoxicity, indicating good biocompatibility in vitro of CeO&lt;inf&gt;2&lt;/inf&gt;-based nanocomposites and a potential for biomedical applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104305</affiliation-url><afid>60104305</afid><affilname>West Pomeranian University of Technology</affilname><name-variant>West Pomeranian University of Technology</name-variant><affiliation-city>Szczecin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002414</affiliation-url><afid>60002414</afid><affilname>National Institute for Materials Science Tsukuba</affilname><name-variant>Natl. Inst. for Materials Science</name-variant><affiliation-city>Tsukuba</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027509</affiliation-url><afid>60027509</afid><affilname>Universita degli Studi di Roma Tor Vergata</affilname><name-variant>University of Rome Tor Vergata</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55407773900</author-url><authid>55407773900</authid><authname>El Fray M.</authname><surname>El Fray</surname><given-name>M.</given-name><initials>M.</initials><afid>60104305</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56606180600</author-url><authid>56606180600</authid><authname>Strzalkowska D.</authname><surname>Strzalkowska</surname><given-name>D.</given-name><initials>D.</initials><afid>60104305</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23995457800</author-url><authid>23995457800</authid><authname>Mandoli C.</authname><surname>Mandoli</surname><given-name>C.</given-name><initials>C.</initials><afid>60002414</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23995762600</author-url><authid>23995762600</authid><authname>Pagliari F.</authname><surname>Pagliari</surname><given-name>F.</given-name><initials>F.</initials><afid>60027509</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003866711</author-url><authid>7003866711</authid><authname>Di Nardo P.</authname><surname>Di Nardo</surname><given-name>P.</given-name><initials>P.</initials><afid>60027509</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005813511</author-url><authid>7005813511</authid><authname>Traversa E.</authname><surname>Traversa</surname><given-name>E.</given-name><initials>E.</initials><afid>60002414</afid></author><authkeywords>Biocompatibility | Nanocomposites | PET-DLA copolyesters | Phase structure</authkeywords><intid>1035789729</intid><source-id>17813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929206971"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929206971?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929206971&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929206971&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0091743515001474"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929206971</prism:url><dc:identifier>SCOPUS_ID:84929206971</dc:identifier><eid>2-s2.0-84929206971</eid><dc:title>Psychological distress as a determinant of changes in body mass index over a period of 10 years</dc:title><dc:creator>Cloostermans L.</dc:creator><prism:publicationName>Preventive Medicine</prism:publicationName><prism:issn>00917435</prism:issn><prism:eIssn>10960260</prism:eIssn><prism:volume>77</prism:volume><prism:pageRange>17-22</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ypmed.2015.04.020</prism:doi><pii>S0091743515001474</pii><dc:description>Â© 2015 Elsevier Inc. Objective: To examine the longitudinal relationship between psychological distress and body mass index (BMI) changes over a period of five and ten years. Method: Data were used from the Dutch, prospective, population based Doetinchem Cohort study over the period 1995/1999 until 2005/2009 (N=5504). Psychological distress was assessed using the Mental Health Inventory (MHI-5). BMI (kg/m&lt;sup&gt;2&lt;/sup&gt;) was calculated from measured body height and body weight. GEE analyses were used to examine the relationship between psychological distress at baseline and BMI change, and the development of overweight over five years. Linear and logistic regression analyses were used to examine these relations over ten years. Results: Psychological distress predicted an extra overall increase in BMI of 0.14kg/m&lt;sup&gt;2&lt;/sup&gt; (95% CI 0.03-0.25) over five years and an increase of 0.18kg/m&lt;sup&gt;2&lt;/sup&gt; (95% CI 0.01-0.35) over ten years, when comparing psychologically distressed participants to psychologically healthy participants. This was especially the case among persons with normal weight (five years; B=0.26kg/m&lt;sup&gt;2&lt;/sup&gt;, 95% CI=0.12-0.40/ten years; B=0.32kg/m&lt;sup&gt;2&lt;/sup&gt; 95% CI=0.11-0.53) and moderate overweight (five years: B=0.18kg/m&lt;sup&gt;2&lt;/sup&gt;, 95% CI=0.02-0.35) at baseline. Psychological distress did not predict the development of overweight five and ten years later. Conclusion: The results in this study indicated that psychological distress predicted an increased risk in gaining weight, but did not result in an increased risk for developing overweight.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026125</affiliation-url><afid>60026125</afid><affilname>National Institute of Public Health and the Environment</affilname><name-variant>National Institute for Public Health and the Environment</name-variant><affiliation-city>Bilthoven</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001997</affiliation-url><afid>60001997</afid><affilname>VU University Medical Center</affilname><name-variant>Free University Hospital</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56320284600</author-url><authid>56320284600</authid><authname>Cloostermans L.</authname><surname>Cloostermans</surname><given-name>Laura</given-name><initials>L.</initials><afid>60026125</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6701594535</author-url><authid>6701594535</authid><authname>Picavet H.</authname><surname>Picavet</surname><given-name>H. Susan J</given-name><initials>H.S.J.</initials><afid>60026125</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603558508</author-url><authid>6603558508</authid><authname>Bemelmans W.</authname><surname>Bemelmans</surname><given-name>Wanda J E</given-name><initials>W.J.E.</initials><afid>60026125</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7003301273</author-url><authid>7003301273</authid><authname>Verschuren W.</authname><surname>Verschuren</surname><given-name>W. M Monique</given-name><initials>W.M.M.</initials><afid>60026125</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602603836</author-url><authid>6602603836</authid><authname>Proper K.</authname><surname>Proper</surname><given-name>Karin I.</given-name><initials>K.I.</initials><afid>60026125</afid><afid>60001997</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602603836</author-url><authid>6602603836</authid><authname>Proper K.</authname><surname>Proper</surname><given-name>Karin I.</given-name><initials>K.I.</initials><afid>60026125</afid><afid>60001997</afid></author><authkeywords>Body mass index | Body weight | Cohort studies | Mental health</authkeywords><intid>1785918106</intid><source-id>17665</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924527833"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924527833?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924527833&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924527833&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0889157515000356"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924527833</prism:url><dc:identifier>SCOPUS_ID:84924527833</dc:identifier><eid>2-s2.0-84924527833</eid><dc:title>Phenolic compounds and antioxidant activity of Macedonian red wines</dc:title><dc:creator>Ivanova-Petropulos V.</dc:creator><prism:publicationName>Journal of Food Composition and Analysis</prism:publicationName><prism:issn>08891575</prism:issn><prism:volume>41</prism:volume><prism:pageRange>1-14</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jfca.2015.01.002</prism:doi><pii>S0889157515000356</pii><dc:description>Â© 2015 Elsevier Inc. The quantitative composition of phenolic compounds and antioxidant activity of Vranec, Merlot and Cabernet Sauvignon wines produced in 2006, 2007 and 2008 were determined and compared. The phenolic profile was established using high-performance liquid chromatography coupled with diode array detector and on line mass spectrometry (HPLC-DAD-ESI-MS and MS/MS) technique. A total of 65 phenolic compounds were determined in the wines including 14 anthocyanins, 18 pyranoanthocyanins, 16 flavonols, 8 hydroxycinnamic acids and their derivatives, 4 stilbenes, gallic acid and 4 flavan-3-ols. Hydroxyphenyl-pyranoanthocyanin content is reported for the first time in Macedonian red wines, ranging between 1.09 and 10.4. mg/L. 10-Carboxy-pyranomalvidin-3-glucoside and 10- p-hydroxyphenyl-pyranomalvidin-3-glucoside were the main compounds from vitisin-like and hydroxyphenyl-like pyranoanthocyanins, respectively. Vranec wines produced in 2008 presented highest concentration of anthocyanins (508. mg/L), vitisins (53.1. mg/L), hydroxyphenyl-pyranoanthocyanins (7.35. mg/L), flavonols (120. mg/L), hydroxycinnamic acid derivatives (352. mg/L), flavan-3-ols (98.9. mg/L), stilbenes (43.9. mg/L) and antioxidant activity (12.5. mM/L TE). Cabernet Sauvignon and Merlot had highest flavonols (152 and 119. mg/L) and flavan-3-ols concentration (150 and 111. mg/L) in 2006 and 2007, respectively, indicating the important role of variety, climate, storage conditions and winemaking techniques in wine phenolic composition. Factor analysis showed classification of wines according to the variety and content of the phenolic families and color characteristics.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106263509</affiliation-url><afid>106263509</afid><affilname>Goce Delcev University</affilname><name-variant>Goce Delcev University</name-variant><affiliation-city/><affiliation-country>Macedonia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000823</affiliation-url><afid>60000823</afid><affilname>Universidad de Castilla-La Mancha</affilname><name-variant>University of Castilla-La Mancha</name-variant><affiliation-city>Ciudad Real</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004737</affiliation-url><afid>60004737</afid><affilname>Pecsi Tudomanyegyetem</affilname><name-variant>University of Pecs</name-variant><affiliation-city>Pecs</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072629</affiliation-url><afid>60072629</afid><affilname>SS Cyril and Methodius University</affilname><name-variant>Ss. Cyril and Methodius University</name-variant><affiliation-city>Skopje</affiliation-city><affiliation-country>Macedonia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072629</affiliation-url><afid>60072629</afid><affilname>SS Cyril and Methodius University</affilname><name-variant>Ss. Cyril and Methodius University</name-variant><affiliation-city>Skopje</affiliation-city><affiliation-country>Macedonia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004737</affiliation-url><afid>60004737</afid><affilname>Pecsi Tudomanyegyetem</affilname><name-variant>University of Pecs</name-variant><affiliation-city>Pecs</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55811322700</author-url><authid>55811322700</authid><authname>Ivanova-Petropulos V.</authname><surname>Ivanova-Petropulos</surname><given-name>Violeta</given-name><initials>V.</initials><afid>106263509</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55919617300</author-url><authid>55919617300</authid><authname>HermosÃ­n-GutiÃ©rrez I.</authname><surname>HermosÃ­n-GutiÃ©rrez</surname><given-name>Isidro</given-name><initials>I.</initials><afid>60000823</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6701406703</author-url><authid>6701406703</authid><authname>Boros B.</authname><surname>Boros</surname><given-name>BorbÃ¡la</given-name><initials>B.</initials><afid>60004737</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55892871100</author-url><authid>55892871100</authid><authname>Stefova M.</authname><surname>Stefova</surname><given-name>Marina</given-name><initials>M.</initials><afid>60072629</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:35563332500</author-url><authid>35563332500</authid><authname>Stafilov T.</authname><surname>Stafilov</surname><given-name>TrajÄe</given-name><initials>T.</initials><afid>60072629</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:35796372900</author-url><authid>35796372900</authid><authname>Vojnoski B.</authname><surname>Vojnoski</surname><given-name>Borimir</given-name><initials>B.</initials><afid>60072629</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8774093300</author-url><authid>8774093300</authid><authname>DÃ¶rnyei Ã.</authname><surname>DÃ¶rnyei</surname><given-name>Ãgnes</given-name><initials>Ã.</initials><afid>60004737</afid><afid>60004737</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8774093300</author-url><authid>8774093300</authid><authname>DÃ¶rnyei Ã.</authname><surname>DÃ¶rnyei</surname><given-name>Ãgnes</given-name><initials>Ã.</initials><afid>60004737</afid><afid>60004737</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003343781</author-url><authid>7003343781</authid><authname>KilÃ¡r F.</authname><surname>KilÃ¡r</surname><given-name>Ferenc</given-name><initials>F.</initials><afid>60004737</afid><afid>60004737</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7003343781</author-url><authid>7003343781</authid><authname>KilÃ¡r F.</authname><surname>KilÃ¡r</surname><given-name>Ferenc</given-name><initials>F.</initials><afid>60004737</afid><afid>60004737</afid></author><authkeywords>Anthocyanins | Antioxidant activity | Food analysis | Food composition | HPLC-DAD-ESI-MS | Phenolic compounds | Pigments | Red wine | Vranec</authkeywords><intid>2035163908</intid><source-id>20582</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927728319"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927728319?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927728319&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927728319&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S002199911500220X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927728319</prism:url><dc:identifier>SCOPUS_ID:84927728319</dc:identifier><eid>2-s2.0-84927728319</eid><dc:title>A diffuse-interface immersed-boundary method for two-dimensional simulation of flows with moving contact lines on curved substrates</dc:title><dc:creator>Liu H.</dc:creator><prism:publicationName>Journal of Computational Physics</prism:publicationName><prism:issn>00219991</prism:issn><prism:eIssn>10902716</prism:eIssn><prism:volume>294</prism:volume><prism:pageRange>484-502</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jcp.2015.03.059</prism:doi><pii>S002199911500220X</pii><dc:description>Â© 2015 Elsevier Inc. We propose an approach to simulate flows with moving contact lines (MCLs) on curved substrates on a Cartesian mesh. The approach combines an immersed boundary method with a three-component diffuse-interface model and a characteristic MCL model. The immersed boundary method is able to accurately enforce the no-slip boundary condition at the solid surface, thereby circumventing the penetration of the gas and the liquid into the solid by convection. On the other hand, using the three-component diffuse-interface model can prevent the gas and liquid from infiltrating into the solid substrate through the diffusive fluxes during the interface evolution. A combination of these two methods appears to effectively conserve the mass of the phases in the computation. The characteristic MCL model not only allows the contact lines to move on the curved boundaries, but makes the gas-liquid interface to intersect the solid object at an angle in consistence with the prescribed contact angle, even with the variation of surface tangent at the solid substrate. We examine the performance of the approach through a variety of numerical experiments. The mass conservation and interface shapes at equilibrium were tested through the simulation of drop spreading on a circular cylinder. The dynamic behaviors of moving contact lines were validated by simulating the droplet spreading on a flat substrate, and we compared the numerical results against theoretical predictions and previous experimental observations. The method was also applied to the simulations of flows with curved boundaries and moving contact lines, such as drop impact on a sphere and water entry of a sphere. Finally, we studied the penetration process of a two-dimensional drop into a porous substrate that consists of a cluster of circular cylinders.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019118</affiliation-url><afid>60019118</afid><affilname>University of Science and Technology of China</affilname><name-variant>Univ. of Sci. and Technol. of China</name-variant><affiliation-city>Hefei</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56593858400</author-url><authid>56593858400</authid><authname>Liu H.</authname><surname>Liu</surname><given-name>Hao Ran</given-name><initials>H.R.</initials><afid>60019118</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55178080300</author-url><authid>55178080300</authid><authname>Ding H.</authname><surname>Ding</surname><given-name>Hang</given-name><initials>H.</initials><afid>60019118</afid></author><authkeywords>Complex geometry | Diffuse interface model | Immersed boundary method | Interfacial dynamics | Moving contact lines</authkeywords><intid>1535666949</intid><source-id>13191</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84921467852"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84921467852?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84921467852&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84921467852&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S2352154615000121"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84921467852</prism:url><dc:identifier>SCOPUS_ID:84921467852</dc:identifier><eid>2-s2.0-84921467852</eid><dc:title>Catecholamine mechanisms in the prefrontal cortex: Proven strategies for enhancing higher cognitive function</dc:title><dc:creator>Berridge C.</dc:creator><prism:publicationName>Current Opinion in Behavioral Sciences</prism:publicationName><prism:eIssn>23521546</prism:eIssn><prism:volume>4</prism:volume><prism:pageRange>33-40</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cobeha.2015.01.002</prism:doi><pii>S2352154615000121</pii><dc:description>Â© 2015 Elsevier Ltd. Multiple psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), are associated with prefrontal cognitive dysfunction. The catecholamine neurotransmitters, norepinephrine and dopamine, are key modulators of prefrontal cognition. Moreover, pharmacological treatments for prefrontal dysfunction target catecholamines. Recent studies identify neurocircuitry, receptor mechanisms and intracellular pathways involved in catecholamine modulation of prefrontal cognition. Consistent with these observations, additional research identifies a pivotal role of prefrontal catecholamines in the cognition-enhancing effects of all approved pharmacological treatments for ADHD. Combined, this research suggests the clinical efficacy of ADHD medications involve catecholamine receptor mediated modulation of specific intracellular pathways and ion channels that strengthen PFC circuit function. Novel medications targeting different components of these pathways may result in improved treatments of PFC cognitive dysfunction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032179</affiliation-url><afid>60032179</afid><affilname>University of Wisconsin Madison</affilname><name-variant>University of Wisconsin</name-variant><affiliation-city>Madison</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017994</affiliation-url><afid>60017994</afid><affilname>Yale University School of Medicine</affilname><name-variant>Yale University School of Medicine</name-variant><affiliation-city>New Haven</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7003720865</author-url><authid>7003720865</authid><authname>Berridge C.</authname><surname>Berridge</surname><given-name>Craig W.</given-name><initials>C.W.</initials><afid>60032179</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006151102</author-url><authid>7006151102</authid><authname>Arnsten A.</authname><surname>Arnsten</surname><given-name>Amy F T</given-name><initials>A.F.T.</initials><afid>60017994</afid></author><intid>1784655122</intid><source-id>21100363813</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84926305703"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84926305703?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84926305703&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84926305703&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0887233315000272"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84926305703</prism:url><dc:identifier>SCOPUS_ID:84926305703</dc:identifier><eid>2-s2.0-84926305703</eid><dc:title>Gold nanoparticles do not induce myotube cytotoxicity but increase the susceptibility to cell death</dc:title><dc:creator>Leite P.</dc:creator><prism:publicationName>Toxicology in Vitro</prism:publicationName><prism:issn>08872333</prism:issn><prism:eIssn>18793177</prism:eIssn><prism:volume>29</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:pageRange>819-827</prism:pageRange><prism:coverDate>2015-08-01</prism:coverDate><prism:coverDisplayDate>August 01, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.tiv.2015.02.010</prism:doi><pii>S0887233315000272</pii><dc:description>Â© 2015 Elsevier Ltd. Gold nanoparticles (AuNP) have been widely used for many applications, including as biological carriers. A better understanding concerning AuNP safety on muscle cells is crucial, since it could be a potential tool in the nanomedicine field. Here, we describe the impact of polyethylene glycol-coated gold nanoparticles (PEG-AuNP) interaction with differentiated skeletal muscle C2C12 cells on cell viability, mitochondria function, cell signaling related to survival, cytokine levels and susceptibility to apoptosis. Intracellular localization of 4.5. nm PEG-AuNP diameter size was evidenced by STEM-in-SEM in myotube cells. Methods for cytotoxicity analysis showed that PEG-AuNP did not affect cell viability, but intracellular ATP levels and mitochondrial membrane potential increased. Phosphorylation of ERK was not altered but p-AKT levels reduced (. p&lt;. 0.01). Pre-treatment of cells with PEG-AuNP followed by staurosporine induction increased the caspases-3/7 activity. Indeed, cytokines analysis revealed a sharp increase of IFN-Î³ and TGF-Î²1 levels after PEG-AuNP treatment, suggesting that inflammatory and fibrotic phenotypes process were activated. These data demonstrate that PEG-AuNP affect the myotube physiology leading these cells to be more susceptible to death stimuli in the presence of staurosporine. Altogether, these results present evidence that PEG-AuNP affect the susceptibility to apoptosis of muscle cells, contributing to development of safer strategies for intramuscular delivery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115125753</affiliation-url><afid>115125753</afid><affilname>DivisÃ£o de Biologia Celular e Bioengenharia</affilname><name-variant>DivisÃ£o de Biologia Celular e Bioengenharia</name-variant><affiliation-city/><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069940</affiliation-url><afid>60069940</afid><affilname>Instituto Nacional de Metrologia</affilname><name-variant>Instituto Nacional de Metrologia</name-variant><affiliation-city>Rio de Janeiro</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001865</affiliation-url><afid>60001865</afid><affilname>Universidade Federal Fluminense</affilname><name-variant>Universidade Federal Fluminense</name-variant><affiliation-city>Niteroi</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35740984000</author-url><authid>35740984000</authid><authname>Leite P.</authname><surname>Leite</surname><given-name>Paulo EmÃ­lio CorrÃªa</given-name><initials>P.E.C.</initials><afid>115125753</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55065609600</author-url><authid>55065609600</authid><authname>Pereira M.</authname><surname>Pereira</surname><given-name>Mariana Rodrigues</given-name><initials>M.R.</initials><afid>60001865</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56581127600</author-url><authid>56581127600</authid><authname>Santos C.</authname><surname>Santos</surname><given-name>Carlos Antonio do Nascimento</given-name><initials>C.A.d.N.</initials><afid>115125753</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7202215092</author-url><authid>7202215092</authid><authname>Campos A.</authname><surname>Campos</surname><given-name>Andrea Porto Carreiro</given-name><initials>A.P.C.</initials><afid>60069940</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56581781800</author-url><authid>56581781800</authid><authname>Esteves T.</authname><surname>Esteves</surname><given-name>Ticiana Mota</given-name><initials>T.M.</initials><afid>115125753</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602186629</author-url><authid>6602186629</authid><authname>Granjeiro J.</authname><surname>Granjeiro</surname><given-name>JosÃ© Mauro</given-name><initials>J.M.</initials><afid>115125753</afid><afid>60001865</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602186629</author-url><authid>6602186629</authid><authname>Granjeiro J.</authname><surname>Granjeiro</surname><given-name>JosÃ© Mauro</given-name><initials>J.M.</initials><afid>115125753</afid><afid>60001865</afid></author><authkeywords>Bioengineering | Gold nanoparticle | Inflammation | Nanotoxicity | PEG | Skeletal muscle</authkeywords><intid>535431864</intid><source-id>25224</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226483"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226483?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226483&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226483&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226483</prism:url><dc:identifier>SCOPUS_ID:84930226483</dc:identifier><eid>2-s2.0-84930226483</eid><dc:title>Development of clinical practice guidelines for supportive care in childhood cancerâprioritization of topics using a Delphi approach</dc:title><dc:creator>Loeffen E.</dc:creator><prism:publicationName>Supportive Care in Cancer</prism:publicationName><prism:issn>09414355</prism:issn><prism:eIssn>14337339</prism:eIssn><prism:volume>23</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>1987-1995</prism:pageRange><prism:coverDate>2015-07-30</prism:coverDate><prism:coverDisplayDate>30 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00520-014-2559-7</prism:doi><dc:description>Â© 2014, Springer-Verlag Berlin Heidelberg. Introduction: Currently, very few guidelines for supportive care for children with cancer exist. In the Netherlands, nationwide guidelines are over 10Â years old and mostly based on expert opinion. Consequently, there is growing support and need for clinical practice guidelines (CPGs), which ought to be developed with a well-defined methodology and include a systematic search of literature, evidence summaries, and a transparent description of the decision process for the final recommendations. Development of CPGs is time consuming; therefore, it is important to prioritize topics for which there is the greatest clinical demand. Objectives: This study aims to prioritize childhood cancer supportive care topics for development of CPGs. Methods: A Delphi survey consisting of two rounds was conducted to prioritize relevant childhood cancer supportive care topics for the development of CPGs. A group of experts comprising 15 pediatric oncologists, 15 pediatric oncology nurses, and 15 general pediatricians involved in care for childhood cancer patients were invited to participate. All relevant supportive care topics in childhood cancer were rated. Results: In both rounds, 36 panellists (82Â %) responded. Agreement between panellists was very good, with an intraclass correlation coefficient of 0.918 (95Â % confidence interval (CI) = 0.849â0.966, p &lt; 0.001) in round 2. The ten topics with the highest score in the final round were infection, sepsis, febrile neutropenia, pain, nausea/vomiting, restrictions in daily life and activities, palliative care, procedural sedation, terminal care, and oral mucositis. Conclusion: We successfully used a Delphi survey to prioritize childhood cancer supportive care topics for the development of CPGs. This is a first step towards uniform and evidence-based Dutch guidelines in supportive care in childhood cancer. Even though performed nationally, we believe that this study can also be regarded as an example starting point for international development of CPGs in the field of supportive care in cancer or any other field for that matter.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070240</affiliation-url><afid>60070240</afid><affilname>University of Groningen Medical Center Beatrix Children's Hospital</affilname><name-variant>University Medical Center Groningen</name-variant><affiliation-city>Groningen</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60070178</affiliation-url><afid>60070178</afid><affilname>Emma Kinderziekenhuis</affilname><name-variant>University of Amsterdam</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032114</affiliation-url><afid>60032114</afid><affilname>Erasmus University Medical Center</affilname><name-variant>Erasmus Medical Center</name-variant><affiliation-city>Rotterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001997</affiliation-url><afid>60001997</afid><affilname>VU University Medical Center</affilname><name-variant>Free University Hospital</name-variant><affiliation-city>Amsterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015618</affiliation-url><afid>60015618</afid><affilname>Leiden University Medical Center - LUMC</affilname><name-variant>University Hospital</name-variant><affiliation-city>Leiden</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032724</affiliation-url><afid>60032724</afid><affilname>University Medical Center Utrecht</affilname><name-variant>University Medical Center Utrecht</name-variant><affiliation-city>Utrecht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002573</affiliation-url><afid>60002573</afid><affilname>Radboud University Nijmegen Medical Centre</affilname><name-variant>University Hospital Nijmegen</name-variant><affiliation-city>Nijmegen</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032114</affiliation-url><afid>60032114</afid><affilname>Erasmus University Medical Center</affilname><name-variant>Erasmus Medical Center</name-variant><affiliation-city>Rotterdam</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56255674100</author-url><authid>56255674100</authid><authname>Loeffen E.</authname><surname>Loeffen</surname><given-name>E. A H</given-name><initials>E.A.H.</initials><afid>60070240</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:28267954400</author-url><authid>28267954400</authid><authname>Mulder R.</authname><surname>Mulder</surname><given-name>R. L.</given-name><initials>R.L.</initials><afid>60070178</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005620037</author-url><authid>7005620037</authid><authname>Kremer L.</authname><surname>Kremer</surname><given-name>L. C M</given-name><initials>L.C.M.</initials><afid>60070178</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701452876</author-url><authid>6701452876</authid><authname>Michiels E.</authname><surname>Michiels</surname><given-name>E. M C</given-name><initials>E.M.C.</initials><afid>60032114</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6601960999</author-url><authid>6601960999</authid><authname>Abbink F.</authname><surname>Abbink</surname><given-name>F. C H</given-name><initials>F.C.H.</initials><afid>60001997</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7102282023</author-url><authid>7102282023</authid><authname>Ball L.</authname><surname>Ball</surname><given-name>L. M.</given-name><initials>L.M.</initials><afid>60015618</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56662873300</author-url><authid>56662873300</authid><authname>Segers H.</authname><surname>Segers</surname><given-name>H.</given-name><initials>H.</initials><afid>60032724</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6507197949</author-url><authid>6507197949</authid><authname>Mavinkurve-Groothuis A.</authname><surname>Mavinkurve-Groothuis</surname><given-name>A. M C</given-name><initials>A.M.C.</initials><afid>60002573</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56662826200</author-url><authid>56662826200</authid><authname>Smit F.</authname><surname>Smit</surname><given-name>F. J.</given-name><initials>F.J.</initials><afid>60032114</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56663151000</author-url><authid>56663151000</authid><authname>Vonk I.</authname><surname>Vonk</surname><given-name>I. J M</given-name><initials>I.J.M.</initials><afid>60032114</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56663270700</author-url><authid>56663270700</authid><authname>vd Wetering M.</authname><surname>vd Wetering</surname><given-name>M. D.</given-name><initials>M.D.</initials><afid>60070178</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:6602640587</author-url><authid>6602640587</authid><authname>Tissing W.</authname><surname>Tissing</surname><given-name>W. J E</given-name><initials>W.J.E.</initials><afid>60070240</afid></author><authkeywords>Childhood cancer | Clinical practice guidelines | Delphi | Guidelines | Supportive care</authkeywords><intid>36086395</intid><source-id>13147</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930181740"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930181740?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930181740&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930181740&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930181740</prism:url><dc:identifier>SCOPUS_ID:84930181740</dc:identifier><eid>2-s2.0-84930181740</eid><dc:title>Combined blockade of angiotensin II and prorenin receptors ameliorates podocytic apoptosis induced by IgA-activated mesangial cells</dc:title><dc:creator>Leung J.</dc:creator><prism:publicationName>Apoptosis</prism:publicationName><prism:issn>13608185</prism:issn><prism:eIssn>1573675X</prism:eIssn><prism:volume>20</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>907-920</prism:pageRange><prism:coverDate>2015-07-30</prism:coverDate><prism:coverDisplayDate>30 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s10495-015-1117-1</prism:doi><dc:description>Â© 2015 Springer Science+Business Media New York. Glomerulo-podocytic communication plays an important role in the podocytic injury in IgA nephropathy (IgAN). In this study, we examine the role of podocytic angiotensin II receptor subtype 1 (AT1R) and prorenin receptor (PRR) in podocytic apoptosis in IgAN. Polymeric IgA (pIgA) was isolated from patients with IgAN and healthy controls. Conditioned media were prepared from growth arrested human mesangial cells (HMC) incubated with pIgA from patients with IgAN (IgA-HMC media) or healthy controls (Ctl-HMC media). A human podocyte cell line was used as a model to examine the regulation of the expression of AT1R, PRR, TNF-Î± and CTGF by IgA-HMC media. Podocytic nephrin expression, annexin V binding and caspase 3 activity were used as the functional readout of podocytic apoptosis. IgA-HMC media had no effect on AngII release by podocytes. IgA-HMC media significantly up-regulated the expression of AT1R and PRR, down-regulated nephrin expression and induced apoptosis in podocytes. Mono-blockade of AT1R, PRR, TNF-Î± or CTGF partially reduced podocytic apoptosis. IgA-HMC media activated NFÎºB, notch1 and HEY1 expression by podocytes and dual blockade of AT1R with PRR, or anti-TNF-Î± with anti-CTGF, effectively rescued the podocytic apoptosis induced by IgA-HMC media. Our data suggests that pIgA-activated HMC up-regulates the expression of AT1R and PRR expression by podocytes and the associated activation of NFÎºB and notch signalling pathways play an essential role in the podocytic apoptosis induced by glomerulo-podocytic communication in IgAN. Simultaneously targeting the AT1R and PRR could be a potential therapeutic option to reduce the podocytic injury in IgAN.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006541</affiliation-url><afid>60006541</afid><affilname>The University of Hong Kong</affilname><name-variant>University of Hong Kong</name-variant><affiliation-city>Pokfulam</affiliation-city><affiliation-country>Hong Kong</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020650</affiliation-url><afid>60020650</afid><affilname>University of Bristol</affilname><name-variant>University of Bristol</name-variant><affiliation-city>Bristol</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005140</affiliation-url><afid>60005140</afid><affilname>Hong Kong Sanatorium and Hospital</affilname><name-variant>Hong Kong Sanatorium and Hospital</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7202180349</author-url><authid>7202180349</authid><authname>Leung J.</authname><surname>Leung</surname><given-name>Joseph C K</given-name><initials>J.C.K.</initials><afid>60006541</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56214867000</author-url><authid>56214867000</authid><authname>Chan L.</authname><surname>Chan</surname><given-name>Loretta Y Y</given-name><initials>L.Y.Y.</initials><afid>60006541</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7103095853</author-url><authid>7103095853</authid><authname>Saleem M.</authname><surname>Saleem</surname><given-name>M. A.</given-name><initials>M.A.</initials><afid>60020650</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005677484</author-url><authid>7005677484</authid><authname>Mathieson P.</authname><surname>Mathieson</surname><given-name>P. W.</given-name><initials>P.W.</initials><afid>60006541</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56070415600</author-url><authid>56070415600</authid><authname>Tang S.</authname><surname>Tang</surname><given-name>Sydney C W</given-name><initials>S.C.W.</initials><afid>60006541</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55845418650</author-url><authid>55845418650</authid><authname>Lai K.</authname><surname>Lai</surname><given-name>Kar Neng</given-name><initials>K.N.</initials><afid>60005140</afid></author><authkeywords>Apoptosis | AT1R | IgAN | NFÎºB | Notch1 | Podocytes | Prorenin receptor</authkeywords><intid>1536079821</intid><source-id>18403</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930227397"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930227397?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930227397&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930227397&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930227397</prism:url><dc:identifier>SCOPUS_ID:84930227397</dc:identifier><eid>2-s2.0-84930227397</eid><dc:title>Irregular rhythm and atrial metabolism are key for the evolution of proarrhythmic atrial remodeling in atrial fibrillation</dc:title><dc:creator>Heijman J.</dc:creator><prism:publicationName>Basic Research in Cardiology</prism:publicationName><prism:issn>03008428</prism:issn><prism:eIssn>14351803</prism:eIssn><prism:volume>110</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00395-015-0498-1</prism:doi><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018869</affiliation-url><afid>60018869</afid><affilname>Maastricht University</affilname><name-variant>University of Limburg</name-variant><affiliation-city>Maastricht</affiliation-city><affiliation-country>Netherlands</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014264</affiliation-url><afid>60014264</afid><affilname>Universitat Duisburg-Essen</affilname><name-variant>University of Essen</name-variant><affiliation-city>Essen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ed</subtype><subtypeDescription>Editorial</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26639405700</author-url><authid>26639405700</authid><authname>Heijman J.</authname><surname>Heijman</surname><given-name>Jordi</given-name><initials>J.</initials><afid>60018869</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7004474534</author-url><authid>7004474534</authid><authname>Dobrev D.</authname><surname>Dobrev</surname><given-name>Dobromir</given-name><initials>D.</initials><afid>60014264</afid></author><intid>1536086890</intid><source-id>22488</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930225620"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930225620?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930225620&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930225620&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930225620</prism:url><dc:identifier>SCOPUS_ID:84930225620</dc:identifier><eid>2-s2.0-84930225620</eid><dc:title>Arrhythmia causes lipid accumulation and reduced glucose uptake</dc:title><dc:creator>Lenski M.</dc:creator><prism:publicationName>Basic Research in Cardiology</prism:publicationName><prism:issn>03008428</prism:issn><prism:eIssn>14351803</prism:eIssn><prism:volume>110</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00395-015-0497-2</prism:doi><dc:description>Â© 2015, Springer-Verlag Berlin Heidelberg. Atrial fibrillation (AF) is characterized by irregular contractions of atrial cardiomyocytes and increased energy demand. The aim of this study was to characterize the influence of arrhythmia on glucose and fatty acid (FA) metabolism in cardiomyocytes, mice and human left atrial myocardium. Compared to regular pacing, irregular (pseudo-random variation at the same number of contractions/min) pacing of neonatal rat cardiomyocytes induced shorter action potential durations and effective refractory periods and increased diastolic [Ca&lt;sup&gt;2+&lt;/sup&gt;]&lt;inf&gt;c&lt;/inf&gt;. This was associated with the activation of Ca&lt;sup&gt;2+&lt;/sup&gt;/calmodulin-dependent protein kinase II (CaMKII) and AMP-activated protein kinase (AMPK). Membrane expression of fatty acid translocase (FAT/CD36) and &lt;sup&gt;14&lt;/sup&gt;C-palmitic acid uptake were augmented while membrane expression of glucose transporter subtype 4 (GLUT-4) as well as &lt;sup&gt;3&lt;/sup&gt;H-glucose uptake were reduced. Inhibition of AMPK and CaMKII prevented these arrhythmia-induced metabolic changes. Similar alterations of FA metabolism were observed in a transgenic mouse model (RacET) for spontaneous AF. Consistent with these findings samples of left atrial myocardium of patients with AF compared to matched samples of patients with sinus rhythm showed up-regulation of CaMKII and AMPK and increased membrane expression of FAT/CD36, resulting in lipid accumulation. These changes of FA metabolism were accompanied by decreased membrane expression of GLUT-4, increased glycogen content and increased expression of the pro-apoptotic protein bax. Irregular pacing of cardiomyocytes increases diastolic [Ca&lt;sup&gt;2+&lt;/sup&gt;]&lt;inf&gt;c&lt;/inf&gt; and activation of CaMKII and AMPK resulting in lipid accumulation, reduced glucose uptake and increased glycogen synthesis. These metabolic changes are accompanied by an activation of pro-apoptotic signalling pathways.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023686</affiliation-url><afid>60023686</afid><affilname>Universitatsklinikum des Saarlandes Medizinische Fakultat der Universitat des Saarlandes</affilname><name-variant>University of Saarland</name-variant><affiliation-city>Homburg</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60033241</affiliation-url><afid>60033241</afid><affilname>Universitat des Saarlandes</affilname><name-variant>Saarland University</name-variant><affiliation-city>Saarbrucken</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016653</affiliation-url><afid>60016653</afid><affilname>Rheinisch-Westfalische Technische Hochschule Aachen</affilname><name-variant>RWTH Aachen</name-variant><affiliation-city>Aachen</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">12</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25925984300</author-url><authid>25925984300</authid><authname>Lenski M.</authname><surname>Lenski</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60023686</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56663190800</author-url><authid>56663190800</authid><authname>Schleider G.</authname><surname>Schleider</surname><given-name>Gregor</given-name><initials>G.</initials><afid>60023686</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:12774698800</author-url><authid>12774698800</authid><authname>Kohlhaas M.</authname><surname>Kohlhaas</surname><given-name>Michael</given-name><initials>M.</initials><afid>60023686</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662881300</author-url><authid>56662881300</authid><authname>Adrian L.</authname><surname>Adrian</surname><given-name>Lucas</given-name><initials>L.</initials><afid>60023686</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:17134319700</author-url><authid>17134319700</authid><authname>Adam O.</authname><surname>Adam</surname><given-name>Oliver</given-name><initials>O.</initials><afid>60023686</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:36143483500</author-url><authid>36143483500</authid><authname>Tian Q.</authname><surname>Tian</surname><given-name>Qinghai</given-name><initials>Q.</initials><afid>60033241</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6603413524</author-url><authid>6603413524</authid><authname>Kaestner L.</authname><surname>Kaestner</surname><given-name>Lars</given-name><initials>L.</initials><afid>60033241</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006185866</author-url><authid>7006185866</authid><authname>Lipp P.</authname><surname>Lipp</surname><given-name>Peter</given-name><initials>P.</initials><afid>60033241</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602645182</author-url><authid>6602645182</authid><authname>Lehrke M.</authname><surname>Lehrke</surname><given-name>Michael</given-name><initials>M.</initials><afid>60016653</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:6701763468</author-url><authid>6701763468</authid><authname>Maack C.</authname><surname>Maack</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60023686</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35392235500</author-url><authid>35392235500</authid><authname>BÃ¶hm M.</authname><surname>BÃ¶hm</surname><given-name>Michael</given-name><initials>M.</initials><afid>60023686</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:26643295500</author-url><authid>26643295500</authid><authname>Laufs U.</authname><surname>Laufs</surname><given-name>Ulrich</given-name><initials>U.</initials><afid>60023686</afid></author><authkeywords>Arrhythmia | Atrial fibrillation | Metabolism | Remodelling</authkeywords><intid>1536088108</intid><source-id>22488</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226951"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226951?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226951&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226951&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226951</prism:url><dc:identifier>SCOPUS_ID:84930226951</dc:identifier><eid>2-s2.0-84930226951</eid><dc:title>ZAK induces cardiomyocyte hypertrophy and brain natriuretic peptide expression via p38/JNK signaling and GATA4/c-Jun transcriptional factor activation</dc:title><dc:creator>Hsieh Y.</dc:creator><prism:publicationName>Molecular and Cellular Biochemistry</prism:publicationName><prism:issn>03008177</prism:issn><prism:eIssn>15734919</prism:eIssn><prism:volume>405</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11010-015-2389-z</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Cardiomyocyte hypertrophy is an adaptive response of heart to various stress conditions. During the period of stress accumulation, transition from physiological hypertrophy to pathological hypertrophy results in the promotion of heart failure. Our previous studies found that ZAK, a sterile alpha motif and leucine zipper containing kinase, was highly expressed in infarcted human hearts and demonstrated that overexpression of ZAK induced cardiac hypertrophy. This study evaluates, cellular events associated with the expression of two doxycycline (Dox) inducible Tet-on ZAK expression systems, a Tet-on ZAK WT (wild-type), and a Tet-on ZAK DN (mutant, Dominant-negative form) in H9c2 myoblast cells; Tet-on ZAK WT was found to increase cell size and hypertrophic marker BNP in a dose-dependent manner. To ascertain the mechanism of ZAK-mediated hypertrophy, expression analysis with various inhibitors of the related upstream and downstream proteins was performed. Tet-on ZAK WT expression triggered the p38 and JNK pathway and also activated the expression and nuclear translocation of p-GATA4 and p-c-Jun transcription factors, without the involvement of p-ERK or NFATc3. However, Tet-on ZAK DN showed no effect on the p38 and JNK signaling cascade. The results showed that the inhibitors of JNK1/2 and p38 significantly suppressed ZAK-induced BNP expression. The results show the role of ZAK and/or the ZAK downstream events such as JNK and p38 phosphorylation, c-Jun, and GATA-4 nuclear translocation in cardiac hypertrophy. ZAK and/or the ZAK downstream p38, and JNK pathway could therefore be potential targets to ameliorate cardiac hypertrophy symptoms in ZAK-overexpressed patients.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60072429</affiliation-url><afid>60072429</afid><affilname>Asia University Taiwan</affilname><name-variant>Asia University</name-variant><affiliation-city>Wufong</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092855</affiliation-url><afid>60092855</afid><affilname>National Taiwan Sport University</affilname><name-variant>National Taiwan Sport University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011234</affiliation-url><afid>60011234</afid><affilname>Chia-Nan University of Pharmacy and Science Taiwan</affilname><name-variant>Chia Nan University of Pharmacy and Science</name-variant><affiliation-city>Tainan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027502</affiliation-url><afid>60027502</afid><affilname>Taipei City Hospital Taiwan</affilname><name-variant>Taipei City Hospital</name-variant><affiliation-city>Taipei</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031941</affiliation-url><afid>60031941</afid><affilname>China Medical University Hospital Taichung</affilname><name-variant>China Medical University Hospital</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60022174</affiliation-url><afid>60022174</afid><affilname>Changhua Christian Hospital Taiwan</affilname><name-variant>Changhua Christian Hospital</name-variant><affiliation-city>Chang-Hua</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60075700</affiliation-url><afid>60075700</afid><affilname>Jen-Teh Junior College of Medicine, Nursing and Management</affilname><name-variant>Jen-Teh Junior College of Medicine</name-variant><affiliation-city>Miao-li</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013041</affiliation-url><afid>60013041</afid><affilname>Bharathiar University</affilname><name-variant>Bharathiar University</name-variant><affiliation-city>Coimbatore</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006988</affiliation-url><afid>60006988</afid><affilname>China Medical University Taichung</affilname><name-variant>China Medical University</name-variant><affiliation-city>Taichung</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662693500</author-url><authid>56662693500</authid><authname>Hsieh Y.</authname><surname>Hsieh</surname><given-name>You Liang</given-name><initials>Y.L.</initials><afid>60072429</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35758074400</author-url><authid>35758074400</authid><authname>Tsai Y.</authname><surname>Tsai</surname><given-name>Ying Lan</given-name><initials>Y.L.</initials><afid>60092855</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36197312200</author-url><authid>36197312200</authid><authname>Shibu M.</authname><surname>Shibu</surname><given-name>Marthandam Asokan</given-name><initials>M.A.</initials><afid>60006988</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56662635600</author-url><authid>56662635600</authid><authname>Su C.</authname><surname>Su</surname><given-name>Chia chi</given-name><initials>C.c.</initials><afid>60006988</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55325394800</author-url><authid>55325394800</authid><authname>Chung L.</authname><surname>Chung</surname><given-name>Li Chin</given-name><initials>L.C.</initials><afid>60011234</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8883719400</author-url><authid>8883719400</authid><authname>Pai P.</authname><surname>Pai</surname><given-name>Peiying</given-name><initials>P.</initials><afid>60027502</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56638861000</author-url><authid>56638861000</authid><authname>Kuo C.</authname><surname>Kuo</surname><given-name>Chia Hua</given-name><initials>C.H.</initials><afid>60031941</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8609976500</author-url><authid>8609976500</authid><authname>Yeh Y.</authname><surname>Yeh</surname><given-name>Yu Lan</given-name><initials>Y.L.</initials><afid>60022174</afid><afid>60075700</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8609976500</author-url><authid>8609976500</authid><authname>Yeh Y.</authname><surname>Yeh</surname><given-name>Yu Lan</given-name><initials>Y.L.</initials><afid>60022174</afid><afid>60075700</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6507790287</author-url><authid>6507790287</authid><authname>Viswanadha V.</authname><surname>Viswanadha</surname><given-name>Vijaya Padma</given-name><initials>V.P.</initials><afid>60013041</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7406883142</author-url><authid>7406883142</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chih Yang</given-name><initials>C.Y.</initials><afid>60072429</afid><afid>60006988</afid><afid>60006988</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7406883142</author-url><authid>7406883142</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chih Yang</given-name><initials>C.Y.</initials><afid>60072429</afid><afid>60006988</afid><afid>60006988</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7406883142</author-url><authid>7406883142</authid><authname>Huang C.</authname><surname>Huang</surname><given-name>Chih Yang</given-name><initials>C.Y.</initials><afid>60072429</afid><afid>60006988</afid><afid>60006988</afid></author><authkeywords>Cardiac hypertrophy | Mixed lineage kinase | Sterile alpha motif and leucine zipper containing kinase</authkeywords><intid>1536088201</intid><source-id>14134</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930195930"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930195930?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930195930&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930195930&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930195930</prism:url><dc:identifier>SCOPUS_ID:84930195930</dc:identifier><eid>2-s2.0-84930195930</eid><dc:title>Prostanoids and NSAIDs in Cardiovascular Biology and Disease</dc:title><dc:creator>Weksler B.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0514-9</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Prostanoids and related arachidonic acid derivatives are important physiologic modulators in arteries, as well as mediators of inflammation, hemostasis, and cell proliferation. Their participation in atherosclerosis and in acute thrombotic events is complex, as demonstrated by untoward cardiovascular (CV) effects associated with clinical use of inhibitors of prostaglandin synthesis for treatment of chronic pain, inflammatory states, or cancer prophylaxis. Newer understanding of the pathophysiology of atherosclerosis and the pharmacology of prostanoids promises potential resolution of current problems resulting from the hazards of available prostanoid-altering drugs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007997</affiliation-url><afid>60007997</afid><affilname>Weill Cornell Medical College</affilname><name-variant>Cornell University Medical College</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7006736335</author-url><authid>7006736335</authid><authname>Weksler B.</authname><surname>Weksler</surname><given-name>Babettte B.</given-name><initials>B.B.</initials><afid>60007997</afid></author><authkeywords>Aspirin | Coxib | Cyclooxygenase | Eicosanoids | Prostaglandins | Thromboxanes</authkeywords><intid>36086437</intid><article-number>41</article-number><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930201246"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930201246?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930201246&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930201246&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930201246</prism:url><dc:identifier>SCOPUS_ID:84930201246</dc:identifier><eid>2-s2.0-84930201246</eid><dc:title>Malignant MCA Stroke: an Update on Surgical Decompression and Future Directions</dc:title><dc:creator>Maciel C.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0519-4</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Despite a decline over the past decade in overall stroke mortality, hemispheric strokes retain a strikingly high mortality due to their potential for malignant edema and herniation. The pathogenesis of ischemic cerebral edema is steered by disruption of ionic homeostasis in the neurogliovascular unit. Significant effort has been made to identify potential medical therapies targeting edema formation with promising results. To date, decompressive craniectomy remains the therapy with the most robust impact on mortality. Historically, patient selection for surgical treatment of malignant supratentorial strokes has focused on a strict age cutoff and hemispheric dominance. Recent evidence supports a significant mortality benefit in elderly population, although the impact in morbidity is modest. Careful patient selection for surgical treatment in conjunction with comprehensive neurocritical care and inclusion of family in the educated decision making process remain the mainstay of care for such shattering disease.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015232</affiliation-url><afid>60015232</afid><affilname>Yale-New Haven Hospital</affilname><name-variant>Yale New Haven Hospital</name-variant><affiliation-city>New Haven</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015232</affiliation-url><afid>60015232</afid><affilname>Yale-New Haven Hospital</affilname><name-variant>Yale New Haven Hospital</name-variant><affiliation-city>New Haven</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015232</affiliation-url><afid>60015232</afid><affilname>Yale-New Haven Hospital</affilname><name-variant>Yale New Haven Hospital</name-variant><affiliation-city>New Haven</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662854200</author-url><authid>56662854200</authid><authname>Maciel C.</authname><surname>Maciel</surname><given-name>Carolina B.</given-name><initials>C.B.</initials><afid>60015232</afid><afid>60015232</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662854200</author-url><authid>56662854200</authid><authname>Maciel C.</authname><surname>Maciel</surname><given-name>Carolina B.</given-name><initials>C.B.</initials><afid>60015232</afid><afid>60015232</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8415971600</author-url><authid>8415971600</authid><authname>Sheth K.</authname><surname>Sheth</surname><given-name>Kevin N.</given-name><initials>K.N.</initials><afid>60015232</afid><afid>60015232</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:8415971600</author-url><authid>8415971600</authid><authname>Sheth K.</authname><surname>Sheth</surname><given-name>Kevin N.</given-name><initials>K.N.</initials><afid>60015232</afid><afid>60015232</afid></author><authkeywords>Decompressive craniectomy | Decompressive hemicraniectomy | Edema | Hemispheric stroke | Infarction | Malignant edema | Malignant ischemic stroke | Middle cerebral artery stroke | Space occupying stroke | Surgical decompression</authkeywords><intid>1036081682</intid><article-number>40</article-number><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930210833"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930210833?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930210833&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930210833&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930210833</prism:url><dc:identifier>SCOPUS_ID:84930210833</dc:identifier><eid>2-s2.0-84930210833</eid><dc:title>Relationship between serum IgA/C3 ratio and severity of histological lesions using the Oxford classification in children with IgA nephropathy</dc:title><dc:creator>Mizerska-Wasiak M.</dc:creator><prism:publicationName>Pediatric Nephrology</prism:publicationName><prism:issn>0931041X</prism:issn><prism:eIssn>1432198X</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:pageRange>1113-1120</prism:pageRange><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00467-014-3024-z</prism:doi><dc:description>Â© 2015, IPNA. Background: The aim of this study was to evaluate the usefulness of serum immunoglobulin A/complement factor 3 (IgA/C3) ratio for predicting histological severity of kidney lesions in children with IgA nephropathy (IgAN) based on World Health Organization (WHO) and the Oxford classification (OC). Methods: We studied 89 children with IgAN with a mean age of 11.38 Â± 4.1Â years (range 2â18Â years). Based on available medical records, we retrospectively evaluated clinical data, IgA/C3 ratio, and kidney biopsy findings using the five-grade WHO classification and the OC The mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), tubular atrophy/interstitial fibrosis (T) (MEST) score (absent = 0, present = 1) calculated as the sum of M+E+S+T ranging from 0 to 4. Results: Mean IgA/C3 ratio values were significantly higher (P &lt; 0.05) in patients with M1, S1, and T1 compared with M0, S0, and T0, respectively (P &lt; 0.05); there were no differences in the WHO classification. We found a significant positive correlation between the IgA/C3 ratio and proteinuria (r = 0.24) and determined optimal cutoff values of the IgA/C3 ratio, with a corresponding confidence interval for specific MEST scores. Conclusions: The IgA/C3 ratio in children with IgAN may be a useful marker of the severity of lesions found in kidney biopsy as evaluated using the OC.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069009</affiliation-url><afid>60069009</afid><affilname>Medical University of Warsaw</affilname><name-variant>Medical University of Warsaw</name-variant><affiliation-city>Warsaw</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069009</affiliation-url><afid>60069009</afid><affilname>Medical University of Warsaw</affilname><name-variant>Medical University of Warsaw</name-variant><affiliation-city>Warsaw</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026724</affiliation-url><afid>60026724</afid><affilname>Uniwersytet Medyczny w Bialymstoku</affilname><name-variant>Medical University of Bialystok</name-variant><affiliation-city>Bialystok</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087278</affiliation-url><afid>60087278</afid><affilname>Uniwersytecki Szpital Dzieciecy, Krakow</affilname><name-variant>University Children's Hospital of Cracow</name-variant><affiliation-city>Krakow</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:100611647</affiliation-url><afid>100611647</afid><affilname>Provincial Children's Hospital</affilname><name-variant>Provincial Children's Hospital</name-variant><affiliation-city>Torun</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069011</affiliation-url><afid>60069011</afid><affilname>Medical University of Lublin</affilname><name-variant>Medical University</name-variant><affiliation-city>Lublin</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60087496</affiliation-url><afid>60087496</afid><affilname>Instytut Pomnik-Centrum Zdrowia Dziecka</affilname><name-variant>Children's Memorial Health Institute</name-variant><affiliation-city>Warsaw</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007108</affiliation-url><afid>60007108</afid><affilname>AKademia Medyczna Wroclawiu</affilname><name-variant>Wroclaw Medical University</name-variant><affiliation-city>Wroclaw</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027573</affiliation-url><afid>60027573</afid><affilname>Slaski Uniwersytet Medyczny w Katowicach</affilname><name-variant>Medical University of Silesia</name-variant><affiliation-city>Katowice</affiliation-city><affiliation-country>Poland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">17</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:24402410600</author-url><authid>24402410600</authid><authname>Mizerska-Wasiak M.</authname><surname>Mizerska-Wasiak</surname><given-name>MaÅgorzata</given-name><initials>M.</initials><afid>60069009</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602766770</author-url><authid>6602766770</authid><authname>MaÅdyk J.</authname><surname>MaÅdyk</surname><given-name>Jadwiga</given-name><initials>J.</initials><afid>60069009</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:35103522900</author-url><authid>35103522900</authid><authname>Rybi-SzumiÅska A.</authname><surname>Rybi-SzumiÅska</surname><given-name>Agnieszka</given-name><initials>A.</initials><afid>60026724</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7006126105</author-url><authid>7006126105</authid><authname>Wasilewska A.</authname><surname>Wasilewska</surname><given-name>Anna</given-name><initials>A.</initials><afid>60026724</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56320644500</author-url><authid>56320644500</authid><authname>Miklaszewska M.</authname><surname>Miklaszewska</surname><given-name>Monika</given-name><initials>M.</initials><afid>60087278</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7005455377</author-url><authid>7005455377</authid><authname>Pietrzyk J.</authname><surname>Pietrzyk</surname><given-name>Jacek</given-name><initials>J.</initials><afid>60087278</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:23468991500</author-url><authid>23468991500</authid><authname>Firszt-Adamczyk A.</authname><surname>Firszt-Adamczyk</surname><given-name>Agnieszka</given-name><initials>A.</initials><afid>100611647</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23470761000</author-url><authid>23470761000</authid><authname>Stankiewicz R.</authname><surname>Stankiewicz</surname><given-name>Roman</given-name><initials>R.</initials><afid>100611647</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:14013627200</author-url><authid>14013627200</authid><authname>BieniaÅ B.</authname><surname>BieniaÅ</surname><given-name>Beata</given-name><initials>B.</initials><afid>60069011</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7003879702</author-url><authid>7003879702</authid><authname>ZajÄczkowska M.</authname><surname>ZajÄczkowska</surname><given-name>MaÅgorzata</given-name><initials>M.</initials><afid>60069011</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:6508076467</author-url><authid>6508076467</authid><authname>Gadomska-Prokop K.</authname><surname>Gadomska-Prokop</surname><given-name>Katarzyna</given-name><initials>K.</initials><afid>60087496</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:13606275800</author-url><authid>13606275800</authid><authname>Grenda R.</authname><surname>Grenda</surname><given-name>Ryszard</given-name><initials>R.</initials><afid>60087496</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:37097890000</author-url><authid>37097890000</authid><authname>PukajÅo-Marczyk A.</authname><surname>PukajÅo-Marczyk</surname><given-name>Agnieszka</given-name><initials>A.</initials><afid>60007108</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:55947656800</author-url><authid>55947656800</authid><authname>ZwoliÅska D.</authname><surname>ZwoliÅska</surname><given-name>Danuta</given-name><initials>D.</initials><afid>60007108</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7004923496</author-url><authid>7004923496</authid><authname>SzczepaÅska M.</authname><surname>SzczepaÅska</surname><given-name>Maria</given-name><initials>M.</initials><afid>60027573</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:56132513600</author-url><authid>56132513600</authid><authname>Turczyn A.</authname><surname>Turczyn</surname><given-name>Agnieszka</given-name><initials>A.</initials><afid>60069009</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:7004227114</author-url><authid>7004227114</authid><authname>Roszkowska-Blaim M.</authname><surname>Roszkowska-Blaim</surname><given-name>Maria</given-name><initials>M.</initials><afid>60069009</afid></author><authkeywords>Children | IgA nephropathy | IgA/C3 serum ratio | Oxford classification | Renal biopsy</authkeywords><intid>1786087717</intid><source-id>20471</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929960665"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929960665?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929960665&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929960665&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929960665</prism:url><dc:identifier>SCOPUS_ID:84929960665</dc:identifier><eid>2-s2.0-84929960665</eid><dc:title>Protective effects of N-acetylcysteine against hyperoxaluria induced mitochondrial dysfunction in male wistar rats</dc:title><dc:creator>Sharma M.</dc:creator><prism:publicationName>Molecular and Cellular Biochemistry</prism:publicationName><prism:issn>03008177</prism:issn><prism:eIssn>15734919</prism:eIssn><prism:volume>405</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:pageRange>105-114</prism:pageRange><prism:coverDate>2015-07-29</prism:coverDate><prism:coverDisplayDate>29 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11010-015-2402-6</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. The purpose of the present study was to evaluate the nephro-protective potential of N-acetylcysteine against hyperoxaluria-induced renal mitochondrial dysfunction in rats. Nine days dosing of 0.4Â % ethylene glycol +1Â % ammonium chloride, developed hyperoxaluria in male wistar rats which resulted in renal injury and dysfunction as supported by increased level of urinary lactate dehydrogenase, calcium, and decreased creatinine clearance. Mitochondrial oxidative strain in hyperoxaluric animals was evident by decreased levels of superoxide dismutase, glutathione peroxidase, glutathione reductase, reduced glutathione, and an increased lipid peroxidation. Declined activities of respiratory chain enzymes and tricarboxylic acid cycle enzymes showed mitochondrial dysfunction in hyperoxaluric animals. N-acetylcysteine (50Â mg/kg, i.p.), by virtue of its âSH reviving power, was able to increase the glutathione levels and thus decrease the oxidative stress in renal mitochondria. Hence, mitochondrial damage is, evidently, an essential event in ethylene glycol-induced hyperoxaluria and N-acetylcysteine presented itself as a safe and effective remedy in combating nephrolithiasis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018526</affiliation-url><afid>60018526</afid><affilname>Panjab University</affilname><name-variant>Panjab University</name-variant><affiliation-city>Chandigarh</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018526</affiliation-url><afid>60018526</afid><affilname>Panjab University</affilname><name-variant>Panjab University</name-variant><affiliation-city>Chandigarh</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56580954400</author-url><authid>56580954400</authid><authname>Sharma M.</authname><surname>Sharma</surname><given-name>Minu</given-name><initials>M.</initials><afid>60018526</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:27168621500</author-url><authid>27168621500</authid><authname>Kaur T.</authname><surname>Kaur</surname><given-name>Tanzeer</given-name><initials>T.</initials><afid>60018526</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36906530100</author-url><authid>36906530100</authid><authname>Singla S.</authname><surname>Singla</surname><given-name>S. K.</given-name><initials>S.K.</initials><afid>60018526</afid></author><authkeywords>Antioxidant | Hyperoxaluria | Mitochondria | N-acetylcysteine | Oxidative stress | Vitamin E</authkeywords><intid>1536042336</intid><source-id>14134</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930226986"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930226986?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930226986&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930226986&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930226986</prism:url><dc:identifier>SCOPUS_ID:84930226986</dc:identifier><eid>2-s2.0-84930226986</eid><dc:title>Splenic leukocytes mediate the hyperglycemic exacerbation of myocardial infarct size in mice</dc:title><dc:creator>Tian Y.</dc:creator><prism:publicationName>Basic Research in Cardiology</prism:publicationName><prism:issn>03008428</prism:issn><prism:eIssn>14351803</prism:eIssn><prism:volume>110</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:coverDate>2015-07-28</prism:coverDate><prism:coverDisplayDate>28 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00395-015-0496-3</prism:doi><dc:description>Â© 2015, Springer-Verlag Berlin Heidelberg. Acute hyperglycemia during acute myocardial infarction is associated with worse myocardial injury and increased mortality. Using a mouse model of myocardial ischemia/reperfusion injury, we tested the hypothesis that acute hyperglycemia activates splenic leukocytes and subsequently exacerbates myocardial infarct size. We then examined whether the adverse effects of hyperglycemia could be attenuated by a potent anti-inflammatory agent (an agonist of the adenosine A&lt;inf&gt;2A&lt;/inf&gt; receptor) administered immediately prior to reperfusion. C57BL6 (WT) mice underwent 30-min LAD occlusion and 60-min reperfusion with or without prior splenectomy. Acute hyperglycemia before ischemia increased myocardial infarct size (IS) by 43Â % (pÂ &lt;Â 0.05). Splenectomy before ischemia did not change IS (vs. control, pÂ =Â NS) but did serve to prevent the exacerbation of IS by hyperglycemia. Acute hyperglycemia activated splenic leukocytes by increasing formyl peptide receptor expression and reactive oxygen species production before ischemia, and enhanced splenic neutrophil release with resultant peripheral neutrophilia and increased myocardial neutrophil infiltration during reperfusion. Acute adoptive transfer of splenic leukocytes to splenectomized mice before ischemia restored the hyperglycemic exacerbation of infarct size. ATL146e, an adenosine 2A receptor (A&lt;inf&gt;2A&lt;/inf&gt;R) agonist, abolished neutrophilia during reperfusion and reduced IS in hyperglycemic mice. ATL146e also reduced IS in splenectomized hyperglycemic mice with transfer of WT splenic leukocytes, but not with transfer of splenic leukocytes from A&lt;inf&gt;2A&lt;/inf&gt;R knockout mice. Acute hyperglycemia prior to myocardial ischemia and reperfusion exacerbates IS by activating splenic leukocytes. ATL146e administered at reperfusion suffices to abrogate the hyperglycemic exacerbation of IS by acting on A&lt;inf&gt;2A&lt;/inf&gt;Rs on splenic leukocytes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021918</affiliation-url><afid>60021918</afid><affilname>University of Virginia</affilname><name-variant>University of Virginia</name-variant><affiliation-city>Charlottesville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021918</affiliation-url><afid>60021918</afid><affilname>University of Virginia</affilname><name-variant>University of Virginia</name-variant><affiliation-city>Charlottesville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021918</affiliation-url><afid>60021918</afid><affilname>University of Virginia</affilname><name-variant>University of Virginia</name-variant><affiliation-city>Charlottesville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011715</affiliation-url><afid>60011715</afid><affilname>Tianjin Medical University</affilname><name-variant>Tianjin Medical University General Hospital</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:46661312200</author-url><authid>46661312200</authid><authname>Tian Y.</authname><surname>Tian</surname><given-name>Yikui</given-name><initials>Y.</initials><afid>60021918</afid><afid>60011715</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:46661312200</author-url><authid>46661312200</authid><authname>Tian Y.</authname><surname>Tian</surname><given-name>Yikui</given-name><initials>Y.</initials><afid>60021918</afid><afid>60011715</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35509133600</author-url><authid>35509133600</authid><authname>French B.</authname><surname>French</surname><given-name>Brent A.</given-name><initials>B.A.</initials><afid>60021918</afid><afid>60021918</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35509133600</author-url><authid>35509133600</authid><authname>French B.</authname><surname>French</surname><given-name>Brent A.</given-name><initials>B.A.</initials><afid>60021918</afid><afid>60021918</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7103325917</author-url><authid>7103325917</authid><authname>Kron I.</authname><surname>Kron</surname><given-name>Irving L.</given-name><initials>I.L.</initials><afid>60021918</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7405435811</author-url><authid>7405435811</authid><authname>Yang Z.</authname><surname>Yang</surname><given-name>Zequan</given-name><initials>Z.</initials><afid>60021918</afid><afid>60021918</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7405435811</author-url><authid>7405435811</authid><authname>Yang Z.</authname><surname>Yang</surname><given-name>Zequan</given-name><initials>Z.</initials><afid>60021918</afid><afid>60021918</afid></author><authkeywords>Adenosine 2A receptor | Hyperglycemia | Inflammatory response | Myocardial ischemia/reperfusion injury | Splenic leukocytes</authkeywords><intid>1036082167</intid><source-id>22488</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930198645"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930198645?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930198645&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930198645&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930198645</prism:url><dc:identifier>SCOPUS_ID:84930198645</dc:identifier><eid>2-s2.0-84930198645</eid><dc:title>The Neurology of Solid Organ Transplantation</dc:title><dc:creator>Avila J.</dc:creator><prism:publicationName>Current Neurology and Neuroscience Reports</prism:publicationName><prism:issn>15284042</prism:issn><prism:eIssn>15346293</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-27</prism:coverDate><prism:coverDisplayDate>27 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11910-015-0560-2</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Transplantation is the rescue treatment for end-stage organ failure with more than 110,000 solid organs transplantations performed worldwide annually. Recent advances in transplantation procedures and posttransplantation management have improved long-term survival and quality of life of transplant recipients, shifting the focus from acute perioperative critical care needs toward long-term chronic medical problems. Neurologic complications affect up to 30â60Â % of solid organ transplant recipients. Common etiologies include opportunistic infections and toxicities of antirejection medications, and wide spectrum of toxic and metabolic disturbances. Most complications are common to all allograft types, but some are relatively specific for individual allograft types (e.g., central pontine myelinolysis in liver transplant recipients). Close collaboration between neurologists and other transplant team members is essential for effective management. Early recognition of complications and accurate diagnosis leading to timely treatment is essential to reduce the morbidity and improve the overall transplant outcome.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012018</affiliation-url><afid>60012018</afid><affilname>University of Pittsburgh Medical Center</affilname><name-variant>University of Pittsburgh Medical Center</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56662759300</author-url><authid>56662759300</authid><authname>Avila J.</authname><surname>Avila</surname><given-name>J. David</given-name><initials>J.D.</initials><afid>60012018</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005663432</author-url><authid>7005663432</authid><authname>Å½ivkoviÄ S.</authname><surname>Å½ivkoviÄ</surname><given-name>SaÅ¡a</given-name><initials>S.</initials><afid>60012018</afid></author><authkeywords>Immunosuppression | Neurologic complications | Neurotoxicity | Opportunistic infection | Solid organ transplantation</authkeywords><intid>1536086977</intid><article-number>38</article-number><source-id>14989</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930204112"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930204112?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930204112&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930204112&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930204112</prism:url><dc:identifier>SCOPUS_ID:84930204112</dc:identifier><eid>2-s2.0-84930204112</eid><dc:title>Neuromodulation Therapies for Geriatric Depression</dc:title><dc:creator>GÃ¡lvez V.</dc:creator><prism:publicationName>Current Psychiatry Reports</prism:publicationName><prism:issn>15233812</prism:issn><prism:eIssn>15351645</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-27</prism:coverDate><prism:coverDisplayDate>27 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11920-015-0592-y</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Depression is frequent in old age and its prognosis is poorer than in younger populations. The use of pharmacological treatments in geriatric depression is limited by specific pharmacodynamic age-related factors that can diminish tolerability and increase the risk of drug interactions. The possibility of modulating cerebral activity using brain stimulation techniques could result in treating geriatric depression more effectively while reducing systemic side effects and medication interactions. This may subsequently improve treatment adherence and overall prognosis in the older patient. Among clinically available neuromodulatory techniques, electroconvulsive therapy (ECT) remains the gold standard for the treatment of severe depression in the elderly. Studies have proven that ECT is more effective and has a faster onset of action than antidepressants in the treatment of severe, unipolar, geriatric depression and that older age is a predictor of rapid ECT response and remission. The application of novel and more tolerable forms of ECT for geriatric depression is currently being examined. Preliminary results suggest that right unilateral ultrabrief ECT (RUL-UB ECT) is a promising intervention, with similar efficacy to brief-pulse ECT and fewer adverse cognitive effects. Overall findings in repetitive transcranial magnetic stimulation (rTMS) suggest that it is a safe intervention in geriatric depression. Higher rTMS stimulation intensity and more treatments may need to be given in the elderly to achieve optimal results. There is no specific data on vagus nerve stimulation in the elderly. Transcranial direct current stimulation, magnetic seizure therapy and deep brain stimulation are currently experimental, and more data from geriatric samples is needed.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011463</affiliation-url><afid>60011463</afid><affilname>University of New South Wales Faculty of Medicine</affilname><name-variant>University of New South Wales</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60104962</affiliation-url><afid>60104962</afid><affilname>Black Dog Institute</affilname><name-variant>Black Dog Institute</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000260</affiliation-url><afid>60000260</afid><affilname>St George Hospital</affilname><name-variant>St George Hospital</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">13</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36716261400</author-url><authid>36716261400</authid><authname>GÃ¡lvez V.</authname><surname>GÃ¡lvez</surname><given-name>VerÃ²nica</given-name><initials>V.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36716261400</author-url><authid>36716261400</authid><authname>GÃ¡lvez V.</authname><surname>GÃ¡lvez</surname><given-name>VerÃ²nica</given-name><initials>V.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56041115000</author-url><authid>56041115000</authid><authname>Ho K.</authname><surname>Ho</surname><given-name>Kerrie Anne</given-name><initials>K.A.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56041115000</author-url><authid>56041115000</authid><authname>Ho K.</authname><surname>Ho</surname><given-name>Kerrie Anne</given-name><initials>K.A.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15749244200</author-url><authid>15749244200</authid><authname>Alonzo A.</authname><surname>Alonzo</surname><given-name>Angelo</given-name><initials>A.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:15749244200</author-url><authid>15749244200</authid><authname>Alonzo A.</authname><surname>Alonzo</surname><given-name>Angelo</given-name><initials>A.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55476540900</author-url><authid>55476540900</authid><authname>Martin D.</authname><surname>Martin</surname><given-name>Donel</given-name><initials>D.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55476540900</author-url><authid>55476540900</authid><authname>Martin D.</authname><surname>Martin</surname><given-name>Donel</given-name><initials>D.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55892726900</author-url><authid>55892726900</authid><authname>George D.</authname><surname>George</surname><given-name>Duncan</given-name><initials>D.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55892726900</author-url><authid>55892726900</authid><authname>George D.</authname><surname>George</surname><given-name>Duncan</given-name><initials>D.</initials><afid>60011463</afid><afid>60104962</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7103026596</author-url><authid>7103026596</authid><authname>Loo C.</authname><surname>Loo</surname><given-name>Colleen K.</given-name><initials>C.K.</initials><afid>60011463</afid><afid>60104962</afid><afid>60000260</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7103026596</author-url><authid>7103026596</authid><authname>Loo C.</authname><surname>Loo</surname><given-name>Colleen K.</given-name><initials>C.K.</initials><afid>60011463</afid><afid>60104962</afid><afid>60000260</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7103026596</author-url><authid>7103026596</authid><authname>Loo C.</authname><surname>Loo</surname><given-name>Colleen K.</given-name><initials>C.K.</initials><afid>60011463</afid><afid>60104962</afid><afid>60000260</afid></author><authkeywords>Depression | Electroconvulsive therapy (ECT) | Geriatric | Neuromodulation | Repetitive transcranial magnetic stimulation (rTMS) | Transcranial direct current stimulation (tDCS)</authkeywords><intid>536087391</intid><article-number>59</article-number><source-id>15011</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930207179"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930207179?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930207179&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930207179&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930207179</prism:url><dc:identifier>SCOPUS_ID:84930207179</dc:identifier><eid>2-s2.0-84930207179</eid><dc:title>Retinal Vascular Changes are a Marker for Cerebral Vascular Diseases</dc:title><dc:creator>Moss H.</dc:creator><prism:publicationName>Current Neurology and Neuroscience Reports</prism:publicationName><prism:issn>15284042</prism:issn><prism:eIssn>15346293</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-27</prism:coverDate><prism:coverDisplayDate>27 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11910-015-0561-1</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. The retinal circulation is a potential marker of cerebral vascular disease because it shares origin and drainage with the intracranial circulation and because it can be directly visualized using ophthalmoscopy. Cross-sectional and cohort studies have demonstrated associations between chronic retinal and cerebral vascular disease, acute retinal and cerebral vascular disease, and chronic retinal vascular disease and acute cerebral vascular disease. In particular, certain qualitative features of retinopathy, retinal artery occlusion, and increased retinal vein caliber are associated with concurrent and future cerebrovascular events. These associations persist after accounting for confounding variables known to be disease-causing in both circulations, which supports the potential use of retinal vasculature findings to stratify individuals with regards to cerebral vascular disease risk.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027561</affiliation-url><afid>60027561</afid><affilname>University of Illinois at Chicago</affilname><name-variant>University of Illinois at Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027561</affiliation-url><afid>60027561</afid><affilname>University of Illinois at Chicago</affilname><name-variant>University of Illinois at Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115293634</affiliation-url><afid>115293634</afid><affilname>UIC Department of Ophthalmology and Visual Sciences (M/C 648)</affilname><name-variant>UIC Department of Ophthalmology and Visual Sciences (M/C 648)</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35090549500</author-url><authid>35090549500</authid><authname>Moss H.</authname><surname>Moss</surname><given-name>Heather E.</given-name><initials>H.E.</initials><afid>60027561</afid><afid>60027561</afid><afid>115293634</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35090549500</author-url><authid>35090549500</authid><authname>Moss H.</authname><surname>Moss</surname><given-name>Heather E.</given-name><initials>H.E.</initials><afid>60027561</afid><afid>60027561</afid><afid>115293634</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35090549500</author-url><authid>35090549500</authid><authname>Moss H.</authname><surname>Moss</surname><given-name>Heather E.</given-name><initials>H.E.</initials><afid>60027561</afid><afid>60027561</afid><afid>115293634</afid></author><authkeywords>Arteries | Retina | Stroke | Veins</authkeywords><intid>1786087228</intid><article-number>40</article-number><source-id>14989</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930199161"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930199161?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930199161&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930199161&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930199161</prism:url><dc:identifier>SCOPUS_ID:84930199161</dc:identifier><eid>2-s2.0-84930199161</eid><dc:title>Treatment of Chronic Inflammatory Demyelinating Polyneuropathy</dc:title><dc:creator>Kleyman I.</dc:creator><prism:publicationName>Current Neurology and Neuroscience Reports</prism:publicationName><prism:issn>15284042</prism:issn><prism:eIssn>15346293</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-27</prism:coverDate><prism:coverDisplayDate>27 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11910-015-0563-z</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Chronic inflammatory demyelinating polyneuropathy (CIDP) is one of the acquired demyelinating neuropathies and is considered to be immune mediated. Diagnosis is typically based on clinical history, neurologic examination, electrophysiologic studies, CSF studies, and pathologic examination. Early diagnosis and treatment is important to prevent irreversible axonal loss and optimize improvement in function. The first-line agents for treatment are intravenous immunoglobulin (IVIg), corticosteroids, and plasmapheresis, which have all been demonstrated to be effective in controlled studies. Studies have not shown a significant difference between these three treatments, and the initial choice of therapy is often based on availability, cost, ease of administration, and side effect profile. If patients do not respond to one of these agents, they may respond to one of the others and sometimes in combination. If the first-line agents are not effective, chemotherapeutic or immunosuppressive agents may be considered. There are limited controlled studies of these modalities, and they are often used in conjunction with a first-line treatment. The majority of patients require long-term therapy to maintain a response and to prevent relapse.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030162</affiliation-url><afid>60030162</afid><affilname>Columbia University in the City of New York</affilname><name-variant>Columbia University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027565</affiliation-url><afid>60027565</afid><affilname>Columbia University Medical Center</affilname><name-variant>Columbia University</name-variant><affiliation-city>New York</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54398042800</author-url><authid>54398042800</authid><authname>Kleyman I.</authname><surname>Kleyman</surname><given-name>Inna</given-name><initials>I.</initials><afid>60030162</afid><afid>60027565</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54398042800</author-url><authid>54398042800</authid><authname>Kleyman I.</authname><surname>Kleyman</surname><given-name>Inna</given-name><initials>I.</initials><afid>60030162</afid><afid>60027565</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603926056</author-url><authid>6603926056</authid><authname>Brannagan T.</authname><surname>Brannagan</surname><given-name>Thomas H.</given-name><initials>T.H.</initials><afid>60030162</afid></author><authkeywords>Chronic inflammatory demyelinating polyneuropathy (CIDP) | Corticosteroids | Intravenous immunoglobulin (IVIg) | Plasmapheresis</authkeywords><intid>1536088356</intid><article-number>47</article-number><source-id>14989</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930211118"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930211118?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930211118&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930211118&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930211118</prism:url><dc:identifier>SCOPUS_ID:84930211118</dc:identifier><eid>2-s2.0-84930211118</eid><dc:title>Dual Antiplatelet Therapy in Acute Ischemic Stroke</dc:title><dc:creator>Asdaghi N.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-26</prism:coverDate><prism:coverDisplayDate>26 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0515-8</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Stroke recurrence is common in the early period after a cerebral ischemic event. Treatment with an antiplatelet agent is recommended to reduce recurrent stroke and death in patients with a non-cardioembolic ischemic stroke and transient ischemic attack. Compared to monotherapy, dual antiplatelet therapy has more robust inhibition of platelet activation but a higher risk of systemic bleeding and intracranial hemorrhage. Randomized controlled trials and meta-analyses suggest that short-term use of dual antiplatelet treatment initiated early after ischemic stroke and TIA reduces the risk of recurrent stroke and major vascular events without significantly increasing the hemorrhagic complication rates, particularly in those with large-vessel disease, while long-term dual antiplatelet treatment increases the risk of systemic and intracranial hemorrhage over time, offsetting any potential benefit. Until further data becomes available, clinicians should carefully assess this risk and benefit in each case and continually reevaluate the need for prolonged dual antiplatelet therapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021519</affiliation-url><afid>60021519</afid><affilname>University of Miami Leonard M. Miller School of Medicine</affilname><name-variant>University of Miami</name-variant><affiliation-city>Miami</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16480099900</author-url><authid>16480099900</authid><authname>Asdaghi N.</authname><surname>Asdaghi</surname><given-name>Negar</given-name><initials>N.</initials><afid>60021519</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7103391458</author-url><authid>7103391458</authid><authname>Romano J.</authname><surname>Romano</surname><given-name>Jose G.</given-name><initials>J.G.</initials><afid>60021519</afid></author><authkeywords>Antiplatelet therapy | Aspirin | Cerebral infarction | Clopidogrel | Ischemic stroke | Transient ischemic attack</authkeywords><intid>1536087008</intid><article-number>37</article-number><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930202185"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930202185?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930202185&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930202185&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930202185</prism:url><dc:identifier>SCOPUS_ID:84930202185</dc:identifier><eid>2-s2.0-84930202185</eid><dc:title>Update on Blood Pressure Control and Renal Outcomes in Diabetes Mellitus</dc:title><dc:creator>Joven M.</dc:creator><prism:publicationName>Current Diabetes Reports</prism:publicationName><prism:issn>15344827</prism:issn><prism:eIssn>15390829</prism:eIssn><prism:volume>15</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-26</prism:coverDate><prism:coverDisplayDate>26 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11892-015-0613-6</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Diabetic nephropathy (DN) is associated with a high incidence of cardiovascular (CV) morbidity and mortality. Although relationships between hypertension and diabetic nephropathy are complex, blood pressure (BP) control is an important management strategy in the prevention of onset and progression of DN in patients with diabetes mellitus (DM). Recent guidelines recommend less stringent BP targets among patients with type 2 DM and chronic kidney disease. These recommendations are based mostly on lack of benefit in CV outcomes with a low BP target. We review the current information on efficacy of BP control in improving renal outcomes in patients with type 2 DM. Presently, although intensive BP control has been was beneficial in decreasing albuminuria, it has not translated into reductions in risks of hard renal endpoints, such as progression to end-stage renal disease, the need for renal replacement therapy, and mortality from renal causes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012028</affiliation-url><afid>60012028</afid><affilname>Creighton University</affilname><name-variant>Creighton University</name-variant><affiliation-city>Omaha</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:107064832</affiliation-url><afid>107064832</afid><affilname>VA Nebraska-Western Iowa Health Care System</affilname><name-variant>VA Nebraska-Western Iowa Health Care System</name-variant><affiliation-city>Omaha</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55980974100</author-url><authid>55980974100</authid><authname>Joven M.</authname><surname>Joven</surname><given-name>Mark Henry</given-name><initials>M.H.</initials><afid>60012028</afid><afid>107064832</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55980974100</author-url><authid>55980974100</authid><authname>Joven M.</authname><surname>Joven</surname><given-name>Mark Henry</given-name><initials>M.H.</initials><afid>60012028</afid><afid>107064832</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55568521800</author-url><authid>55568521800</authid><authname>Anderson R.</authname><surname>Anderson</surname><given-name>Robert J.</given-name><initials>R.J.</initials><afid>60012028</afid><afid>107064832</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55568521800</author-url><authid>55568521800</authid><authname>Anderson R.</authname><surname>Anderson</surname><given-name>Robert J.</given-name><initials>R.J.</initials><afid>60012028</afid><afid>107064832</afid></author><authkeywords>Albuminuria | Blood pressure control | Blood pressure targets | Chronic kidney disease | Renal outcomes | Type 2 diabetes mellitus</authkeywords><intid>1036081646</intid><article-number>44</article-number><source-id>25465</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930203712"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930203712?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930203712&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930203712&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930203712</prism:url><dc:identifier>SCOPUS_ID:84930203712</dc:identifier><eid>2-s2.0-84930203712</eid><dc:title>Effects of Exercise on Gene Expression of Inflammatory Markers in Human Peripheral Blood Cells: A Systematic Review</dc:title><dc:creator>Gjevestad G.</dc:creator><prism:publicationName>Current Cardiovascular Risk Reports</prism:publicationName><prism:issn>19329520</prism:issn><prism:eIssn>19329563</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-26</prism:coverDate><prism:coverDisplayDate>26 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s12170-015-0463-4</prism:doi><dc:description>Â© 2015, The Author(s). Regular physical activity seems to be one of the most important contributors to prevent disease and promote health. Being physically active reduces the risk of developing chronic diseases such as cardiovascular disease, diabetes, and some types of cancers. The molecular mechanisms are however not fully elucidated. Depending on duration and intensity, exercise will cause disruption of muscle fibers triggering a temporary inflammatory response. This response may not only involve the muscle tissue, but also peripheral tissues such as white blood cells, which are important components of the immune system. The immune system plays a vital role in the development of atherosclerosis, thereby making white blood cells relevant to study when looking at molecular mechanisms induced by physical activity. In this review, we summarize the existing literature on exercise and gene expression in humanÂ white blood cells, and discuss these results in relation to inflammation and atherosclerosis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010348</affiliation-url><afid>60010348</afid><affilname>Universitetet i Oslo</affilname><name-variant>University of Oslo</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60080290</affiliation-url><afid>60080290</afid><affilname>TINE BA</affilname><name-variant>TINE Norwegian Dairies BA</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60105037</affiliation-url><afid>60105037</afid><affilname>Oslo University Hospital</affilname><name-variant>Oslo University Hospital</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60068730</affiliation-url><afid>60068730</afid><affilname>HÃ¸gskolen i Oslo og Akershus</affilname><name-variant>Oslo University College</name-variant><affiliation-city>Oslo</affiliation-city><affiliation-country>Norway</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663249000</author-url><authid>56663249000</authid><authname>Gjevestad G.</authname><surname>Gjevestad</surname><given-name>Gyrd O.</given-name><initials>G.O.</initials><afid>60010348</afid><afid>60080290</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56663249000</author-url><authid>56663249000</authid><authname>Gjevestad G.</authname><surname>Gjevestad</surname><given-name>Gyrd O.</given-name><initials>G.O.</initials><afid>60010348</afid><afid>60080290</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603578893</author-url><authid>6603578893</authid><authname>Holven K.</authname><surname>Holven</surname><given-name>Kirsten B.</given-name><initials>K.B.</initials><afid>60010348</afid><afid>60105037</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6603578893</author-url><authid>6603578893</authid><authname>Holven K.</authname><surname>Holven</surname><given-name>Kirsten B.</given-name><initials>K.B.</initials><afid>60010348</afid><afid>60105037</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6507729473</author-url><authid>6507729473</authid><authname>Ulven S.</authname><surname>Ulven</surname><given-name>Stine M.</given-name><initials>S.M.</initials><afid>60068730</afid></author><authkeywords>Atherosclerosis | Exercise | Gene expression | Inflammation | Leukocytes | Lymphocytes | Monocytes | PBMCs | Peripheral mononuclear blood cells | Physical activity</authkeywords><intid>1036081891</intid><article-number>34</article-number><source-id>19500157062</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929492792"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929492792?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929492792&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929492792&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929492792</prism:url><dc:identifier>SCOPUS_ID:84929492792</dc:identifier><eid>2-s2.0-84929492792</eid><dc:title>Myocardial mitochondrial dysfunction in mice lacking adiponectin receptor 1</dc:title><dc:creator>Koentges C.</dc:creator><prism:publicationName>Basic Research in Cardiology</prism:publicationName><prism:issn>03008428</prism:issn><prism:eIssn>14351803</prism:eIssn><prism:volume>110</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00395-015-0495-4</prism:doi><dc:description>Â© 2015, Springer-Verlag Berlin Heidelberg. Hypoadiponectinemia is an independent predictor of cardiovascular disease, impairs mitochondrial function in skeletal muscle, and has been linked to the pathogenesis of Type 2 diabetes. In models of Type 2 diabetes, myocardial mitochondrial function is impaired, which is improved by increasing serum adiponectin levels. We aimed to define the roles of adiponectin receptor 1 (AdipoR1) and 2 (AdipoR2) in adiponectin-evoked regulation of mitochondrial function in the heart. In isolated working hearts in mice lacking AdipoR1, myocardial oxygen consumption was increased without a concomitant increase in cardiac work, resulting in reduced cardiac efficiency. Activities of mitochondrial oxidative phosphorylation (OXPHOS) complexes were reduced, accompanied by reduced OXPHOS protein levels, phosphorylation of AMP-activated protein kinase, sirtuin 1 activity, and peroxisome proliferator-activated receptor Î³ coactivator-1Î± (PGC-1Î±) signaling. Decreased ATP/O ratios suggested myocardial mitochondrial uncoupling in AdipoR1-deficient mice, which was normalized by lowering increased mitochondrial 4-hydroxynonenal levels following treatment with the mitochondria-targeted antioxidant Mn (III) tetrakis (4-benzoic acid) porphyrin. Lack of AdipoR2 did not impair mitochondrial function and coupling in the heart. Thus, lack of AdipoR1 impairs myocardial mitochondrial function and coupling, suggesting that impaired AdipoR1 signaling may contribute to mitochondrial dysfunction and mitochondrial uncoupling in Type 2 diabetic hearts.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025641</affiliation-url><afid>60025641</afid><affilname>Universitat Freiburg im Breisgau</affilname><name-variant>UniversitÃ¤t Freiburg</name-variant><affiliation-city>Freiburg im Breisgau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025641</affiliation-url><afid>60025641</afid><affilname>Universitat Freiburg im Breisgau</affilname><name-variant>UniversitÃ¤t Freiburg</name-variant><affiliation-city>Freiburg im Breisgau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027086</affiliation-url><afid>60027086</afid><affilname>University of Alabama at Birmingham</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city>Birmingham</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009788</affiliation-url><afid>60009788</afid><affilname>University of Iowa Caver College of Medicine</affilname><name-variant>University of Iowa College of Medicine</name-variant><affiliation-city>Iowa City</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023251</affiliation-url><afid>60023251</afid><affilname>Universitatsklinikum Jena und Medizinische Fakultat</affilname><name-variant>University Hospital Jena</name-variant><affiliation-city>Jena</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024805</affiliation-url><afid>60024805</afid><affilname>Universitats Klinikum Freiburg und Medizinische Fakultat</affilname><name-variant>University Hospital Freiburg</name-variant><affiliation-city>Freiburg im Breisgau</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:43461304500</author-url><authid>43461304500</authid><authname>Koentges C.</authname><surname>Koentges</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60025641</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56283778700</author-url><authid>56283778700</authid><authname>KÃ¶nig A.</authname><surname>KÃ¶nig</surname><given-name>Alexandra</given-name><initials>A.</initials><afid>60025641</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56573985600</author-url><authid>56573985600</authid><authname>Pfeil K.</authname><surname>Pfeil</surname><given-name>Katharina</given-name><initials>K.</initials><afid>60025641</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56647829500</author-url><authid>56647829500</authid><authname>HÃ¶lscher M.</authname><surname>HÃ¶lscher</surname><given-name>Maximilian E.</given-name><initials>M.E.</initials><afid>60025641</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:54411397900</author-url><authid>54411397900</authid><authname>Schnick T.</authname><surname>Schnick</surname><given-name>Tilman</given-name><initials>T.</initials><afid>60025641</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6602484414</author-url><authid>6602484414</authid><authname>Wende A.</authname><surname>Wende</surname><given-name>Adam R.</given-name><initials>A.R.</initials><afid>60027086</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35750551200</author-url><authid>35750551200</authid><authname>Schrepper A.</authname><surname>Schrepper</surname><given-name>Andrea</given-name><initials>A.</initials><afid>60023251</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:25824781900</author-url><authid>25824781900</authid><authname>Cimolai M.</authname><surname>Cimolai</surname><given-name>Maria C.</given-name><initials>M.C.</initials><afid>60025641</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55322677800</author-url><authid>55322677800</authid><authname>Kersting S.</authname><surname>Kersting</surname><given-name>Sophia</given-name><initials>S.</initials><afid>60025641</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56573314000</author-url><authid>56573314000</authid><authname>Hoffmann M.</authname><surname>Hoffmann</surname><given-name>Michael M.</given-name><initials>M.M.</initials><afid>60025641</afid><afid>60024805</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56573314000</author-url><authid>56573314000</authid><authname>Hoffmann M.</authname><surname>Hoffmann</surname><given-name>Michael M.</given-name><initials>M.M.</initials><afid>60025641</afid><afid>60024805</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56648089600</author-url><authid>56648089600</authid><authname>Asal J.</authname><surname>Asal</surname><given-name>Judith</given-name><initials>J.</initials><afid>60025641</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:44661443200</author-url><authid>44661443200</authid><authname>Osterholt M.</authname><surname>Osterholt</surname><given-name>Moritz</given-name><initials>M.</initials><afid>60023251</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:24399452400</author-url><authid>24399452400</authid><authname>Odening K.</authname><surname>Odening</surname><given-name>Katja E.</given-name><initials>K.E.</initials><afid>60025641</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:7003954480</author-url><authid>7003954480</authid><authname>Doenst T.</authname><surname>Doenst</surname><given-name>Torsten</given-name><initials>T.</initials><afid>60023251</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:55851623900</author-url><authid>55851623900</authid><authname>Hein L.</authname><surname>Hein</surname><given-name>Lutz</given-name><initials>L.</initials><afid>60025641</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:7202417444</author-url><authid>7202417444</authid><authname>Abel E.</authname><surname>Abel</surname><given-name>E. Dale</given-name><initials>E.D.</initials><afid>60009788</afid></author><author seq="17"><author-url>http://api.elsevier.com/content/author/author_id:56465466300</author-url><authid>56465466300</authid><authname>Bode C.</authname><surname>Bode</surname><given-name>Christoph</given-name><initials>C.</initials><afid>60025641</afid></author><author seq="18"><author-url>http://api.elsevier.com/content/author/author_id:22233449600</author-url><authid>22233449600</authid><authname>Bugger H.</authname><surname>Bugger</surname><given-name>Heiko</given-name><initials>H.</initials><afid>60025641</afid></author><authkeywords>Adiponectin receptor | Heart | Mitochondria</authkeywords><intid>2035959163</intid><article-number>4</article-number><source-id>22488</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929412304"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929412304?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929412304&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929412304&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929412304</prism:url><dc:identifier>SCOPUS_ID:84929412304</dc:identifier><eid>2-s2.0-84929412304</eid><dc:title>Assessment of Mitral Valve Disease: A Review of Imaging Modalities</dc:title><dc:creator>Motiwala S.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0390-1</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Mitral valve disease (MVD) related to mitral valve prolapse (MVP), coronary artery disease (CAD), and calcific mitral stenosis, is increasing in prevalence across the USA and Europe in the context of a longer life expectancy and aging population. In developing countries, rheumatic heart disease remains a major cause of MVD. Echocardiography represents the primary diagnostic modality for assessment of the mitral valve (MV). With the implementation of three-dimensional imaging, echocardiography has become an indispensable tool to evaluate the morphology, geometry, and function of the MV apparatus in the pre-operative setting. However, recognition of its limitations and advances in newer technologies have led to a growing interest in other imaging modalities such as cardiac magnetic resonance (CMR). Although still not widely available, CMR is an essential complement to echocardiography, especially when poor image quality, significant variability in flow diameter measurements, and geometric assumptions of flow orifice preclude accurate quantification of mitral regurgitation on echocardiographic images. In addition, CMR can reliably provide quantitative determination of ventricular volumes and function, hence facilitating surgical decision-making when serial linear echocardiographic measurements are discrepant. Finally, CMR assessment of fibrosis using late gadolinium enhancement allows better understanding of the interactions between MVD and the myocardium in both MVP and MVD related to CAD or other myopathy. In this review, we summarize the role of the available imaging modalities in understanding valvular pathology and determining severity of regurgitation or stenosis. Recently published valvular guidelines highlight the importance of monitoring MVD progression and the shift to intervention earlier in the course of disease. In this context, we also discuss the potential role of echocardiography and CMR in identifying early stages of MVD and/or pre-clinical markers of myocardial dysfunction.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002746</affiliation-url><afid>60002746</afid><affilname>Harvard Medical School</affilname><name-variant>Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002746</affiliation-url><afid>60002746</afid><affilname>Harvard Medical School</affilname><name-variant>Harvard Medical School</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56646287100</author-url><authid>56646287100</authid><authname>Motiwala S.</authname><surname>Motiwala</surname><given-name>Shweta R.</given-name><initials>S.R.</initials><afid>60002746</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23004254500</author-url><authid>23004254500</authid><authname>Delling F.</authname><surname>Delling</surname><given-name>Francesca N.</given-name><initials>F.N.</initials><afid>60002746</afid></author><authkeywords>Cardiac magnetic resonance | Echocardiography | Mitral regurgitation | Mitral stenosis | Mitral valve disease | Mitral valve prolapse</authkeywords><intid>1035951300</intid><article-number>2</article-number><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929411583"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929411583?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929411583&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929411583&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929411583</prism:url><dc:identifier>SCOPUS_ID:84929411583</dc:identifier><eid>2-s2.0-84929411583</eid><dc:title>Cardiac Arrest: the Changing Incidence of Ventricular Fibrillation</dc:title><dc:creator>Keller S.</dc:creator><prism:publicationName>Current Treatment Options in Cardiovascular Medicine</prism:publicationName><prism:issn>10928464</prism:issn><prism:eIssn>15343189</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11936-015-0392-z</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York (outside the USA). There are more than 300,000 out-of-hospital cardiac arrests (OHCA) in the USA annually, which can be grouped into those presenting with tachyarrhythmic (shockable) rhythms and those presenting with non-tachyarrhythmic rhythms. The incidence of tachyarrhythmic rhythms, which include ventricular fibrillation (VF) and pulseless ventricular tachycardia (VT), has been noted to be progressively decreasing in multiple studies of OHCA. Improved medical and surgical therapies for ischemic heart disease, and the widespread use of implantable cardiac defibrillators (ICDs), have likely contributed to a declining incidence of VF arrest and may result in conversion of an otherwise VF event into a pulseless electrical activity (PEA) arrest. As the incidence of VF has declined, it is unclear if the absolute incidence of non-tachyarrhythmic rhythms has increased or remained largely unchanged. This article discusses the changing rates of presenting rhythms in sudden cardiac arrest, the underlying cellular mechanisms of PEA, the factors contributing to the relative increase in the rate of PEA arrests, and current treatment options.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006577</affiliation-url><afid>60006577</afid><affilname>National Institutes of Health, Bethesda</affilname><name-variant>National Institute of Health</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001117</affiliation-url><afid>60001117</afid><affilname>The Johns Hopkins School of Medicine</affilname><name-variant>Johns Hopkins School of Medicine</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001117</affiliation-url><afid>60001117</afid><affilname>The Johns Hopkins School of Medicine</affilname><name-variant>Johns Hopkins School of Medicine</name-variant><affiliation-city>Baltimore</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56123782200</author-url><authid>56123782200</authid><authname>Keller S.</authname><surname>Keller</surname><given-name>Steven P.</given-name><initials>S.P.</initials><afid>60006577</afid><afid>60001117</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56123782200</author-url><authid>56123782200</authid><authname>Keller S.</authname><surname>Keller</surname><given-name>Steven P.</given-name><initials>S.P.</initials><afid>60006577</afid><afid>60001117</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56664671000</author-url><authid>56664671000</authid><authname>Halperin H.</authname><surname>Halperin</surname><given-name>Henry R.</given-name><initials>H.R.</initials><afid>60001117</afid></author><authkeywords>Cardiopulmonary resuscitation | Chest compressions | Defibrillation | Pulseless electrical activity | Sudden cardiac arrest | Ventricular fibrillation</authkeywords><intid>1535954032</intid><article-number>1</article-number><source-id>23154</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929407489"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929407489?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929407489&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929407489&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929407489</prism:url><dc:identifier>SCOPUS_ID:84929407489</dc:identifier><eid>2-s2.0-84929407489</eid><dc:title>Assessment and Treatment of Anxiety Disorders in Children and Adolescents</dc:title><dc:creator>Wehry A.</dc:creator><prism:publicationName>Current Psychiatry Reports</prism:publicationName><prism:issn>15233812</prism:issn><prism:eIssn>15351645</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11920-015-0591-z</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Recent advances in the developmental epidemiology, neurobiology, and treatment of pediatric anxiety disorders have increased our understanding of these conditions and herald improved outcomes for affected children and adolescents. This article reviews the current epidemiology, longitudinal trajectory, and neurobiology of anxiety disorders in youth. Additionally, we summarize the current evidence for both psychotherapeutic and psychopharmacologic treatments of fear-based anxiety disorders (e.g., generalized, social, and separation anxiety disorders) in children and adolescents. Current data suggest that these disorders begin in childhood and adolescence, exhibit homotypic continuity, and increase the risk of secondary anxiety and mood disorders. Psychopharmacologic trials involving selective serotonin reuptake inhibitors (SSRIs) and selective serotonin norepinephrine reuptake inhibitors (SSNRIs) are effective in pediatric patients with anxiety disorders and have generally demonstrated moderate effect sizes. Additionally, current data support cognitive behavioral therapy (CBT) for the treatment of these conditions in youth and suggest that the combination of psychotherapy + an SSRI may be associated with greater improvement than would be expected with either treatment as monotherapy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025152</affiliation-url><afid>60025152</afid><affilname>University of Cincinnati</affilname><name-variant>University of Cincinnati</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018353</affiliation-url><afid>60018353</afid><affilname>Technische Universitat Dresden</affilname><name-variant>Technische UniversitÃ¤t Dresden</name-variant><affiliation-city>Dresden</affiliation-city><affiliation-country>Germany</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027561</affiliation-url><afid>60027561</afid><affilname>University of Illinois at Chicago</affilname><name-variant>University of Illinois at Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030440</affiliation-url><afid>60030440</afid><affilname>Cincinnati Children's Hospital Medical Center</affilname><name-variant>Children's Hospital Medical Center</name-variant><affiliation-city>Cincinnati</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55208956500</author-url><authid>55208956500</authid><authname>Wehry A.</authname><surname>Wehry</surname><given-name>Anna M.</given-name><initials>A.M.</initials><afid>60025152</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35333592900</author-url><authid>35333592900</authid><authname>Beesdo-Baum K.</authname><surname>Beesdo-Baum</surname><given-name>Katja</given-name><initials>K.</initials><afid>60018353</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56648366000</author-url><authid>56648366000</authid><authname>Hennelly M.</authname><surname>Hennelly</surname><given-name>Meghann M.</given-name><initials>M.M.</initials><afid>60027561</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56649481800</author-url><authid>56649481800</authid><authname>Connolly S.</authname><surname>Connolly</surname><given-name>Sucheta D.</given-name><initials>S.D.</initials><afid>60027561</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003998278</author-url><authid>7003998278</authid><authname>Strawn J.</authname><surname>Strawn</surname><given-name>Jeffrey R.</given-name><initials>J.R.</initials><afid>60025152</afid><afid>60030440</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003998278</author-url><authid>7003998278</authid><authname>Strawn J.</authname><surname>Strawn</surname><given-name>Jeffrey R.</given-name><initials>J.R.</initials><afid>60025152</afid><afid>60030440</afid></author><authkeywords>Antidepressant | Anxiety disorders</authkeywords><intid>2035950798</intid><article-number>3</article-number><source-id>15011</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929463124"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929463124?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929463124&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929463124&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929463124</prism:url><dc:identifier>SCOPUS_ID:84929463124</dc:identifier><eid>2-s2.0-84929463124</eid><dc:title>Coronary Artery Disease Progression: Insights from Cardiac CT</dc:title><dc:creator>Yeh V.</dc:creator><prism:publicationName>Current Cardiovascular Imaging Reports</prism:publicationName><prism:issn>19419066</prism:issn><prism:eIssn>19419074</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s12410-015-9341-1</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Coronary plaque progression is a multi-faceted process influenced by cardiovascular risk factors, as well as the presence, extent, stenosis, morphology, and vulnerability of plaque, which may ultimately result in myocardial infarction or death. Traditionally, intravascular ultrasound (IVUS) has been the primary modality to study atherosclerosis progression. However, it is invasive and impractical for screening or monitoring. While coronary artery calcium (CAC) scoring has been widely studied as a non-invasive method to measure plaque progression, it is limited to visualization of stenosis and non-calcified plaque. Coronary computed tomographic angiography (CCTA) allows for visualization of the severity of stenosis, plaque burden, plaque morphology, and ability to differentiate between plaque types. Furthermore, certain CCTA plaque features are useful in identifying vulnerable plaque including low attenuation plaque, positive remodeling, spotty calcification, and napkin-ring sign. This review covers multiple aspects of plaque progressionâits pathophysiology, clinical implications, and use of novel non-invasive technology for the assessment of plaque progression over time.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032023</affiliation-url><afid>60032023</afid><affilname>UCLA Medical Center</affilname><name-variant>UCLA Medical Center</name-variant><affiliation-city>Los Angeles</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56647895500</author-url><authid>56647895500</authid><authname>Yeh V.</authname><surname>Yeh</surname><given-name>Victoria</given-name><initials>V.</initials><afid>60032023</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56602487200</author-url><authid>56602487200</authid><authname>Nakanishi R.</authname><surname>Nakanishi</surname><given-name>Rine</given-name><initials>R.</initials><afid>60032023</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55367861700</author-url><authid>55367861700</authid><authname>Budoff M.</authname><surname>Budoff</surname><given-name>Matthew J.</given-name><initials>M.J.</initials><afid>60032023</afid></author><authkeywords>Coronary artery disease | Coronary computed tomographic angiography | Plaque progression</authkeywords><intid>1785964185</intid><article-number>2</article-number><source-id>19600157307</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929402815"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929402815?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929402815&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929402815&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929402815</prism:url><dc:identifier>SCOPUS_ID:84929402815</dc:identifier><eid>2-s2.0-84929402815</eid><dc:title>Prevention of Stroke in Rheumatoid Arthritis</dc:title><dc:creator>Dhillon N.</dc:creator><prism:publicationName>Current Treatment Options in Neurology</prism:publicationName><prism:issn>10928480</prism:issn><prism:eIssn>15343138</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11940-015-0356-3</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Recognizing that systemic inflammation is a major contributor to the increased risk of cardiovascular disease (CVD), including stroke, in rheumatoid arthritis (RA) serves as the basis for prevention strategies for cerebrovascular disease in RA. In addition to traditional cardiovascular risk factors, recognize that RA may be an independent risk factor for cerebrovascular accident (CVA). The risk of CVD should be assessed in each patient with RA, utilizing modified risk score calculators. Careful monitoring and control of systemic inflammation should be undertaken in conjunction with assessing each patientâs CVD risk, acknowledging the benefits and risks of specific RA-directed therapies. Emphasis should be given to early and aggressive control of inflammation in RA patients, particularly those with seropositivity, increased inflammatory markers, long disease duration (&gt;10Â years), and/or extra-articular manifestations. In RA patients requiring glucocorticoid therapy, attempts should be made to use or wean to the minimal effective dose (preferably less than 7.5Â mg/day). It should be recognized that both disease-modifying antirheumatic drugs (DMARDs), particularly methotrexate, and tumor necrosis factor (TNF)-alpha inhibitors partially mitigate the risk of CVD. In patients with inadequate control of inflammation with DMARDs, consideration should be given to switch to anti-TNF agents earlier in the disease process. Modifiable risk factors should be addressed as per guidelines for the general population. Active RA may be considered as a risk equivalent to diabetes mellitus when applying these guidelines. With regard to lipid management and use of statin therapy, further studies are required given the apparent âlipid paradoxâ in RA. Use of aspirin for primary prevention in RA has not been well studied; however, when aspirin is used for secondary prevention, one should recognize that concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the antiplatelet effect. Given the cardiovascular risk associated with NSAIDs, the lowest possible dose for the shortest time should be used.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012018</affiliation-url><afid>60012018</afid><affilname>University of Pittsburgh Medical Center</affilname><name-variant>University of Pittsburgh Medical Center</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36349854600</author-url><authid>36349854600</authid><authname>Dhillon N.</authname><surname>Dhillon</surname><given-name>Namrata</given-name><initials>N.</initials><afid>60012018</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:9036594200</author-url><authid>9036594200</authid><authname>Liang K.</authname><surname>Liang</surname><given-name>Kimberly</given-name><initials>K.</initials><afid>60012018</afid></author><authkeywords>Atherosclerosis | Cardiovascular disease | Cerebrovascular disease | Prevention | Rheumatoid arthritis | Stroke</authkeywords><intid>1035951173</intid><article-number>4</article-number><source-id>15013</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929401738"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929401738?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929401738&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929401738&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929401738</prism:url><dc:identifier>SCOPUS_ID:84929401738</dc:identifier><eid>2-s2.0-84929401738</eid><dc:title>Voltage-Dependent Calcium Channels in Chondrocytes: Roles in Health and Disease</dc:title><dc:creator>Matta C.</dc:creator><prism:publicationName>Current Rheumatology Reports</prism:publicationName><prism:issn>15233774</prism:issn><prism:eIssn>15346307</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11926-015-0521-4</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Chondrocytes, the single cell type in adult articular cartilage, have conventionally been considered to be non-excitable cells. However, recent evidence suggests that their resting membrane potential (RMP) is less negative than that of excitable cells, and they are fully equipped with channels that control ion, water and osmolyte movement across the chondrocyte membrane. Amongst calcium-specific ion channels, members of the voltage-dependent calcium channel (VDCC) family are expressed in chondrocytes where they are functionally active. L-type VDCC inhibitors such as nifedipine and verapamil have contributed to our understanding of the roles of these ion channels in chondrogenesis, chondrocyte signalling and mechanotransduction. In this narrative review, we discuss published data indicating that VDCC function is vital for chondrocyte health, especially in regulating proliferation and maturation. We also highlight the fact that activation of VDCC function appears to accompany various inflammatory aspects of osteoarthritis (OA) and, based on in vitro data, the application of nifedipine and/or verapamil may be a promising approach for ameliorating OA severity. However, very few studies on clinical outcomes are available regarding the influence of calcium antagonists, which are used primarily for treating cardiovascular conditions in OA patients. This review is intended to stimulate further research on the chondrocyte âchannelomeâ, contribute to the development of novel therapeutic strategies and facilitate the retargeting and repositioning of existing pharmacological agents currently used for other comorbidities for the treatment of OA.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021097</affiliation-url><afid>60021097</afid><affilname>University of Surrey</affilname><name-variant>University of Surrey</name-variant><affiliation-city>Surrey</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004400</affiliation-url><afid>60004400</afid><affilname>Debreceni Egyetem</affilname><name-variant>University of Debrecen</name-variant><affiliation-city>Debrecen</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015138</affiliation-url><afid>60015138</afid><affilname>University of Nottingham</affilname><name-variant>University of Nottingham</name-variant><affiliation-city>Nottingham</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004582</affiliation-url><afid>60004582</afid><affilname>King Abdulaziz University</affilname><name-variant>King Abdulaziz University</name-variant><affiliation-city>Jeddah</affiliation-city><affiliation-country>Saudi Arabia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8320719800</author-url><authid>8320719800</authid><authname>Matta C.</authname><surname>Matta</surname><given-name>Csaba</given-name><initials>C.</initials><afid>60021097</afid><afid>60004400</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:8320719800</author-url><authid>8320719800</authid><authname>Matta C.</authname><surname>Matta</surname><given-name>Csaba</given-name><initials>C.</initials><afid>60021097</afid><afid>60004400</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6507940814</author-url><authid>6507940814</authid><authname>ZÃ¡kÃ¡ny R.</authname><surname>ZÃ¡kÃ¡ny</surname><given-name>RÃ³za</given-name><initials>R.</initials><afid>60004400</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003311894</author-url><authid>7003311894</authid><authname>Mobasheri A.</authname><surname>Mobasheri</surname><given-name>Ali</given-name><initials>A.</initials><afid>60021097</afid><afid>60015138</afid><afid>60004582</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003311894</author-url><authid>7003311894</authid><authname>Mobasheri A.</authname><surname>Mobasheri</surname><given-name>Ali</given-name><initials>A.</initials><afid>60021097</afid><afid>60015138</afid><afid>60004582</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003311894</author-url><authid>7003311894</authid><authname>Mobasheri A.</authname><surname>Mobasheri</surname><given-name>Ali</given-name><initials>A.</initials><afid>60021097</afid><afid>60015138</afid><afid>60004582</afid></author><authkeywords>Calcium channel blockers | Cartilage | Chondrocyte | Joint inflammation | Nifedipine | Osteoarthritis (OA) | Verapamil | Voltage-dependent calcium channel</authkeywords><intid>1535955546</intid><article-number>1</article-number><source-id>19212</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929416012"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929416012?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929416012&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929416012&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929416012</prism:url><dc:identifier>SCOPUS_ID:84929416012</dc:identifier><eid>2-s2.0-84929416012</eid><dc:title>Intra-Arterial Therapy for Acute Ischemic Stroke: a Golden Age</dc:title><dc:creator>Cougo-Pinto P.</dc:creator><prism:publicationName>Current Treatment Options in Neurology</prism:publicationName><prism:issn>10928480</prism:issn><prism:eIssn>15343138</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11940-015-0360-7</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. With the recent publication of multiple trials demonstrating the superiority of the endovascular treatment of patients presenting with stroke from large vessel occlusion (LVO) over medical management, the emergent care of these patients is entering a new era. This realization justifies an aggressive treatment approach with these stroke patients, given the poor natural history of the disease. In general, treatment should occur as quickly as is reasonably possible. Patients with NIHSS &gt;8 should be considered, and if &lt;6Â h from onset imaging selection achieved with CT and CTA. Those with ASPECTS &gt;5, LVO and intermediate or good collaterals should be treated emergently. For patients with clinical deficits presenting in later timeframes MRI should be used to define core infarct size and therefore treatment eligibility. MRI might also be considered for the workup of stroke patients in centers that can offer it rapidly. Recanalization should be attempted with a stentriever or using a direct aspiration technique, with the patient under conscious sedation rather than general anesthesia, if that is a safe option. Angiographically, the goal is reperfusion of mTICI 2b/3. Post-procedure, the patient should be admitted to an intensive care setting and assessed for inpatient rehabilitation placement as soon as stable. Continuous institutional process improvement ensures that optimization of treatment times and logistics is an ongoing endeavor. Finally, patient outcomes should be assessed at three months, most commonly using the modified Rankin score.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019578</affiliation-url><afid>60019578</afid><affilname>Monash University</affilname><name-variant>Monash University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023882</affiliation-url><afid>60023882</afid><affilname>Arhus Universitetshospital</affilname><name-variant>Aarhus University Hospital</name-variant><affiliation-city>Arhus</affiliation-city><affiliation-country>Denmark</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008088</affiliation-url><afid>60008088</afid><affilname>Universidade de Sao Paulo - USP</affilname><name-variant>University of SÃ£o Paulo</name-variant><affiliation-city>Sao Paulo</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55375491300</author-url><authid>55375491300</authid><authname>Cougo-Pinto P.</authname><surname>Cougo-Pinto</surname><given-name>Pedro Telles</given-name><initials>P.T.</initials><afid>60029929</afid><afid>60008088</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55375491300</author-url><authid>55375491300</authid><authname>Cougo-Pinto P.</authname><surname>Cougo-Pinto</surname><given-name>Pedro Telles</given-name><initials>P.T.</initials><afid>60029929</afid><afid>60008088</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7401681775</author-url><authid>7401681775</authid><authname>Chandra R.</authname><surname>Chandra</surname><given-name>Ronil V.</given-name><initials>R.V.</initials><afid>60019578</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7003703200</author-url><authid>7003703200</authid><authname>Simonsen C.</authname><surname>Simonsen</surname><given-name>Claus Z.</given-name><initials>C.Z.</initials><afid>60023882</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56468666400</author-url><authid>56468666400</authid><authname>Hirsch J.</authname><surname>Hirsch</surname><given-name>Joshua A.</given-name><initials>J.A.</initials><afid>60029929</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:12806200800</author-url><authid>12806200800</authid><authname>Leslie-Mazwi T.</authname><surname>Leslie-Mazwi</surname><given-name>Thabele</given-name><initials>T.</initials><afid>60029929</afid></author><authkeywords>Acute stroke | Angiography | Endovascular therapy | Intra-arterial therapy | Ischemic stroke | Large vessel occlusion | Proximal occlusion | Recanalization | Reperfusion | Treatment</authkeywords><intid>2035949846</intid><article-number>3</article-number><source-id>15013</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929415569"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929415569?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929415569&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929415569&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929415569</prism:url><dc:identifier>SCOPUS_ID:84929415569</dc:identifier><eid>2-s2.0-84929415569</eid><dc:title>New Research on Anxiety Disorders in the Elderly and an Update on Evidence-Based Treatments</dc:title><dc:creator>Andreescu C.</dc:creator><prism:publicationName>Current Psychiatry Reports</prism:publicationName><prism:issn>15233812</prism:issn><prism:eIssn>15351645</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11920-015-0595-8</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Anxiety disorders are frequently encountered in the elderly, but they are largely undetected and untreated. Epidemiological studies indicate a prevalence ranging from 1.2 to 15Â %. With the exception of generalized anxiety disorder and agoraphobia, which can often start in late life, most anxiety disorders in older patients are chronic and have their onset earlier in life. Anxiety disorders are an often unrecognized cause of distress, disability, and mortality risk in older adults, and they have been associated with cardiovascular disease, stroke, and cognitive decline. The mechanisms of anxiety in older adults differ from that in younger adults due to age-related neuropathology, as well as the loss and isolation so prominent in late life. Our review intends to provide a comprehensive summary of the most recent research done in the field of anxiety disorders in the elderly. Recent findings in clinical research, neuroimaging, neuroendocrinology, and neuropsychology are covered. An update on treatment options is discussed, including pharmacological and non-pharmacological alternatives.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028131</affiliation-url><afid>60028131</afid><affilname>Western Psychiatric Institute &amp; Clinic</affilname><name-variant>University of Pittsburgh</name-variant><affiliation-city>Pittsburgh</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36884091300</author-url><authid>36884091300</authid><authname>Andreescu C.</authname><surname>Andreescu</surname><given-name>Carmen</given-name><initials>C.</initials><afid>60028131</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7005672125</author-url><authid>7005672125</authid><authname>Varon D.</authname><surname>Varon</surname><given-name>Daniel</given-name><initials>D.</initials><afid>60028131</afid></author><authkeywords>Anxiety disorders | Elderly | Evidence-based treatment | Neurobiological research</authkeywords><intid>1035951145</intid><article-number>4</article-number><source-id>15011</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929460540"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929460540?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929460540&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929460540&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929460540</prism:url><dc:identifier>SCOPUS_ID:84929460540</dc:identifier><eid>2-s2.0-84929460540</eid><dc:title>Carotid Bypass for Carotid Occlusion</dc:title><dc:creator>Hage Z.</dc:creator><prism:publicationName>Current Atherosclerosis Reports</prism:publicationName><prism:issn>15233804</prism:issn><prism:eIssn>15346242</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-22</prism:coverDate><prism:coverDisplayDate>22 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11883-015-0517-6</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. The 2-year risk of ipsilateral ischemic stroke following internal carotid artery occlusion (ICAO) in a patient undergoing maximal medical therapy is 5â8Â % per year. While medical therapy may reduce the risk of stroke, it does not completely eliminate it. Since the 1985 extracranial-intracranial (EC-IC) bypass study, additional trials have been conducted to further investigate the usefulness of EC-IC bypass surgery in more selected patients with cerebral ischemia and impaired hemodynamic reserve. These important studies will be briefly reviewed in this article, as well as a discussion regarding the utility of bypass surgery for ICAO in current clinical practice. In addition, a short discussion regarding the pathophysiology of carotid occlusion will be presented. We will also highlight our own institutional patient selection criteria based on the latest methods for hemodynamic assessment, as well as our intraoperative flow assisted surgical techniques (FAST), and post-operative patient follow-up.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027561</affiliation-url><afid>60027561</afid><affilname>University of Illinois at Chicago</affilname><name-variant>University of Illinois at Chicago</name-variant><affiliation-city>Chicago</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:16244675400</author-url><authid>16244675400</authid><authname>Hage Z.</authname><surname>Hage</surname><given-name>Ziad A.</given-name><initials>Z.A.</initials><afid>60027561</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56647862700</author-url><authid>56647862700</authid><authname>Behbahani M.</authname><surname>Behbahani</surname><given-name>Mandana</given-name><initials>M.</initials><afid>60027561</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56648356400</author-url><authid>56648356400</authid><authname>Amin-Hanjani S.</authname><surname>Amin-Hanjani</surname><given-name>Sepideh</given-name><initials>S.</initials><afid>60027561</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56648359000</author-url><authid>56648359000</authid><authname>Charbel F.</authname><surname>Charbel</surname><given-name>Fady T.</given-name><initials>F.T.</initials><afid>60027561</afid></author><authkeywords>Blood flow | Carotid occlusion | EC-IC bypass | Hemodynamic reserve | Stroke</authkeywords><intid>2035958955</intid><article-number>1</article-number><source-id>23116</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928494469"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928494469?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928494469&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928494469&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527304005340"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928494469</prism:url><dc:identifier>SCOPUS_ID:84928494469</dc:identifier><eid>2-s2.0-84928494469</eid><dc:title>Prevalence of Helicobacter pylori infection and its association with cardiovascular risk factors in Korean adults</dc:title><dc:creator>Sung K.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>102</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>411-417</prism:pageRange><prism:coverDate>2015-07-20</prism:coverDate><prism:coverDisplayDate>20 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2004.05.040</prism:doi><pii>S0167527304005340</pii><dc:description>Â© 2004 Elsevier Ireland Ltd. All rights reserved. Objective The purpose of this study is to evaluate the prevalence of Helicobacter pylori (H. pylori) infection and its association with cardiovascular risk factors in healthy Korean adults. In 58981 subjects who participated in health screening program, the proportion of seropositive subjects for H. pylori and its association with cardiovascular risk factors was evaluated. Results A total of 70.9% of participants were tested positive for the H. pylori antibody. The seropositivity was highest in the age group of 50 and 60 years old. More male subjects tended to be infected with H. pylori (p&lt;0.05) than female subjects except for the age group of 50s. H. pylori seropositive subjects tended to be older than seronegative subjects (41.5 vs. 39.2 years old). After adjusting for age, H. pylori-seropositive group showed higher mean values for total cholesterol, triglyceride, low-density lipoprotein (LDL)-cholesterol, apolipoprotein B and lower values for high-density lipoprotein (HDL)-cholesterol, apolipoprotein A1 (p&lt;0.05). In univariate correlation analysis, age, total cholesterol, LDL-cholesterol and apolipoprotein B were positively correlated and HDL-cholesterol and apolipoprotein A1 were negatively correlated with H. pylori immunoglobulin G (IgG) titers (p&lt;0.05). The multiple analysis of covariance analysis (MANCOVA) for the H. pylori infection status showed triglyceride, HDL-cholesterol and apolipoproteins associated with H. pylori infection significantly (p&lt;0.05). In the analysis performed only in the H. pylori-seropositive group, no difference between the groups with and without peptic ulcer were shown according to the risk factors except HDL-cholesterol (p=0.031). Conclusions H. pylori infection is prevalent in Korean adults and is associated with cardiovascular risk factors, especially with triglyceride, HDL-cholesterol and apolipoproteins, independently from the presence of peptic ulcer. This is in line with the previous study results in which H. pylori infection per se might be one of the factors affecting atherosclerosis through modulation of lipid profiles, which needs further research.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010484</affiliation-url><afid>60010484</afid><affilname>Samsung Group</affilname><name-variant>Samsung Group</name-variant><affiliation-city>Seongnam</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007511</affiliation-url><afid>60007511</afid><affilname>Sungkyunkwan University</affilname><name-variant>Sungkyunkwan University</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60081368</affiliation-url><afid>60081368</afid><affilname>Inje University Paik Hospital</affilname><name-variant>Inje University College of Medicine</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><pubmed-id>16004885</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7201459743</author-url><authid>7201459743</authid><authname>Sung K.</authname><surname>Sung</surname><given-name>Ki Chul</given-name><initials>K.C.</initials><afid>60010484</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56605962400</author-url><authid>56605962400</authid><authname>Rhee E.</authname><surname>Rhee</surname><given-name>Eun Jung</given-name><initials>E.J.</initials><afid>60010484</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56591340200</author-url><authid>56591340200</authid><authname>Ryu S.</authname><surname>Ryu</surname><given-name>Seung Ho</given-name><initials>S.H.</initials><afid>60007511</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8721162300</author-url><authid>8721162300</authid><authname>Beck S.</authname><surname>Beck</surname><given-name>Sung Ho</given-name><initials>S.H.</initials><afid>60081368</afid></author><authkeywords>Atherosclerosis | Helicobacter pylori | Lipid profiles | Risk factors</authkeywords><intid>1035789475</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928485346"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928485346?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928485346&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928485346&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0167527304005595"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928485346</prism:url><dc:identifier>SCOPUS_ID:84928485346</dc:identifier><eid>2-s2.0-84928485346</eid><dc:title>Elevated level of plasma homocysteine in patients with slow coronary flow</dc:title><dc:creator>Riza Erbay A.</dc:creator><prism:publicationName>International Journal of Cardiology</prism:publicationName><prism:issn>01675273</prism:issn><prism:eIssn>18741754</prism:eIssn><prism:volume>102</prism:volume><prism:issueIdentifier>3</prism:issueIdentifier><prism:pageRange>419-423</prism:pageRange><prism:coverDate>2015-07-20</prism:coverDate><prism:coverDisplayDate>20 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijcard.2004.05.064</prism:doi><pii>S0167527304005595</pii><dc:description>Â© 2004 Elsevier Ireland Ltd. All rights reserved. Background Elevated plasma levels of homocysteine are currently considered a major, independent risk factor for cardiovascular diseases. Recently, several investigators have suggested that even mild elevation in plasma homocysteine level can severely disturb vascular endothelial function and subsequently impair coronary blood flow. Accordingly, we investigated plasma homocysteine level in patients with slow coronary flow. Method Study population included 53 patients with angiographically proven normal coronary arteries and slow coronary flow in all three coronary vessels (group I, 21 females, 32 males, mean age=48Â±9 years), and 50 subjects with angiographically proven normal coronary arteries without associated slow coronary flow (group II, 22 females, 28 males, mean age=50Â±8 years). Coronary flow rates of all patients and control subjects were documented by Thrombolysis In Myocardial Infarction frame count (TIMI frame count). All patients in group I had TIMI frame counts greater than two standard deviations above those of control subjects (group II) and, therefore, were accepted as exhibiting slow coronary flow. The mean TIMI frame count for each patient and control subject was calculated by adding the TIMI frame counts for each major epicardial coronary artery and then dividing the obtained value into 3. Plasma homocysteine level was measured in all patients and control subjects using commercially available homocysteine kits. Results There was no statistically significant difference between two groups in respect to age, gender, hypertension, diabetes mellitus, hyperlipidemia and cigarette smoking (p&gt;0.05). Plasma homocysteine level of patients with slow coronary flow were found to be significantly higher than those of control subjects (15.5Â±5.7 vs. 8.7Â±4.2 Î¼M/l, respectively, p&lt;0.001). Moreover, we found a significant positive correlation between plasma homocysteine level and mean TIMI frame count (r=0.660, p&lt;0.001). Conclusion We have shown that patients with slow coronary flow have raised level of plasma homocysteine compared to control subjects with normal coronary flow. This data suggests that elevated level of plasma homocysteine may play a role in the pathogenesis of slow coronary flow.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000593</affiliation-url><afid>60000593</afid><affilname>Turkiye Yuksek Ihtisas Hospital</affilname><name-variant>TÃ¼rkiye YÃ¼ksek Ihtisas Hospital</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000593</affiliation-url><afid>60000593</afid><affilname>Turkiye Yuksek Ihtisas Hospital</affilname><name-variant>TÃ¼rkiye YÃ¼ksek Ihtisas Hospital</name-variant><affiliation-city>Ankara</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60027720</affiliation-url><afid>60027720</afid><affilname>Inonu Universitesi Tip Fakultesi</affilname><name-variant>Inonu University School of Medicine</name-variant><affiliation-city>Malatya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><pubmed-id>16004886</pubmed-id><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6504171484</author-url><authid>6504171484</authid><authname>Riza Erbay A.</authname><surname>Riza Erbay</surname><given-name>Ali</given-name><initials>A.</initials><afid>60000593</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7003487752</author-url><authid>7003487752</authid><authname>Turhan H.</authname><surname>Turhan</surname><given-name>Hasan</given-name><initials>H.</initials><afid>60000593</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8502606100</author-url><authid>8502606100</authid><authname>Yasar A.</authname><surname>Yasar</surname><given-name>Ayse Saatci</given-name><initials>A.S.</initials><afid>60000593</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:6701556280</author-url><authid>6701556280</authid><authname>Ayaz S.</authname><surname>Ayaz</surname><given-name>Selime</given-name><initials>S.</initials><afid>60000593</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:36928650100</author-url><authid>36928650100</authid><authname>Sahin O.</authname><surname>Sahin</surname><given-name>Onur</given-name><initials>O.</initials><afid>60000593</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6701389056</author-url><authid>6701389056</authid><authname>Senen K.</authname><surname>Senen</surname><given-name>Kubilay</given-name><initials>K.</initials><afid>60000593</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6602073625</author-url><authid>6602073625</authid><authname>Sasmaz H.</authname><surname>Sasmaz</surname><given-name>Hatice</given-name><initials>H.</initials><afid>60000593</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7004009443</author-url><authid>7004009443</authid><authname>Yetkin E.</authname><surname>Yetkin</surname><given-name>Ertan</given-name><initials>E.</initials><afid>60027720</afid></author><authkeywords>Endothelial dysfunction | Homocysteine | Slow coronary flow</authkeywords><intid>2035788691</intid><source-id>23774</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359658"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359658?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359658&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359658&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359658</prism:url><dc:identifier>SCOPUS_ID:84929359658</dc:identifier><eid>2-s2.0-84929359658</eid><dc:title>Neuroprotection After Major Cardiovascular Surgery</dc:title><dc:creator>Torres J.</dc:creator><prism:publicationName>Current Treatment Options in Neurology</prism:publicationName><prism:issn>10928480</prism:issn><prism:eIssn>15343138</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-18</prism:coverDate><prism:coverDisplayDate>18 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11940-015-0357-2</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Neurologic injury is a common complication of major cardiovascular procedures including coronary artery bypass graft (CABG) surgery, coronary valve replacement, and aortic aneurysm surgery. However, despite ongoing research in the field of neuroprotection, there are currently few pharmacologic and interventional options to effectively protect the brain and spinal cord in the postoperative period. CSF drainage after aortic surgery currently stands as the only neuroprotective intervention that has been consistently shown to protect the spinal cord from ischemic injury, leading to significantly fewer patients with paraplegia and paraparesis. There is promising but conflicting evidence about the potential benefits of agents such as dexmedetomidine, lidocaine, magnesium, and erythropoietin in preventing postoperative stroke and cognitive dysfunction. Postoperative hypothermia has also been studied in preventing neurologic injury after cardiopulmonary bypass. With the rate of cardiovascular surgeries increasing yearly, further investigations are needed to validate many of these therapies and discover new ways to protect the brain and spinal cord from intraoperative and postoperative injuries in this high-risk population.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112471818</affiliation-url><afid>112471818</afid><affilname>NYU Langone Medical Center</affilname><name-variant>NYU Langone Medical Center</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55550722000</author-url><authid>55550722000</authid><authname>Torres J.</authname><surname>Torres</surname><given-name>Jose</given-name><initials>J.</initials><afid>112471818</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643819300</author-url><authid>56643819300</authid><authname>Ishida K.</authname><surname>Ishida</surname><given-name>Koto</given-name><initials>K.</initials><afid>112471818</afid></author><authkeywords>Cardiovascular | Dexmedetomidine | Erythropoietin | Hypothermia | Lidocaine | Magnesium sulfate | Neuroprotection | Surgery</authkeywords><intid>1035940016</intid><source-id>15013</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929353732"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929353732?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929353732&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929353732&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929353732</prism:url><dc:identifier>SCOPUS_ID:84929353732</dc:identifier><eid>2-s2.0-84929353732</eid><dc:title>Coronary Artery Anomalies: a Pictorial Review</dc:title><dc:creator>McLarry J.</dc:creator><prism:publicationName>Current Cardiovascular Imaging Reports</prism:publicationName><prism:issn>19419066</prism:issn><prism:eIssn>19419074</prism:eIssn><prism:volume>8</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-18</prism:coverDate><prism:coverDisplayDate>18 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s12410-015-9339-8</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Coronary artery anomalies range in prevalence from 0.2 to 2.3Â % of the population. They range from benign incidental findings to an important cause of sudden cardiac death (SCD). In fact, coronary anomalies are the second leading cause of SCD in athletes and are responsible for â¼30Â % of SCD in the young. Clinically, anomalous coronary arteries arising from the opposite sinus and anomalous left coronary artery arising from the pulmonary artery are the most important as they are associated with the highest risk of mortality. Several high-risk features and their pathophysiology are reviewed. Multiple imaging modalities have been utilized to study coronary artery anomalies; however, coronary computed tomography angiography (CTA) is uniquely suited to characterize coronary artery anomalies as it allows for clear elucidation of origin, course, and termination in relationship to other relevant anatomy with high spatial resolution. This paper will provide an overview of the wide spectrum of coronary artery anomalies and variants, review the most relevant coronary CTA imaging features for each, and differentiate benign from malignant varieties.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016733</affiliation-url><afid>60016733</afid><affilname>Oregon Health and Science University</affilname><name-variant>Oregon Health and Science University</name-variant><affiliation-city>Portland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35604201800</author-url><authid>35604201800</authid><authname>McLarry J.</authname><surname>McLarry</surname><given-name>Joel</given-name><initials>J.</initials><afid>60016733</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7007108606</author-url><authid>7007108606</authid><authname>Ferencik M.</authname><surname>Ferencik</surname><given-name>Maros</given-name><initials>M.</initials><afid>60016733</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55568510352</author-url><authid>55568510352</authid><authname>Shapiro M.</authname><surname>Shapiro</surname><given-name>Michael D.</given-name><initials>M.D.</initials><afid>60016733</afid></author><authkeywords>Anomalous coronary artery | Anomalous coronary artery arising from the opposite sinus | Computed tomography | Coronary CTA | Sudden cardiac death</authkeywords><intid>535946336</intid><source-id>19600157307</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929346659"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929346659?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929346659&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929346659&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929346659</prism:url><dc:identifier>SCOPUS_ID:84929346659</dc:identifier><eid>2-s2.0-84929346659</eid><dc:title>Nuclear cardiac myosin light chain 2 modulates NADPH oxidase 2 expression in myocardium: a novel function beyond muscle contraction</dc:title><dc:creator>Zhang Y.</dc:creator><prism:publicationName>Basic Research in Cardiology</prism:publicationName><prism:issn>03008428</prism:issn><prism:eIssn>14351803</prism:eIssn><prism:volume>110</prism:volume><prism:issueIdentifier>4</prism:issueIdentifier><prism:coverDate>2015-07-18</prism:coverDate><prism:coverDisplayDate>18 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00395-015-0494-5</prism:doi><dc:description>Â© 2015, Springer-Verlag Berlin Heidelberg. Recent studies demonstrated that NADPH oxidase 2 (NOX2) expression in myocardium after ischemiaâreperfusion (IR) is significantly upregulated. However, the underlying mechanisms remain unknown. This study aims to determine if nuclear cardiac myosin light chain 2 (MYL2), a well-known regulatory subunit of myosin, functions as a transcription factor to promote NOX2 expression following myocardial IR in a phosphorylation-dependent manner. We examined the phosphorylation status of nuclear MYL2 (p-MYL2) in a rat model of myocardial IR (left main coronary artery subjected to 1Â h ligation and 3Â h reperfusion) injury, which showed IR injury and upregulated NOX2 expression as expected, accompanied by elevated H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; and nuclear p-MYL2 levels; these effects were attenuated by inhibition of myosin light chain kinase (MLCK). Next, we explored the functional relationship of nuclear p-MYL2 with NOX2 expression in H9c2 cell model of hypoxia-reoxygenation (HR) injury. In agreement with our in vivo findings, HR treatment increased apoptosis, NOX2 expression, nuclear p-MYL2 and H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt; levels, and the increases were ameliorated by inhibition of MLCK or knockdown of MYL2. Finally, molecular biology techniques including co-immunoprecipitation (Co-IP), chromatin immunoprecipitation (ChIP), DNA pull-down and luciferase reporter gene assay were utilized to decipher the molecular mechanisms. We found that nuclear p-MYL2 binds to the consensus sequence AGCTCC in NOX2 gene promoter, interacts with RNA polymerase II and transcription factor IIB to form a transcription preinitiation complex, and thus activates NOX2 gene transcription. Our results demonstrate that nuclear MYL2 plays an important role in IR injury by transcriptionally upregulating NOX2 expression to enhance oxidative stress in a phosphorylation-dependent manner.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017060</affiliation-url><afid>60017060</afid><affilname>Central South University China</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017060</affiliation-url><afid>60017060</afid><affilname>Central South University China</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60082821</affiliation-url><afid>60082821</afid><affilname>Xiangya Hospital of Central-south University</affilname><name-variant>Central South University</name-variant><affiliation-city>Changsha</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014569</affiliation-url><afid>60014569</afid><affilname>UT Medical Branch at Galveston</affilname><name-variant>University of Texas Medical Branch</name-variant><affiliation-city>Galveston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25930669700</author-url><authid>25930669700</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yi Shuai</given-name><initials>Y.S.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:25930669700</author-url><authid>25930669700</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yi Shuai</given-name><initials>Y.S.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56437806200</author-url><authid>56437806200</authid><authname>Liu B.</authname><surname>Liu</surname><given-name>Bin</given-name><initials>B.</initials><afid>60017060</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7402870933</author-url><authid>7402870933</authid><authname>Luo X.</authname><surname>Luo</surname><given-name>Xiu Ju</given-name><initials>X.J.</initials><afid>60017060</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55777198200</author-url><authid>55777198200</authid><authname>Li T.</authname><surname>Li</surname><given-name>Ting Bo</given-name><initials>T.B.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55777198200</author-url><authid>55777198200</authid><authname>Li T.</authname><surname>Li</surname><given-name>Ting Bo</given-name><initials>T.B.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56021338100</author-url><authid>56021338100</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jie Jie</given-name><initials>J.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56021338100</author-url><authid>56021338100</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jie Jie</given-name><initials>J.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56608437100</author-url><authid>56608437100</authid><authname>Peng J.</authname><surname>Peng</surname><given-name>Jing Jie</given-name><initials>J.J.</initials><afid>60017060</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56021307800</author-url><authid>56021307800</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiao Jie</given-name><initials>X.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56021307800</author-url><authid>56021307800</authid><authname>Zhang X.</authname><surname>Zhang</surname><given-name>Xiao Jie</given-name><initials>X.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7402815903</author-url><authid>7402815903</authid><authname>Ma Q.</authname><surname>Ma</surname><given-name>Qi Lin</given-name><initials>Q.L.</initials><afid>60082821</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7404571050</author-url><authid>7404571050</authid><authname>Hu C.</authname><surname>Hu</surname><given-name>Chang Ping</given-name><initials>C.P.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7404571050</author-url><authid>7404571050</authid><authname>Hu C.</authname><surname>Hu</surname><given-name>Chang Ping</given-name><initials>C.P.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36063112900</author-url><authid>36063112900</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yuan Jian</given-name><initials>Y.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:36063112900</author-url><authid>36063112900</authid><authname>Li Y.</authname><surname>Li</surname><given-name>Yuan Jian</given-name><initials>Y.J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7401958753</author-url><authid>7401958753</authid><authname>Peng J.</authname><surname>Peng</surname><given-name>Jun</given-name><initials>J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7401958753</author-url><authid>7401958753</authid><authname>Peng J.</authname><surname>Peng</surname><given-name>Jun</given-name><initials>J.</initials><afid>60017060</afid><afid>60017060</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7405861379</author-url><authid>7405861379</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qingjie</given-name><initials>Q.</initials><afid>60014569</afid></author><authkeywords>Cardiac myosin light chain 2 | Ischemia | NADPH oxidase 2 | Reperfusion | Transcription</authkeywords><intid>35943095</intid><source-id>22488</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929379619"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929379619?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929379619&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929379619&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929379619</prism:url><dc:identifier>SCOPUS_ID:84929379619</dc:identifier><eid>2-s2.0-84929379619</eid><dc:title>Serum levels of neopterin in gestational diabetes mellitus: the relationship with Apgar scores</dc:title><dc:creator>Ipekci S.</dc:creator><prism:publicationName>Archives of Gynecology and Obstetrics</prism:publicationName><prism:issn>09320067</prism:issn><prism:eIssn>14320711</prism:eIssn><prism:volume>292</prism:volume><prism:issueIdentifier>1</prism:issueIdentifier><prism:pageRange>103-109</prism:pageRange><prism:coverDate>2015-07-18</prism:coverDate><prism:coverDisplayDate>18 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s00404-015-3615-3</prism:doi><dc:description>Â© 2015, Springer-Verlag Berlin Heidelberg. Purpose: This study was designed to evaluate neopterin levels and low Apgar scores in pregnancies with gestational diabetes mellitus (GDM) vs. normal control pregnancies. Methods: We carried out a cross-sectional study by enrolling 81 pregnant women with GDM and 38 pregnant women without GDM. Results: Maternal and cord blood neopterin levels were higher in women with GDM. There was a significant positive association between fasting blood glucose levels and maternal serum neopterin levels. The results of 50-g oral glucose challenge tests revealed a correlation between maternal and cord neopterin levels. Pregnancies complicated by GDM exhibited lower fetal Apgar scores than those of control subjects. The levels of cord blood neopterin were inversely correlated with an fetal Apgar score of 1Â min in patients with GDM. Conclusions: Patients with GDM had higher maternal and cord blood neopterin levels, and the cord blood neopterin levels are inversely associated with lower Apgar scores in women with GDM. The neopterin levels might be potential predictors of low fetal Apgar scores in women with GDM.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013575</affiliation-url><afid>60013575</afid><affilname>Selcuk Universitesi</affilname><name-variant>SelÃ§uk University</name-variant><affiliation-city>Konya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013575</affiliation-url><afid>60013575</afid><affilname>Selcuk Universitesi</affilname><name-variant>SelÃ§uk University</name-variant><affiliation-city>Konya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013575</affiliation-url><afid>60013575</afid><affilname>Selcuk Universitesi</affilname><name-variant>SelÃ§uk University</name-variant><affiliation-city>Konya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013575</affiliation-url><afid>60013575</afid><affilname>Selcuk Universitesi</affilname><name-variant>SelÃ§uk University</name-variant><affiliation-city>Konya</affiliation-city><affiliation-country>Turkey</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26434675700</author-url><authid>26434675700</authid><authname>Ipekci S.</authname><surname>Ipekci</surname><given-name>Suleyman Hilmi</given-name><initials>S.H.</initials><afid>60013575</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:23009099700</author-url><authid>23009099700</authid><authname>Kebapcilar A.</authname><surname>Kebapcilar</surname><given-name>Ayse Gul</given-name><initials>A.G.</initials><afid>60013575</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:50862253300</author-url><authid>50862253300</authid><authname>Yilmaz S.</authname><surname>Yilmaz</surname><given-name>Setenay Arzu</given-name><initials>S.A.</initials><afid>60013575</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55614226200</author-url><authid>55614226200</authid><authname>Ilhan T.</authname><surname>Ilhan</surname><given-name>Tolgay Tuyan</given-name><initials>T.T.</initials><afid>60013575</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55345981600</author-url><authid>55345981600</authid><authname>Pekin A.</authname><surname>Pekin</surname><given-name>Aybike Tazegul</given-name><initials>A.T.</initials><afid>60013575</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:22956875700</author-url><authid>22956875700</authid><authname>Abusoglu S.</authname><surname>Abusoglu</surname><given-name>Sedat</given-name><initials>S.</initials><afid>60013575</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56506801200</author-url><authid>56506801200</authid><authname>Unlu A.</authname><surname>Unlu</surname><given-name>Ali</given-name><initials>A.</initials><afid>60013575</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:23003660100</author-url><authid>23003660100</authid><authname>Annagur A.</authname><surname>Annagur</surname><given-name>Ali</given-name><initials>A.</initials><afid>60013575</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:36338971800</author-url><authid>36338971800</authid><authname>Celik C.</authname><surname>Celik</surname><given-name>Cetin</given-name><initials>C.</initials><afid>60013575</afid></author><authkeywords>Apgar score | Gestational diabetes mellitus | Inflammation | Neopterin</authkeywords><intid>1535943204</intid><source-id>30082</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929222918"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929222918?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929222918&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929222918&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929222918</prism:url><dc:identifier>SCOPUS_ID:84929222918</dc:identifier><eid>2-s2.0-84929222918</eid><dc:title>Antiangiogenic Treatment of Meningiomas</dc:title><dc:creator>Preusser M.</dc:creator><prism:publicationName>Current Treatment Options in Neurology</prism:publicationName><prism:issn>10928480</prism:issn><prism:eIssn>15343138</prism:eIssn><prism:volume>17</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-16</prism:coverDate><prism:coverDisplayDate>16 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s11940-015-0359-0</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. Meningiomas are the most common intracranial tumors and the majority of cases is curable by surgical resection. Incompletely resected tumors and tumors with signs of increased malignancy (WHO grade II and III tumors) are prone to recur. In meningiomas relapsing after surgical resection and after exhaustion of radiotherapeutic options, drug therapy is to be considered. A variety of drugs has been studied in meningiomas, including hydroxyurea, temozolomide, irinotecan, interferon-alpha, mifepristone, octreotide analogues, megestrol acetate, bevacizumab, sunitinib, vatalinib, imatinib, erlotinib, and gefitinib. Unfortunately, most of these agents have shown no or very limited activity against meningiomas and cannot be recommended for clinical use. Compounds with antiangiogenic properties, i.e., bevacizumab, sunitinib, and vatalinib have shown potential efficacy in uncontrolled studies and should be investigated further, ideally in randomized clinical trials. Emerging clinical studies will evaluate novel medical treatment approaches including the tetra-hydroisoquinoline alkaloid trabectedin (European Organisation for Research and Treatment of Cancer (EORTC) phase II trial 1320) and SMO or AKT inhibitors in molecularly selected cases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011394</affiliation-url><afid>60011394</afid><affilname>Medizinische Universitat Wien</affilname><name-variant>Medical University of Vienna</name-variant><affiliation-city>Vienna</affiliation-city><affiliation-country>Austria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56243091300</author-url><authid>56243091300</authid><authname>Preusser M.</authname><surname>Preusser</surname><given-name>Matthias</given-name><initials>M.</initials><afid>60011394</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7007127932</author-url><authid>7007127932</authid><authname>Marosi C.</authname><surname>Marosi</surname><given-name>Christine</given-name><initials>C.</initials><afid>60011394</afid></author><authkeywords>Antiangiogenesis | Chemotherapy | Meningioma | Targeted agents | Tyrosine kinase inhibitors</authkeywords><intid>1535916751</intid><source-id>15013</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929166068"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929166068?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929166068&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929166068&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929166068</prism:url><dc:identifier>SCOPUS_ID:84929166068</dc:identifier><eid>2-s2.0-84929166068</eid><dc:title>Understanding the Obesity Paradox in Type 2 Diabetes Mellitus</dc:title><dc:creator>Costanzo P.</dc:creator><prism:publicationName>Current Cardiovascular Risk Reports</prism:publicationName><prism:issn>19329520</prism:issn><prism:eIssn>19329563</prism:eIssn><prism:volume>9</prism:volume><prism:issueIdentifier>7</prism:issueIdentifier><prism:coverDate>2015-07-16</prism:coverDate><prism:coverDisplayDate>16 July 2015</prism:coverDisplayDate><prism:doi>10.1007/s12170-015-0461-6</prism:doi><dc:description>Â© 2015, Springer Science+Business Media New York. The term âobesity paradoxâ corresponds to the research observation that overweight or obese patients may counterintuitively have a survival benefit once a disease is established. This appears also true in type 2 diabetes mellitus, where it has been shown that being overweight or obese is associated with better survival. The reasons behind this paradox remain unclear but likely derive from an intricate relationship between insulin resistance, fat storage, and inflammatory responses in type 2 diabetes. In this review, we look at what the potential mechanisms may be underlying this paradox.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030469</affiliation-url><afid>60030469</afid><affilname>University of Hull</affilname><name-variant>University of Hull</name-variant><affiliation-city>Hull</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106614032</affiliation-url><afid>106614032</afid><affilname>Qatar Foundation</affilname><name-variant>Qatar Foundation</name-variant><affiliation-city>Doha</affiliation-city><affiliation-country>Qatar</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110095611</affiliation-url><afid>110095611</afid><affilname>York Teaching Hospitals NHS Trust</affilname><name-variant>York Teaching Hospital Foundation NHS Trust</name-variant><affiliation-city>York</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23569051300</author-url><authid>23569051300</authid><authname>Costanzo P.</authname><surname>Costanzo</surname><given-name>P.</given-name><initials>P.</initials><afid>60030469</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56640692400</author-url><authid>56640692400</authid><authname>Lai D.</authname><surname>Lai</surname><given-name>D.</given-name><initials>D.</initials><afid>110095611</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7005293560</author-url><authid>7005293560</authid><authname>Atkin S.</authname><surname>Atkin</surname><given-name>S. L.</given-name><initials>S.L.</initials><afid>106614032</afid></author><authkeywords>Body mass index | Insulin resistance | Obesity | Obesity paradox | Overweight | Type 2 diabetes mellitus</authkeywords><intid>1035913830</intid><source-id>19500157062</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924760477"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924760477?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924760477&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924760477&amp;origin=inward"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924760477</prism:url><dc:identifier>SCOPUS_ID:84924760477</dc:identifier><eid>2-s2.0-84924760477</eid><dc:title>Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature</dc:title><dc:creator>Serata D.</dc:creator><prism:publicationName>Human Psychopharmacology</prism:publicationName><prism:issn>08856222</prism:issn><prism:eIssn>10991077</prism:eIssn><prism:volume>30</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>70-84</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1002/hup.2461</prism:doi><dc:description>Copyright Â© 2015 John Wiley &amp; Sons, Ltd. Copyright Â© 2015 John Wiley &amp; Sons, Ltd. Objective The purpose of this literature database search-based review was to critically consider and evaluate the findings of literature focusing on efficacy and safety of 5-HT3 antagonists in the treatment of obsessive-compulsive disorder (OCD), so as to test whether preclinical data match clinical therapeutic trials. Design The PubMed database has been searched for papers on 5-HT3 antagonists and OCD in humans and for animal models of OCD and 5-HT3 receptors. Results Of the clinically tested 5-HT3 receptor antagonists, ondansetron has been used to treat OCD in five therapeutic studies, whereas granisetron only in one recent trial. Both showed some efficacy in open studies and superiority to placebo in double-blind studies, along with fair safety. No animal OCD model directly implicated 5-HT3 receptors. Conclusions Overall, results indicate some utility, but the available literature is too scanty to allow for valid conclusions to be drawn. The mismatch between animal models of obsessive-compulsive disorder and clinical data with 5-HT3 antagonists needs more clinical data to ensure that it is not an artefact.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>Villa Rosa Suore Ospedaliere of the Sacred Heart of Jesus</affilname><name-variant>Department of Neuropsychiatry</name-variant><affiliation-city>Viterbo</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114655018</affiliation-url><afid>114655018</afid><affilname>P. Alberto Mileno Onlus Foundation</affilname><name-variant>P. Alberto Mileno Onlus Foundation</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">20</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37003137200</author-url><authid>37003137200</authid><authname>Serata D.</authname><surname>Serata</surname><given-name>Daniele</given-name><initials>D.</initials><afid>60032350</afid><afid/></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:37003137200</author-url><authid>37003137200</authid><authname>Serata D.</authname><surname>Serata</surname><given-name>Daniele</given-name><initials>D.</initials><afid>60032350</afid><afid/></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56478667400</author-url><authid>56478667400</authid><authname>Kotzalidis G.</authname><surname>Kotzalidis</surname><given-name>Georgios D.</given-name><initials>G.D.</initials><afid>60032350</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37051433400</author-url><authid>37051433400</authid><authname>Rapinesi C.</authname><surname>Rapinesi</surname><given-name>Chiara</given-name><initials>C.</initials><afid>60032350</afid><afid/></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37051433400</author-url><authid>37051433400</authid><authname>Rapinesi C.</authname><surname>Rapinesi</surname><given-name>Chiara</given-name><initials>C.</initials><afid>60032350</afid><afid/></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55752060100</author-url><authid>55752060100</authid><authname>Janiri D.</authname><surname>Janiri</surname><given-name>Delfina</given-name><initials>D.</initials><afid>60032350</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55536422300</author-url><authid>55536422300</authid><authname>Di Pietro S.</authname><surname>Di Pietro</surname><given-name>Simone</given-name><initials>S.</initials><afid>60032350</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56480520500</author-url><authid>56480520500</authid><authname>Callovini G.</authname><surname>Callovini</surname><given-name>Gemma</given-name><initials>G.</initials><afid>60032350</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35332737600</author-url><authid>35332737600</authid><authname>Piacentino D.</authname><surname>Piacentino</surname><given-name>Daria</given-name><initials>D.</initials><afid>60032350</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55661025400</author-url><authid>55661025400</authid><authname>Gasperoni C.</authname><surname>Gasperoni</surname><given-name>Carlotta</given-name><initials>C.</initials><afid>60032350</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:6602318309</author-url><authid>6602318309</authid><authname>Brugnoli R.</authname><surname>Brugnoli</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60032350</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56363230500</author-url><authid>56363230500</authid><authname>Ferri V.</authname><surname>Ferri</surname><given-name>Vittoria Rachele</given-name><initials>V.R.</initials><afid>60032350</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:35725381900</author-url><authid>35725381900</authid><authname>Girardi N.</authname><surname>Girardi</surname><given-name>Nicoletta</given-name><initials>N.</initials><afid>60032350</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:7006038740</author-url><authid>7006038740</authid><authname>Tatarelli R.</authname><surname>Tatarelli</surname><given-name>Roberto</given-name><initials>R.</initials><afid>60032350</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:55575011700</author-url><authid>55575011700</authid><authname>Ferracuti S.</authname><surname>Ferracuti</surname><given-name>Stefano</given-name><initials>S.</initials><afid>60032350</afid></author><author seq="14"><author-url>http://api.elsevier.com/content/author/author_id:14059394000</author-url><authid>14059394000</authid><authname>Angeletti G.</authname><surname>Angeletti</surname><given-name>Gloria</given-name><initials>G.</initials><afid>60032350</afid></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7004181693</author-url><authid>7004181693</authid><authname>Girardi P.</authname><surname>Girardi</surname><given-name>Paolo</given-name><initials>P.</initials><afid>60032350</afid><afid/></author><author seq="15"><author-url>http://api.elsevier.com/content/author/author_id:7004181693</author-url><authid>7004181693</authid><authname>Girardi P.</authname><surname>Girardi</surname><given-name>Paolo</given-name><initials>P.</initials><afid>60032350</afid><afid/></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:23982116000</author-url><authid>23982116000</authid><authname>Del Casale A.</authname><surname>Del Casale</surname><given-name>Antonio</given-name><initials>A.</initials><afid>60032350</afid><afid>114655018</afid></author><author seq="16"><author-url>http://api.elsevier.com/content/author/author_id:23982116000</author-url><authid>23982116000</authid><authname>Del Casale A.</authname><surname>Del Casale</surname><given-name>Antonio</given-name><initials>A.</initials><afid>60032350</afid><afid>114655018</afid></author><authkeywords>animal | clinical trials as topic | granisetron | models | obsessive-compulsive disorder | ondansetron | serotonin 5-HT3 receptor antagonists</authkeywords><intid>1035194757</intid><source-id>16102</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922755510"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922755510?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922755510&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922755510&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615001806"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922755510</prism:url><dc:identifier>SCOPUS_ID:84922755510</dc:identifier><eid>2-s2.0-84922755510</eid><dc:title>Polyphenols content, phenolics profile and antioxidant activity of organic red wines produced without sulfur dioxide/sulfites addition in comparison to conventional red wines</dc:title><dc:creator>Garaguso I.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>179</prism:volume><prism:pageRange>336-342</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.01.144</prism:doi><pii>S0308814615001806</pii><dc:description>Â© 2015 Elsevier Ltd. Wine exerts beneficial effects on human health when it is drunk with moderation. Nevertheless, wine may also contain components negatively affecting human health. Among these, sulfites may induce adverse effects after ingestion. We examined total polyphenols and flavonoids content, phenolics profile and antioxidant activity of eight organic red wines produced without sulfur dioxide/sulfites addition in comparison to those of eight conventional red wines. Polyphenols and flavonoids content were slightly higher in organic wines in respect to conventional wines, however differences did not reach statistical significance. The phenolic acids profile was quite similar in both groups of wines. Antioxidant activity was higher in organic wines compared to conventional wines, although differences were not statistically significant. Our results indicate that organic red wines produced without sulfur dioxide/sulfites addition are comparable to conventional red wines with regard to the total polyphenols and flavonoids content, the phenolics profile and the antioxidant activity.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114986887</affiliation-url><afid>114986887</afid><affilname>Centro di Ricerca per Gli Alimenti e la Nutrizione (CRA-NUT)</affilname><name-variant>Centro di Ricerca per Gli Alimenti e la Nutrizione (CRA-NUT)</name-variant><affiliation-city/><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6506207210</author-url><authid>6506207210</authid><authname>Garaguso I.</authname><surname>Garaguso</surname><given-name>Ivana</given-name><initials>I.</initials><afid>114986887</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7006788058</author-url><authid>7006788058</authid><authname>Nardini M.</authname><surname>Nardini</surname><given-name>Mirella</given-name><initials>M.</initials><afid>114986887</afid></author><authkeywords>Antioxidant activity | Organic wine | Polyphenols | Sulfites</authkeywords><intid>534859032</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922567152"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922567152?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922567152&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922567152&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615001636"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922567152</prism:url><dc:identifier>SCOPUS_ID:84922567152</dc:identifier><eid>2-s2.0-84922567152</eid><dc:title>Altered concentrate to forage ratio in cows ration enhanced bioproduction of specific size subpopulation of milk fat globules</dc:title><dc:creator>Mesilati-Stahy R.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>179</prism:volume><prism:pageRange>199-205</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.01.138</prism:doi><pii>S0308814615001636</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. The mechanism underlying the shift in milk-fat-globule (MFG) mean diameter upon changing the concentrate-to-forage ratio in dairy cow rations was investigated. Cows were fed high-concentrate low-forage (HCLF) or high-forage low-concentrate (LCHF) rations for 4 weeks. Mean diameter of MFG, determined in raw whole milk, was 0.4 Î¼m larger in the LCHF-fed vs. HCLF-fed group. The main compositional differences between treatments were found in a specific MFG subgroup with the diameter of 3.3 Î¼m (F1), with higher capric, lauric, myristic and lower oleic acid concentrations in HCLF vs. LCHF milk. Similarly, lipid concentration differences between treatments were only found in F1, with higher triglyceride and phosphatidylethanolamine, and lower sphingomyelin concentrations in LCHF vs. HCLF milk. The higher MFG mean diameter in whole raw LCHF milk might therefore be attributed to increased secretion of F1-group MFG, while fat content and composition in the other MFG size groups remains unchanged.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007903</affiliation-url><afid>60007903</afid><affilname>Hebrew University of Jerusalem</affilname><name-variant>Hebrew University of Jerusalem</name-variant><affiliation-city>Jerusalem</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006723</affiliation-url><afid>60006723</afid><affilname>Agricultural Research Organization of Israel</affilname><name-variant>Volcani Center</name-variant><affiliation-city>Bet Dagan</affiliation-city><affiliation-country>Israel</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:42461817800</author-url><authid>42461817800</authid><authname>Mesilati-Stahy R.</authname><surname>Mesilati-Stahy</surname><given-name>Ronit</given-name><initials>R.</initials><afid>60007903</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:6602569459</author-url><authid>6602569459</authid><authname>Moallem U.</authname><surname>Moallem</surname><given-name>Uzi</given-name><initials>U.</initials><afid>60006723</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56290693400</author-url><authid>56290693400</authid><authname>Magen Y.</authname><surname>Magen</surname><given-name>Yogev</given-name><initials>Y.</initials><afid>60007903</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36617043900</author-url><authid>36617043900</authid><authname>Argov-Argaman N.</authname><surname>Argov-Argaman</surname><given-name>Nurit</given-name><initials>N.</initials><afid>60007903</afid></author><authkeywords>Concentrate to forage ratio | Fatty acid | Membrane | Milk fat globule | Phosphatidylethanolamine | Phospholipid | Sphingomyelin</authkeywords><intid>534830989</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930000295"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930000295?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930000295&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930000295&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0024320515002234"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930000295</prism:url><dc:identifier>SCOPUS_ID:84930000295</dc:identifier><eid>2-s2.0-84930000295</eid><dc:title>Contribution of Musa paradisiaca in the inhibition of Î±-amylase, Î±-glucosidase and Angiotensin-I converting enzyme in streptozotocin induced rats</dc:title><dc:creator>Shodehinde S.</dc:creator><prism:publicationName>Life Sciences</prism:publicationName><prism:issn>00243205</prism:issn><prism:eIssn>18790631</prism:eIssn><prism:volume>133</prism:volume><prism:pageRange>8-14</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.lfs.2015.03.026</prism:doi><pii>S0024320515002234</pii><dc:description>Â© 2015 Elsevier Inc. Abstract Aims Unripe plantain based-diets are part of folklore remedy for the management of diabetes in tropical Africa; however, with the dearth of information on the rationale behind this practice; this study therefore, sought to investigate the antihyperglycemic effect of traditional unripe plantain products (Amala and Booli) in high fat fed/low dose streptozotocin-induced diabetic rats and to provide a possible rationale for their antidiabetic properties. Main methods Diabetes was induced experimentally by high fat fed/low dose streptozotocin-diabetic rats (25 mg/kg body wt.) and the diabetic rats were fed diets supplemented with 20-40% Amala and Booli for 14 days. The effect of the diets on the blood glucose level, pancreatic Î±-amylase, intestinal Î±-glucosidase and Angiotensin-I converting enzyme (ACE) activities and plasma antioxidant status as well as amylose/amylopectin content of the unripe plantain products were determined. Key findings A marked increase in the blood glucose, Î±-amylase, Î±-glucosidase and ACE activities with a corresponding decrease in plasma antioxidant status was recorded in diabetic rats. However, these indices were significantly (P &lt; 0.05) reversed after unripe plantain product supplemented diet treatments for 14 days. Also, the amylose/amylopectin ratio of the products is 1:3. Significance This study revealed that unripe plantain products exert antihyperglycemic effects which could be attributed to the inhibition of Î±-amylase and Î±-glucosidase activities by their constituent phytochemicals as well as their amylose/amylopectin contents in the diabetic rats, hence, providing the possible rationale behind their antidiabetic properties.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014177</affiliation-url><afid>60014177</afid><affilname>Adekunle Ajasin University</affilname><name-variant>Adekunle Ajasin University</name-variant><affiliation-city>Akungba-Akoko</affiliation-city><affiliation-country>Nigeria</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023571</affiliation-url><afid>60023571</afid><affilname>Federal University of Technology, Akure</affilname><name-variant>Federal University of Technology</name-variant><affiliation-city>Akure</affiliation-city><affiliation-country>Nigeria</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35312217600</author-url><authid>35312217600</authid><authname>Shodehinde S.</authname><surname>Shodehinde</surname><given-name>Sidiqat A.</given-name><initials>S.A.</initials><afid>60014177</afid><afid>60023571</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35312217600</author-url><authid>35312217600</authid><authname>Shodehinde S.</authname><surname>Shodehinde</surname><given-name>Sidiqat A.</given-name><initials>S.A.</initials><afid>60014177</afid><afid>60023571</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:26664394200</author-url><authid>26664394200</authid><authname>Ademiluyi A.</authname><surname>Ademiluyi</surname><given-name>Adedayo O.</given-name><initials>A.O.</initials><afid>60023571</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6603569317</author-url><authid>6603569317</authid><authname>Oboh G.</authname><surname>Oboh</surname><given-name>Ganiyu</given-name><initials>G.</initials><afid>60023571</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56490622600</author-url><authid>56490622600</authid><authname>Akindahunsi A.</authname><surname>Akindahunsi</surname><given-name>Afolabi A.</given-name><initials>A.A.</initials><afid>60023571</afid></author><authkeywords>Antioxidants | Streptozotocin | Type 2 diabetes | Unripe plantain | Î±-Amylase | Î±-Glucosidase</authkeywords><intid>1036045268</intid><article-number>14357</article-number><source-id>20473</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84922531218"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84922531218?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84922531218&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84922531218&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615001521"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84922531218</prism:url><dc:identifier>SCOPUS_ID:84922531218</dc:identifier><eid>2-s2.0-84922531218</eid><dc:title>Phytochemical profile of commercially available food plant powders: Their potential role in healthier food reformulations</dc:title><dc:creator>Neacsu M.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>179</prism:volume><prism:pageRange>159-169</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.01.128</prism:doi><pii>S0308814615001521</pii><dc:description>Â© 2015 Elsevier Ltd. All rights reserved. Reformulation of existing processed food or formulation of new foods using natural products (plant-based) will inherently confer to new products with less calories, fat, salt, phosphates and other synthetic components, and higher amounts of fibre, antioxidants, vitamins and other beneficial components. Plant ingredients, such as food plant powders, are currently being used in food manufacturing, predominantly for flavouring and colouring purposes. To expand their use as a food ingredient, freeze-dried powders representing major vegetable groups were characterised by targeted LC-MS/MS analysis of their phytochemicals. All the plant powders were found to be rich in flavonoids, phenolic acids and derivatives; total content in these compounds varied from around 130 mg kg-1 (green pea) to around 930 mg kg-1 (spinach). The food plant powders' phytochemical content represents valuable information for the food industry in the development of healthier novel foods and for the reformulation of existing food products in relation to antioxidants, food preservatives and alternatives to nitrite use.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015875</affiliation-url><afid>60015875</afid><affilname>University of Aberdeen</affilname><name-variant>University of Aberdeen</name-variant><affiliation-city>Aberdeen</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015875</affiliation-url><afid>60015875</afid><affilname>University of Aberdeen</affilname><name-variant>University of Aberdeen</name-variant><affiliation-city>Aberdeen</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015875</affiliation-url><afid>60015875</afid><affilname>University of Aberdeen</affilname><name-variant>University of Aberdeen</name-variant><affiliation-city>Aberdeen</affiliation-city><affiliation-country>United Kingdom</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15841998700</author-url><authid>15841998700</authid><authname>Neacsu M.</authname><surname>Neacsu</surname><given-name>M.</given-name><initials>M.</initials><afid>60015875</afid><afid>60015875</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15841998700</author-url><authid>15841998700</authid><authname>Neacsu M.</authname><surname>Neacsu</surname><given-name>M.</given-name><initials>M.</initials><afid>60015875</afid><afid>60015875</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56511475600</author-url><authid>56511475600</authid><authname>Vaughan N.</authname><surname>Vaughan</surname><given-name>N.</given-name><initials>N.</initials><afid>60015875</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506669159</author-url><authid>6506669159</authid><authname>Raikos V.</authname><surname>Raikos</surname><given-name>V.</given-name><initials>V.</initials><afid>60015875</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56512326200</author-url><authid>56512326200</authid><authname>Multari S.</authname><surname>Multari</surname><given-name>S.</given-name><initials>S.</initials><afid>60015875</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:50561155800</author-url><authid>50561155800</authid><authname>Duncan G.</authname><surname>Duncan</surname><given-name>G. J.</given-name><initials>G.J.</initials><afid>60015875</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7006621571</author-url><authid>7006621571</authid><authname>Duthie G.</authname><surname>Duthie</surname><given-name>G. G.</given-name><initials>G.G.</initials><afid>60015875</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7201960813</author-url><authid>7201960813</authid><authname>Russell W.</authname><surname>Russell</surname><given-name>W. R.</given-name><initials>W.R.</initials><afid>60015875</afid></author><authkeywords>Flavonoids | Food plant powders | Food reformulation | Healthier foods | Phytophenols</authkeywords><intid>1784830604</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928893126"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928893126?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928893126&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928893126&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378517315003579"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928893126</prism:url><dc:identifier>SCOPUS_ID:84928893126</dc:identifier><eid>2-s2.0-84928893126</eid><dc:title>Effect of Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody on regulating the levels of baicalin and amino acids during cerebral ischemia-reperfusion in rats</dc:title><dc:creator>Liu Z.</dc:creator><prism:publicationName>International Journal of Pharmaceutics</prism:publicationName><prism:issn>03785173</prism:issn><prism:eIssn>18733476</prism:eIssn><prism:volume>489</prism:volume><prism:issueIdentifier>1-2</prism:issueIdentifier><prism:pageRange>131-138</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ijpharm.2015.04.049</prism:doi><pii>S0378517315003579</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. Baicalin has many pharmacological activities, including neuroprotective function against ischemia and neurodegeneration. In our previous study, we found that Baicalin-loaded PEGylated cationic solid lipid nanoparticles modified by OX26 antibody (OX26-PEG-CSLN) might be a promising carrier to deliver drugs across the blood-brain barrier for the treatment of brain diseases. So, the aim of this present study was to further elucidate the mechanisms of OX26-PEG-CSLN cerebral ischemia protection by monitoring the changes of extracellular amino acids. In addition, we investigated the effect of OX26-PEG-CSLN on the excitotoxic neuronal injury as well as the pharmacokinetic profiles of baicalin in cerebrospinal fluid during ischemia-reperfusion period. The cerebrospinal fluid was collected by a microdialysis technique and divided into two parts - one part for pharmacokinetic study of baicalin using LC-MS/MS method and the other for pharmacodynamic study which was done by pre- column derivatization of the amino acids and analysis using a high-performance liquid chromatography with fluorescence detector (HPLC-FLD). The pharmacokinetic study showed that the AUC value of OX26-PEG-CSLN was 5.69-fold higher than that of the baicalin solution (Sol) (P &lt; 0.05) and the C&lt;inf&gt;max&lt;/inf&gt; value of OX26-PEG-CSLN was 6.84-fold higher than that of the Sol (P &lt; 0.05). Moreover, the extracellular levels of glutamate (Glu), aspartic acid (Asp), glycine (Gly), taurine (Tau) and Î³-aminobutyric acid (GABA) were measured for monitoring the imbalance of amino acids caused by ischemia and reperfusion. The excitotoxic index (EI) was also calculated for evaluating the imbalance between excitatory amino acid and inhibitory amino acid. The pharmacodynamic study showed that OX26-PEG-CSLN had stronger effect than Sol in reducing the content of aspartic, glutamic acid and increasing the concentrations of glycine, taurine and Î³-aminobutyric acid during ischemia-reperfusion period. In conclusion, OX26-PEG-CSLN improved uptake of baicalin across the BBB into the brain, and elevated bioavailability of baicalin in cerebral spinal fluid of rats under the cerebral ischemia-reperfusion injury. OX26-PEG-CSLN had much higher protection effect against cerebral ischemia injury than Sol by relieving the excitotoxic neuronal injury via regulating amino acid levels in cerebral spinal fluid.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012594</affiliation-url><afid>60012594</afid><affilname>Tianjin University of Traditional Chinese Medicine</affilname><name-variant>Tianjin University of Traditional Chinese Medicine</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012594</affiliation-url><afid>60012594</afid><affilname>Tianjin University of Traditional Chinese Medicine</affilname><name-variant>Tianjin University of Traditional Chinese Medicine</name-variant><affiliation-city>Tianjin</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073473</affiliation-url><afid>60073473</afid><affilname>National Center for Nanoscience and Technology Beijing</affilname><name-variant>National Center for Nanoscience and Technology</name-variant><affiliation-city>Beijing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">21</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55714737200</author-url><authid>55714737200</authid><authname>Liu Z.</authname><surname>Liu</surname><given-name>Zhidong</given-name><initials>Z.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55714737200</author-url><authid>55714737200</authid><authname>Liu Z.</authname><surname>Liu</surname><given-name>Zhidong</given-name><initials>Z.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56016142100</author-url><authid>56016142100</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Li</given-name><initials>L.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56016142100</author-url><authid>56016142100</authid><authname>Zhang L.</authname><surname>Zhang</surname><given-name>Li</given-name><initials>L.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56518800800</author-url><authid>56518800800</authid><authname>He Q.</authname><surname>He</surname><given-name>Qiansong</given-name><initials>Q.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56518800800</author-url><authid>56518800800</authid><authname>He Q.</authname><surname>He</surname><given-name>Qiansong</given-name><initials>Q.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56580679700</author-url><authid>56580679700</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiaolei</given-name><initials>X.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56580679700</author-url><authid>56580679700</authid><authname>Liu X.</authname><surname>Liu</surname><given-name>Xiaolei</given-name><initials>X.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56623119100</author-url><authid>56623119100</authid><authname>Chukwunweike Ikechukwu O.</authname><surname>Chukwunweike Ikechukwu</surname><given-name>Okeke</given-name><initials>O.</initials><afid>60073473</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56622061700</author-url><authid>56622061700</authid><authname>Tong L.</authname><surname>Tong</surname><given-name>Ling</given-name><initials>L.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56622061700</author-url><authid>56622061700</authid><authname>Tong L.</authname><surname>Tong</surname><given-name>Ling</given-name><initials>L.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56621740100</author-url><authid>56621740100</authid><authname>Guo L.</authname><surname>Guo</surname><given-name>Lili</given-name><initials>L.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56621740100</author-url><authid>56621740100</authid><authname>Guo L.</authname><surname>Guo</surname><given-name>Lili</given-name><initials>L.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56518430400</author-url><authid>56518430400</authid><authname>Yang H.</authname><surname>Yang</surname><given-name>Hongyun</given-name><initials>H.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56518430400</author-url><authid>56518430400</authid><authname>Yang H.</authname><surname>Yang</surname><given-name>Hongyun</given-name><initials>H.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55622241500</author-url><authid>55622241500</authid><authname>Zhang Q.</authname><surname>Zhang</surname><given-name>Qian</given-name><initials>Q.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:55622241500</author-url><authid>55622241500</authid><authname>Zhang Q.</authname><surname>Zhang</surname><given-name>Qian</given-name><initials>Q.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55622262800</author-url><authid>55622262800</authid><authname>Zhao H.</authname><surname>Zhao</surname><given-name>Hainan</given-name><initials>H.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:55622262800</author-url><authid>55622262800</authid><authname>Zhao H.</authname><surname>Zhao</surname><given-name>Hainan</given-name><initials>H.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56580941200</author-url><authid>56580941200</authid><authname>Gu X.</authname><surname>Gu</surname><given-name>Xing</given-name><initials>X.</initials><afid>60012594</afid><afid>60012594</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:56580941200</author-url><authid>56580941200</authid><authname>Gu X.</authname><surname>Gu</surname><given-name>Xing</given-name><initials>X.</initials><afid>60012594</afid><afid>60012594</afid></author><authkeywords>Amino acid | Baicalin | Ischemiareperfusion | Microdialysis | Nanoparticles | OX26-PEG-CSLN</authkeywords><intid>2035857056</intid><source-id>22454</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923320950"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923320950?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923320950&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923320950&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0308814615001715"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923320950</prism:url><dc:identifier>SCOPUS_ID:84923320950</dc:identifier><eid>2-s2.0-84923320950</eid><dc:title>Role of quercetin as an alternative for obesity treatment: You are what you eat!</dc:title><dc:creator>Nabavi S.</dc:creator><prism:publicationName>Food Chemistry</prism:publicationName><prism:issn>03088146</prism:issn><prism:eIssn>18737072</prism:eIssn><prism:volume>179</prism:volume><prism:pageRange>305-310</prism:pageRange><prism:coverDate>2015-07-15</prism:coverDate><prism:coverDisplayDate>15 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.foodchem.2015.02.006</prism:doi><pii>S0308814615001715</pii><dc:description>Â© 2015 Elsevier Ltd. Obesity is one of the most serious global health problems, which increases the risk of other different chronic diseases. The crucial role of oxidative stress in the initiation and progression of obesity leads to the hypothesis that antioxidants can be used as therapeutic agents for obesity treatment. Among antioxidants, much attention has been paid to polyphenols due to their negligible adverse effects. Among them, quercetin is one of the most common dietary antioxidants widely distributed in different plant materials, such as fruits, vegetables and cereals. Quercetin shows a wide range of biological and health-promoting effects, such as anticancer, hepatoprotective, antidiabetic, anti-inflammatory and antibacterial activities. Furthermore, quercetin has anti-obesity activity through mitogen-activated protein kinase and adenine monophosphate-activated protein kinase signaling pathways. In this study, we reviewed the available scientific reports concerning the beneficial role of quercetin against obesity with emphasis on its mechanisms of action.</dc:description><citedby-count>1</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010017</affiliation-url><afid>60010017</afid><affilname>Baqiyatallah Medical Sciences University</affilname><name-variant>Baqiyatallah University of Medical Sciences</name-variant><affiliation-city>Tehran</affiliation-city><affiliation-country>Iran</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021199</affiliation-url><afid>60021199</afid><affilname>Consiglio Nazionale delle Ricerche</affilname><name-variant>CNR</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60015197</affiliation-url><afid>60015197</afid><affilname>Universita degli Studi di Pavia</affilname><name-variant>UniversitÃ  di Pavia</name-variant><affiliation-city>Pavia</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:14008765800</author-url><authid>14008765800</authid><authname>Nabavi S.</authname><surname>Nabavi</surname><given-name>Seyed Fazel</given-name><initials>S.F.</initials><afid>60010017</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56517118700</author-url><authid>56517118700</authid><authname>Russo G.</authname><surname>Russo</surname><given-name>Gian Luigi</given-name><initials>G.L.</initials><afid>60021199</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6602560687</author-url><authid>6602560687</authid><authname>Daglia M.</authname><surname>Daglia</surname><given-name>Maria</given-name><initials>M.</initials><afid>60015197</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55621554100</author-url><authid>55621554100</authid><authname>Nabavi S.</authname><surname>Nabavi</surname><given-name>Seyed Mohammad</given-name><initials>S.M.</initials><afid>60010017</afid></author><authkeywords>Adenine monophosphate-activated protein kinase | Antioxidants | Mitogen-activated protein kinase | Obesity | Quercetin</authkeywords><intid>34959591</intid><source-id>24039</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84914118829"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84914118829?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84914118829&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84914118829&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1874390014001001"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84914118829</prism:url><dc:identifier>SCOPUS_ID:84914118829</dc:identifier><eid>2-s2.0-84914118829</eid><dc:title>Phytochemistry and traditional medicine - The revolution continues</dc:title><dc:creator>Cordell G.</dc:creator><prism:publicationName>Phytochemistry Letters</prism:publicationName><prism:issn>18743900</prism:issn><prism:eIssn>18767486</prism:eIssn><prism:volume>10</prism:volume><prism:pageRange>xxviii-xl</prism:pageRange><prism:coverDate>2015-07-12</prism:coverDate><prism:coverDisplayDate>12 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.phytol.2014.06.002</prism:doi><pii>S1874390014001001</pii><dc:description>Â© 2014 Phytochemical Society of Europe. Published by Elsevier B.V. All rights reserved. The use of traditional medicines, phytotherapeuticals, and dietary supplements, should be based on quality, safety, efficacy, and consistency (QSEC). Evidence relating to each of those facets of a plant-based medicine is being hampered, in part, by fourteen myths. While these myths are both powerful and persistent, they must be debunked for significant progress to be made in enhancing integrated global health care. This paper, an update on an earlier report, will examine these myths, and the roles that phytochemistry should play in this process. Some examples of the use of the new strategies will be presented from the contemporary literature, together with a brief summary of a clinical trial of a traditional medicine treatment for obesity, and a summary of activities in the European Union to address issues related to the approval and marketing of traditional Chinese medicine (TCM) products.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:105606529</affiliation-url><afid>105606529</afid><affilname>Natural Products Inc.</affilname><name-variant>Natural Products Inc.</name-variant><affiliation-city>Evanston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013959</affiliation-url><afid>60013959</afid><affilname>University of Florida</affilname><name-variant>University of Florida</name-variant><affiliation-city>Gainesville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36046533300</author-url><authid>36046533300</authid><authname>Cordell G.</authname><surname>Cordell</surname><given-name>Geoffrey A.</given-name><initials>G.A.</initials><afid>105606529</afid><afid>60013959</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:36046533300</author-url><authid>36046533300</authid><authname>Cordell G.</authname><surname>Cordell</surname><given-name>Geoffrey A.</given-name><initials>G.A.</initials><afid>105606529</afid><afid>60013959</afid></author><authkeywords>Integrated approaches | Myths | Phytochemistry | Quality safety and efficacy | Traditional medicine</authkeywords><intid>533435332</intid><source-id>11300153405</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928023578"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928023578?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928023578&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928023578&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0928098715001426"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928023578</prism:url><dc:identifier>SCOPUS_ID:84928023578</dc:identifier><eid>2-s2.0-84928023578</eid><dc:title>2â²[&lt;sup&gt;18&lt;/sup&gt;F]-fluoroethylrhodamine B is a promising radiotracer to measure P-glycoprotein function</dc:title><dc:creator>TrencsÃ©nyi G.</dc:creator><prism:publicationName>European Journal of Pharmaceutical Sciences</prism:publicationName><prism:issn>09280987</prism:issn><prism:eIssn>18790720</prism:eIssn><prism:volume>74</prism:volume><prism:pageRange>27-35</prism:pageRange><prism:coverDate>2015-07-10</prism:coverDate><prism:coverDisplayDate>10 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejps.2015.03.026</prism:doi><pii>S0928098715001426</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. In vivo detection of the emergence of P-glycoprotein (Pgp) mediated multidrug resistance in tumors could be beneficial for patients treated with anticancer drugs. PET technique in combination with appropriate radiotracers could be the most convenient method for detection of Pgp function. Rhodamine derivatives are validated fluorescent probes for measurement of mitochondrial membrane potential and also Pgp function. The aim of this study was to investigate whether 2â²[&lt;sup&gt;18&lt;/sup&gt;F]-fluoroethylrhodamine B (&lt;sup&gt;18&lt;/sup&gt;FRB) a halogenated rhodamine derivative previously synthesized for PET assessment of myocardial perfusion preserved its Pgp substrate character. ATPase assay as well as accumulation experiments carried out using Pgp&lt;sup&gt;+&lt;/sup&gt; and Pgp&lt;sup&gt;-&lt;/sup&gt; human gynecologic (A2780/A2780&lt;sup&gt;AD&lt;/sup&gt; and KB-3-1/KB-V1) and a mouse fibroblast cell pairs (NIH 3T3 and NIH 3T3 MDR1) were applied to study the interaction of &lt;sup&gt;18&lt;/sup&gt;FRB with Pgp. ATPase assay proved that &lt;sup&gt;18&lt;/sup&gt;FRB is a high affinity substrate of Pgp. Pgp&lt;sup&gt;-&lt;/sup&gt; cells accumulated the &lt;sup&gt;18&lt;/sup&gt;FRB rapidly in accordance with its lipophilic character. Dissipation of the mitochondrial proton gradient by a proton ionophore CCCP decreased the accumulation of rhodamine 123 (R123) and &lt;sup&gt;18&lt;/sup&gt;FRB into Pgp&lt;sup&gt;-&lt;/sup&gt; cells. Pgp&lt;sup&gt;+&lt;/sup&gt; cells exhibited very low R123 and &lt;sup&gt;18&lt;/sup&gt;FRB accumulation (around 1-8% of the Pgp&lt;sup&gt;-&lt;/sup&gt; cell lines) which was not sensitive to the mitochondrial proton gradient; rather it was increased by the Pgp inhibitor cyclosporine A (CsA). Based on the above data we conclude that &lt;sup&gt;18&lt;/sup&gt;FRB is a high affinity Pgp substrate and consequently a potential PET tracer to detect multidrug resistant tumors as well as the function of physiological barriers expressing Pgp.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004400</affiliation-url><afid>60004400</afid><affilname>Debreceni Egyetem</affilname><name-variant>University of Debrecen</name-variant><affiliation-city>Debrecen</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60004400</affiliation-url><afid>60004400</afid><affilname>Debreceni Egyetem</affilname><name-variant>University of Debrecen</name-variant><affiliation-city>Debrecen</affiliation-city><affiliation-country>Hungary</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:15842411000</author-url><authid>15842411000</authid><authname>TrencsÃ©nyi G.</authname><surname>TrencsÃ©nyi</surname><given-name>GyÃ¶rgy</given-name><initials>G.</initials><afid>60004400</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56398174200</author-url><authid>56398174200</authid><authname>KertÃ©sz I.</authname><surname>KertÃ©sz</surname><given-name>IstvÃ¡n</given-name><initials>I.</initials><afid>60004400</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8246733300</author-url><authid>8246733300</authid><authname>Krasznai Z.</authname><surname>Krasznai</surname><given-name>ZoÃ¡rd T.</given-name><initials>Z.T.</initials><afid>60004400</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56482175300</author-url><authid>56482175300</authid><authname>MÃ¡tÃ© G.</authname><surname>MÃ¡tÃ©</surname><given-name>GÃ¡bor</given-name><initials>G.</initials><afid>60004400</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55986665500</author-url><authid>55986665500</authid><authname>SzalÃ³ki G.</authname><surname>SzalÃ³ki</surname><given-name>GÃ¡bor</given-name><initials>G.</initials><afid>60004400</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56597968300</author-url><authid>56597968300</authid><authname>SzabÃ³ Judit P.</authname><surname>SzabÃ³ Judit</surname><given-name>P.</given-name><initials>P.</initials><afid>60004400</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6601944589</author-url><authid>6601944589</authid><authname>KÃ¡rpÃ¡ti L.</authname><surname>KÃ¡rpÃ¡ti</surname><given-name>Levente</given-name><initials>L.</initials><afid>60004400</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6701481750</author-url><authid>6701481750</authid><authname>Krasznai Z.</authname><surname>Krasznai</surname><given-name>ZoltÃ¡n</given-name><initials>Z.</initials><afid>60004400</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7004009706</author-url><authid>7004009706</authid><authname>MÃ¡riÃ¡n T.</authname><surname>MÃ¡riÃ¡n</surname><given-name>TerÃ©z</given-name><initials>T.</initials><afid>60004400</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7007186396</author-url><authid>7007186396</authid><authname>Goda K.</authname><surname>Goda</surname><given-name>Katalin</given-name><initials>K.</initials><afid>60004400</afid></author><authkeywords>&lt;sup&gt;18&lt;/sup&gt;FRB | Gynecologic cancer cells | P-glycoprotein | PET</authkeywords><intid>535716333</intid><source-id>21331</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929334633"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929334633?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929334633&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929334633&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0168365915002898"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929334633</prism:url><dc:identifier>SCOPUS_ID:84929334633</dc:identifier><eid>2-s2.0-84929334633</eid><dc:title>Impact insertion of transfer-molded microneedle for localized and minimally invasive ocular drug delivery</dc:title><dc:creator>Kim J.</dc:creator><prism:publicationName>Journal of Controlled Release</prism:publicationName><prism:issn>01683659</prism:issn><prism:eIssn>18734995</prism:eIssn><prism:volume>209</prism:volume><prism:pageRange>272-279</prism:pageRange><prism:coverDate>2015-07-10</prism:coverDate><prism:coverDisplayDate>10 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jconrel.2015.04.041</prism:doi><pii>S0168365915002898</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. It has been challenging for microneedles to deliver drugs effectively to thin tissues with little background support such as the cornea. Herein, we designed a microneedle pen system, a single microneedle with a spring-loaded microneedle applicator to provide impact insertion. To firmly attach solid microneedles with 140 Î¼m in height at the end of macro-scale applicators, a transfer molding process was employed. The fabricated microneedle pens were then applied to mouse corneas. The microneedle pens successfully delivered rhodamine dye deep enough to reach the stromal layer of the cornea with small entry only about 1000 Î¼m&lt;sup&gt;2&lt;/sup&gt;. When compared with syringes or 30G needle tips, microneedle pens could achieve more localized and minimally invasive delivery without any chances of perforation. To investigate the efficacy of microneedle pens as a way of drug delivery, sunitinib malate proven to inhibit in vitro angiogenesis, was delivered to suture-induced angiogenesis model. When compared with delivery by a 30G needle tip dipped with sunitinib malate, only delivery by microneedle pens could effectively inhibit corneal neovascularization in vivo. Microneedle pens could effectively deliver drugs to thin tissues without impairing merits of using microneedles: localized and minimally invasive delivery.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021119</affiliation-url><afid>60021119</afid><affilname>Seoul National University Hospital</affilname><name-variant>Seoul National University Hospital</name-variant><affiliation-city>Jongno-gu</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013682</affiliation-url><afid>60013682</afid><affilname>Seoul National University</affilname><name-variant>Seoul National University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016912</affiliation-url><afid>60016912</afid><affilname>Yonsei University</affilname><name-variant>Yonsei University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018986</affiliation-url><afid>60018986</afid><affilname>Hallym University</affilname><name-variant>Hallym University</name-variant><affiliation-city>Chuncheon</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013682</affiliation-url><afid>60013682</afid><affilname>Seoul National University</affilname><name-variant>Seoul National University</name-variant><affiliation-city>Seoul</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645012800</author-url><authid>56645012800</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jeong Hun</given-name><initials>J.H.</initials><afid>60021119</afid><afid>60013682</afid><afid>60013682</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645012800</author-url><authid>56645012800</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jeong Hun</given-name><initials>J.H.</initials><afid>60021119</afid><afid>60013682</afid><afid>60013682</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56645012800</author-url><authid>56645012800</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jeong Hun</given-name><initials>J.H.</initials><afid>60021119</afid><afid>60013682</afid><afid>60013682</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643517800</author-url><authid>56643517800</authid><authname>Song H.</authname><surname>Song</surname><given-name>Hyun Beom</given-name><initials>H.B.</initials><afid>60021119</afid><afid>60013682</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56643517800</author-url><authid>56643517800</authid><authname>Song H.</authname><surname>Song</surname><given-name>Hyun Beom</given-name><initials>H.B.</initials><afid>60021119</afid><afid>60013682</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56101369400</author-url><authid>56101369400</authid><authname>Lee K.</authname><surname>Lee</surname><given-name>Kang Ju</given-name><initials>K.J.</initials><afid>60016912</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56640865300</author-url><authid>56640865300</authid><authname>Seo I.</authname><surname>Seo</surname><given-name>Il Ho</given-name><initials>I.H.</initials><afid>60016912</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56301567900</author-url><authid>56301567900</authid><authname>Lee J.</authname><surname>Lee</surname><given-name>Ji Yong</given-name><initials>J.Y.</initials><afid>60016912</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56643457300</author-url><authid>56643457300</authid><authname>Lee S.</authname><surname>Lee</surname><given-name>Sang Mok</given-name><initials>S.M.</initials><afid>60018986</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:36014681700</author-url><authid>36014681700</authid><authname>Kim J.</authname><surname>Kim</surname><given-name>Jin Hyoung</given-name><initials>J.H.</initials><afid>60021119</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:15077134200</author-url><authid>15077134200</authid><authname>Ryu W.</authname><surname>Ryu</surname><given-name>Wonhyoung</given-name><initials>W.</initials><afid>60016912</afid></author><authkeywords>Angiogenesis | Drug delivery | Impact insertion | Microneedle | Mouse cornea | Transfer molding</authkeywords><intid>1785945519</intid><source-id>23010</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928994864"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928994864?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928994864&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928994864&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003814"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928994864</prism:url><dc:identifier>SCOPUS_ID:84928994864</dc:identifier><eid>2-s2.0-84928994864</eid><dc:title>Differential effects of GABA in modulating nociceptive vs. non-nociceptive synapses</dc:title><dc:creator>Wang Y.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>298</prism:volume><prism:pageRange>397-409</prism:pageRange><prism:coverDate>2015-07-09</prism:coverDate><prism:coverDisplayDate>July 09, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.04.040</prism:doi><pii>S0306452215003814</pii><dc:description>Â© 2015 IBRO. GABA (Î³-amino-butyric acid) -mediated signaling is normally associated with synaptic inhibition due to ionotropic GABA receptors that gate an inward Cl&lt;sup&gt;-&lt;/sup&gt; current, hyperpolarizing the membrane potential. However, there are also situations where ionotropic GABA receptors trigger a Cl&lt;sup&gt;-&lt;/sup&gt; efflux that results in depolarization. The well-characterized central nervous system of the medicinal leech was used to study the functional significance of opposing effects of GABA at the synaptic circuit level. Specifically, we focused on synapses made by the nociceptive N cell and the non-nociceptive P (pressure) cell that converge onto a common postsynaptic target. It is already known that GABA hyperpolarizes the P cell, but depolarizes the N cell and that inhibition of ionotropic GABA receptors by bicuculline (BIC) has opposing effects on the synapses made by these two inputs; enhancing P cell synaptic transmission, but depressing N cell synapses. The goal of the present study was to determine whether the opposing effects of GABA were due to differences in Cl&lt;sup&gt;-&lt;/sup&gt; homeostasis between the two presynaptic neurons. VU 0240551 (VU), an inhibitor of the Cl&lt;sup&gt;-&lt;/sup&gt; exporter K-Cl co-transporter isoform 2 (KCC2), attenuated GABA-mediated hyperpolarization of the non-nociceptive afferent while bumetanide (BUM), an inhibitor of the Cl&lt;sup&gt;-&lt;/sup&gt; importer Na-K-Cl co-transporter isoform 1 (NKCC1), reduced GABA-mediated depolarization of the nociceptive neuron. VU treatment also enhanced P cell synaptic signaling, similar to the previously observed effects of BIC and consistent with the idea that GABA inhibits synaptic signaling at the presynaptic level. BUM treatment depressed N cell synapses, again similar to what is observed following BIC treatment and suggests that GABA has an excitatory effect on these synapses. The opposing effects of GABA could also be observed at the behavioral level with BIC and VU increasing responsiveness to non-nociceptive stimulation while BIC and BUM decreased responsiveness to nociceptive stimulation. These findings demonstrate that distinct synaptic inputs within a shared neural circuit can be differentially modulated by GABA in a functionally relevant manner.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028179</affiliation-url><afid>60028179</afid><affilname>University of South Dakota</affilname><name-variant>University of South Dakota</name-variant><affiliation-city>Vermillion</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55751736000</author-url><authid>55751736000</authid><authname>Wang Y.</authname><surname>Wang</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60028179</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56574835400</author-url><authid>56574835400</authid><authname>Summers T.</authname><surname>Summers</surname><given-name>T.</given-name><initials>T.</initials><afid>60028179</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36819085300</author-url><authid>36819085300</authid><authname>Peterson W.</authname><surname>Peterson</surname><given-name>W.</given-name><initials>W.</initials><afid>60028179</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56626123300</author-url><authid>56626123300</authid><authname>Miiller E.</authname><surname>Miiller</surname><given-name>E.</given-name><initials>E.</initials><afid>60028179</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7003669609</author-url><authid>7003669609</authid><authname>Burrell B.</authname><surname>Burrell</surname><given-name>B. D.</given-name><initials>B.D.</initials><afid>60028179</afid></author><authkeywords>Chloride | GABA | Nociception | Synaptic transmission</authkeywords><intid>2035879690</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928679327"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928679327?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928679327&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928679327&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003693"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928679327</prism:url><dc:identifier>SCOPUS_ID:84928679327</dc:identifier><eid>2-s2.0-84928679327</eid><dc:title>From cognitive motor preparation to visual processing: The benefits of childhood fitness to brain health</dc:title><dc:creator>Berchicci M.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>298</prism:volume><prism:pageRange>211-219</prism:pageRange><prism:coverDate>2015-07-09</prism:coverDate><prism:coverDisplayDate>July 09, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.04.028</prism:doi><pii>S0306452215003693</pii><dc:description>Â© 2015 IBRO. The association between a fit body and a fit brain in children has led to a rise of behavioral and neuroscientific research. Yet, the relation of cardiorespiratory fitness on premotor neurocognitive preparation with early visual processing has received little attention. Here, 41 healthy, lower and higher fit preadolescent children were administered a modified version of the Eriksen flanker task while electroencephalography (EEG) and behavioral measures were recorded. Event-related potentials (ERPs) locked to the stimulus onset with an earlier than usual baseline (-900/-800. ms) allowed investigation of both the usual post-stimulus (i.e., the P1, N1 and P2) as well as the pre-stimulus ERP components, such as the Bereitschaftspotential (BP) and the prefrontal negativity (pN component). At the behavioral level, aerobic fitness was associated response accuracy, with higher fit children being more accurate than lower fit children. Fitness-related differences selectively emerged at prefrontal brain regions during response preparation, with larger pN amplitude for higher than lower fit children, and at early perceptual stages after stimulus onset, with larger P1 and N1 amplitudes in higher relative to lower fit children. Collectively, the results suggest that the benefits of being aerobically fit appear at the stage of cognitive preparation prior to stimulus presentation and the behavioral response during the performance of a task that challenges cognitive control. Further, it is likely that enhanced activity in prefrontal brain areas may improve cognitive control of visuo-motor tasks, allowing for stronger proactive inhibition and larger early allocation of selective attention resources on relevant external stimuli.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032350</affiliation-url><afid>60032350</afid><affilname>Universita degli Studi di Roma La Sapienza</affilname><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60031707</affiliation-url><afid>60031707</afid><affilname>Michigan State University</affilname><name-variant>Michigan State University</name-variant><affiliation-city>East Lansing</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60005290</affiliation-url><afid>60005290</afid><affilname>University of Illinois</affilname><name-variant>University of Illinois</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014416</affiliation-url><afid>60014416</afid><affilname>IRCCS Fondazione Santa Lucia</affilname><name-variant>Santa Lucia Foundation</name-variant><affiliation-city>Rome</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:6507344064</author-url><authid>6507344064</authid><authname>Berchicci M.</authname><surname>Berchicci</surname><given-name>M.</given-name><initials>M.</initials><afid>60032350</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56603313500</author-url><authid>56603313500</authid><authname>Pontifex M.</authname><surname>Pontifex</surname><given-name>M. B.</given-name><initials>M.B.</initials><afid>60031707</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:37107557800</author-url><authid>37107557800</authid><authname>Drollette E.</authname><surname>Drollette</surname><given-name>E. S.</given-name><initials>E.S.</initials><afid>60005290</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005773430</author-url><authid>7005773430</authid><authname>Pesce C.</authname><surname>Pesce</surname><given-name>C.</given-name><initials>C.</initials><afid>60032350</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56177416200</author-url><authid>56177416200</authid><authname>Hillman C.</authname><surname>Hillman</surname><given-name>C. H.</given-name><initials>C.H.</initials><afid>60005290</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603820862</author-url><authid>6603820862</authid><authname>Di Russo F.</authname><surname>Di Russo</surname><given-name>F.</given-name><initials>F.</initials><afid>60032350</afid><afid>60014416</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603820862</author-url><authid>6603820862</authid><authname>Di Russo F.</authname><surname>Di Russo</surname><given-name>F.</given-name><initials>F.</initials><afid>60032350</afid><afid>60014416</afid></author><authkeywords>Adolescence | Cognition | ERP | Fitness | Motor preparation</authkeywords><intid>1535823392</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929460122"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929460122?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929460122&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929460122&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003759"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929460122</prism:url><dc:identifier>SCOPUS_ID:84929460122</dc:identifier><eid>2-s2.0-84929460122</eid><dc:title>A single intracerebroventricular AÎ²&lt;inf&gt;25-35&lt;/inf&gt; infusion leads to prolonged alterations in arginine metabolism in the rat hippocampus and prefrontal cortex</dc:title><dc:creator>Bergin D.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>298</prism:volume><prism:pageRange>367-379</prism:pageRange><prism:coverDate>2015-07-09</prism:coverDate><prism:coverDisplayDate>July 09, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.04.034</prism:doi><pii>S0306452215003759</pii><dc:description>Â© 2015 IBRO. While amyloid beta (AÎ²) plays a central role in the development of Alzheimer's disease (AD), recent evidence suggests the involvement of arginine metabolism in AD pathogenesis. Earlier research has shown that a single intracerebroventricular (i.c.v.) infusion of pre-aggregated AÎ²&lt;inf&gt;25-35&lt;/inf&gt; (the neurotoxic domain of the full-length AÎ²) altered arginine metabolism in the rat hippocampus (particularly the CA2/3 and dentate gyrus (DG) sub-regions) and prefrontal cortex (PFC) at the time point of 8days post-infusion. The present study measured the levels of l-arginine and its nine downstream metabolites (l-citrulline, l-ornithine, agmatine, putrescine, spermidine, spermine, glutamate, GABA and glutamine) in the hippocampus and PFC at the time points of 42 and 97days following a single bilateral i.c.v. infusion of AÎ²&lt;inf&gt;25-35&lt;/inf&gt; (30nmol/rat) or AÎ²&lt;inf&gt;35-25&lt;/inf&gt; (reverse peptide; 30nmol/rat). At the 42-day time point, AÎ²&lt;inf&gt;25-35&lt;/inf&gt; resulted in decreased levels of glutamate, glutamine and spermine in the CA2/3 sub-region of the hippocampus. At the 97-day time point, however, there were decreased l-ornithine, GABA and putrescine levels, but increased glutamate/GABA ratio, in the PFC and increased spermine levels in the DG sub-region. Cluster analyses showed that l-arginine and its three main metabolites l-citrulline, l-ornithine and agmatine formed distinct groups, which changed as a function of AÎ²&lt;inf&gt;25-35&lt;/inf&gt; at the 42-day and 97-day time points, particularly in the CA2/3 and PFC regions respectively. This study, for the first time, demonstrates that a single i.c.v. infusion of pre-aggregated AÎ²&lt;inf&gt;25-35&lt;/inf&gt; leads to prolonged alterations in arginine metabolism in a region-specific and time-dependent manner, which further supports the involvement of arginine metabolism in AD pathogenesis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029198</affiliation-url><afid>60029198</afid><affilname>Otago School of Medical Sciences</affilname><name-variant>Univ. Otago Med. Sch.</name-variant><affiliation-city>Dunedin</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017311</affiliation-url><afid>60017311</afid><affilname>University of Otago</affilname><name-variant>University of Otago</name-variant><affiliation-city>Dunedin</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017311</affiliation-url><afid>60017311</afid><affilname>University of Otago</affilname><name-variant>University of Otago</name-variant><affiliation-city>Dunedin</affiliation-city><affiliation-country>New Zealand</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">10</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35075791400</author-url><authid>35075791400</authid><authname>Bergin D.</authname><surname>Bergin</surname><given-name>D. H.</given-name><initials>D.H.</initials><afid>60029198</afid><afid>60017311</afid><afid>60017311</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35075791400</author-url><authid>35075791400</authid><authname>Bergin D.</authname><surname>Bergin</surname><given-name>D. H.</given-name><initials>D.H.</initials><afid>60029198</afid><afid>60017311</afid><afid>60017311</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35075791400</author-url><authid>35075791400</authid><authname>Bergin D.</authname><surname>Bergin</surname><given-name>D. H.</given-name><initials>D.H.</initials><afid>60029198</afid><afid>60017311</afid><afid>60017311</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24471883900</author-url><authid>24471883900</authid><authname>Jing Y.</authname><surname>Jing</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60029198</afid><afid>60017311</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24471883900</author-url><authid>24471883900</authid><authname>Jing Y.</authname><surname>Jing</surname><given-name>Y.</given-name><initials>Y.</initials><afid>60029198</afid><afid>60017311</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16680442100</author-url><authid>16680442100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>H.</given-name><initials>H.</initials><afid>60029198</afid><afid>60017311</afid><afid>60017311</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16680442100</author-url><authid>16680442100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>H.</given-name><initials>H.</initials><afid>60029198</afid><afid>60017311</afid><afid>60017311</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16680442100</author-url><authid>16680442100</authid><authname>Zhang H.</authname><surname>Zhang</surname><given-name>H.</given-name><initials>H.</initials><afid>60029198</afid><afid>60017311</afid><afid>60017311</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36065603800</author-url><authid>36065603800</authid><authname>Liu P.</authname><surname>Liu</surname><given-name>P.</given-name><initials>P.</initials><afid>60029198</afid><afid>60017311</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:36065603800</author-url><authid>36065603800</authid><authname>Liu P.</authname><surname>Liu</surname><given-name>P.</given-name><initials>P.</initials><afid>60029198</afid><afid>60017311</afid></author><authkeywords>Amyloid beta | Arginine metabolism | Glutamate | Hippocampus | Polyamines | Prefrontal cortex</authkeywords><intid>1035958471</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928322216"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928322216?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928322216&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928322216&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306452215003358"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928322216</prism:url><dc:identifier>SCOPUS_ID:84928322216</dc:identifier><eid>2-s2.0-84928322216</eid><dc:title>Early free access to hypertonic NaCl solution induces a long-term effect on drinking, brain cell activity and gene expression of adult rat offspring</dc:title><dc:creator>Macchione A.</dc:creator><prism:publicationName>Neuroscience</prism:publicationName><prism:issn>03064522</prism:issn><prism:eIssn>18737544</prism:eIssn><prism:volume>298</prism:volume><prism:pageRange>120-136</prism:pageRange><prism:coverDate>2015-07-09</prism:coverDate><prism:coverDisplayDate>July 09, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroscience.2015.04.004</prism:doi><pii>S0306452215003358</pii><dc:description>Â© 2015 IBRO. Exposure to an altered osmotic environment during a pre/postnatal period can differentially program the fluid intake and excretion pattern profile in a way that persists until adulthood. However, knowledge about the programing effects on the underlying brain neurochemical circuits of thirst and hydroelectrolyte balance, and its relation with behavioral outputs, is limited. We evaluated whether early voluntary intake of hypertonic NaCl solution may program adult offspring fluid balance, plasma vasopressin, neural activity, and brain vasopressin and angiotensinergic receptor type 1a (AT1a)-receptor gene expression. The manipulation (M) period covered dams from 1. week before conception until offspring turned 1-month-old. The experimental groups were (i) Free access to hypertonic NaCl solution (0.45. M NaCl), food (0.18% NaCl) and water [M-Na]; and (ii) Free access to food and water only [M-Ctrol]. Male offspring (2-month-old) were subjected to iv infusion (0.15. ml/min) of hypertonic (1.5. M NaCl), isotonic (0.15. M NaCl) or sham infusion during 20. min. Cumulative water intake (140. min) and drinking latency to the first lick were recorded from the start of the infusion. Our results indicate that, after systemic sodium overload, the M-Na group had increased water intake, and diminished neuronal activity (Fos-immunoreactivity) in the subfornical organ (SFO) and nucleus of the solitary tract. They also showed reduced relative vasopressin (AVP)-mRNA and AT1a-mRNA expression at the supraoptic nucleus and SFO, respectively. The data indicate that the availability of a rich source of sodium during the pre/postnatal period induces a long-term effect on drinking, neural activity, and brain gene expression implicated in the control of hydroelectrolyte balance.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025099</affiliation-url><afid>60025099</afid><affilname>Instituto de Investigacion Medica Mercedes y Martin Ferreyra</affilname><name-variant>Instituto de Investigacion Medica Mercedes y Martin Ferreyra</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000658</affiliation-url><afid>60000658</afid><affilname>Universidad Nacional de Cordoba</affilname><name-variant>Universidad Nacional de Cordoba</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000658</affiliation-url><afid>60000658</afid><affilname>Universidad Nacional de Cordoba</affilname><name-variant>Universidad Nacional de Cordoba</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60012427</affiliation-url><afid>60012427</afid><affilname>Hospital Privado Centro Medico de Cordoba</affilname><name-variant>Hospital Privado Centro MÃ©dico de CÃ³rdoba</name-variant><affiliation-city>Cordoba</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:40161806600</author-url><authid>40161806600</authid><authname>Macchione A.</authname><surname>Macchione</surname><given-name>A. F.</given-name><initials>A.F.</initials><afid>60025099</afid><afid>60000658</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:40161806600</author-url><authid>40161806600</authid><authname>Macchione A.</authname><surname>Macchione</surname><given-name>A. F.</given-name><initials>A.F.</initials><afid>60025099</afid><afid>60000658</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56604220800</author-url><authid>56604220800</authid><authname>Beas C.</authname><surname>Beas</surname><given-name>C.</given-name><initials>C.</initials><afid>60025099</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56024799100</author-url><authid>56024799100</authid><authname>Dadam F.</authname><surname>Dadam</surname><given-name>F. M.</given-name><initials>F.M.</initials><afid>60025099</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:14622322100</author-url><authid>14622322100</authid><authname>Caeiro X.</authname><surname>Caeiro</surname><given-name>X. E.</given-name><initials>X.E.</initials><afid>60025099</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:20734240800</author-url><authid>20734240800</authid><authname>Godino A.</authname><surname>Godino</surname><given-name>A.</given-name><initials>A.</initials><afid>60025099</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56603900100</author-url><authid>56603900100</authid><authname>Ponce L.</authname><surname>Ponce</surname><given-name>L. F.</given-name><initials>L.F.</initials><afid>60025099</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:6507824529</author-url><authid>6507824529</authid><authname>Amigone J.</authname><surname>Amigone</surname><given-name>J. L.</given-name><initials>J.L.</initials><afid>60012427</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6604021745</author-url><authid>6604021745</authid><authname>Vivas L.</authname><surname>Vivas</surname><given-name>L.</given-name><initials>L.</initials><afid>60025099</afid><afid>60000658</afid><afid>60000658</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6604021745</author-url><authid>6604021745</authid><authname>Vivas L.</authname><surname>Vivas</surname><given-name>L.</given-name><initials>L.</initials><afid>60025099</afid><afid>60000658</afid><afid>60000658</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6604021745</author-url><authid>6604021745</authid><authname>Vivas L.</authname><surname>Vivas</surname><given-name>L.</given-name><initials>L.</initials><afid>60025099</afid><afid>60000658</afid><afid>60000658</afid></author><authkeywords>AVP and AT1a mRNA relative gene expression | C-fos | Nucleus of the solitary tract | Pre/postnatal programing | Subfornical organ | Vasopressin</authkeywords><intid>1535766578</intid><source-id>18042</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929395151"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929395151?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929395151&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929395151&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0378427415001745"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929395151</prism:url><dc:identifier>SCOPUS_ID:84929395151</dc:identifier><eid>2-s2.0-84929395151</eid><dc:title>Association between the aldehyde dehydrogenase 2*2 allele and smoking-related chronic airway obstruction in a Japanese general population: A pilot study</dc:title><dc:creator>Morita K.</dc:creator><prism:publicationName>Toxicology Letters</prism:publicationName><prism:issn>03784274</prism:issn><prism:eIssn>18793169</prism:eIssn><prism:volume>236</prism:volume><prism:issueIdentifier>2</prism:issueIdentifier><prism:pageRange>117-122</prism:pageRange><prism:coverDate>2015-07-06</prism:coverDate><prism:coverDisplayDate>July 06, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.toxlet.2015.05.007</prism:doi><pii>S0378427415001745</pii><dc:description>Â© 2015 Published by Elsevier Ireland Ltd. Aldehyde dehydrogenase 2 (ALDH2) detoxifies exogenous and endogenous toxic aldehydes; however, its protective effect against cigarette smoke in airways is unknown. We therefore examined whether the inactive ALDH2*2 allele is associated with smoking-related chronic airway obstruction. We conducted a cross-sectional study including 684 Japanese participants in a health screening program, and a retrospective longitudinal study in the elderly subgroup. The risks of airway obstruction in the ever-smokers with the ALDH2*1/. *2 and *2/. *2 genotypes were two and three times higher, respectively, than in the never-smokers with the ALDH2*1/. *1 genotype. Moreover, the combined effect of smoking and the ALDH2*2 allele was prominent in the asthmatic subjects. In a longitudinal association analysis, the combination of the ALDH2 genotype and pack-years of smoking synergistically increased the risk of airway obstruction. The number of pack-years of smoking at baseline was identified to be a significant predictor of airway obstruction only in the ALDH2*2 allele carriers. In addition, the ALDH2*2 allele was also associated with the incidence of smoking-related airway obstruction, in the Cox proportional hazards model. This pilot study demonstrated for the first time a significant gene-environment interaction between the ALDH2*2 allele and cumulative exposure to cigarette smoke on the risk of airway obstruction.&lt;.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021120</affiliation-url><afid>60021120</afid><affilname>Kumamoto University</affilname><name-variant>Kumamoto University</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60007504</affiliation-url><afid>60007504</afid><affilname>Kumamoto Sekijuji Hospital</affilname><name-variant>Kumamoto Red Cross Hospital</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60021120</affiliation-url><afid>60021120</afid><affilname>Kumamoto University</affilname><name-variant>Kumamoto University</name-variant><affiliation-city>Kumamoto</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:42462045100</author-url><authid>42462045100</authid><authname>Morita K.</authname><surname>Morita</surname><given-name>Kazunori</given-name><initials>K.</initials><afid>60021120</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56645881100</author-url><authid>56645881100</authid><authname>Masuda N.</authname><surname>Masuda</surname><given-name>Natsuki</given-name><initials>N.</initials><afid>60021120</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56502451600</author-url><authid>56502451600</authid><authname>Oniki K.</authname><surname>Oniki</surname><given-name>Kentaro</given-name><initials>K.</initials><afid>60021120</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56502450400</author-url><authid>56502450400</authid><authname>Saruwatari J.</authname><surname>Saruwatari</surname><given-name>Junji</given-name><initials>J.</initials><afid>60021120</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55437742400</author-url><authid>55437742400</authid><authname>Kajiwara A.</authname><surname>Kajiwara</surname><given-name>Ayami</given-name><initials>A.</initials><afid>60021120</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56179259800</author-url><authid>56179259800</authid><authname>Otake K.</authname><surname>Otake</surname><given-name>Koji</given-name><initials>K.</initials><afid>60007504</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56421423500</author-url><authid>56421423500</authid><authname>Ogata Y.</authname><surname>Ogata</surname><given-name>Yasuhiro</given-name><initials>Y.</initials><afid>60007504</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56502870100</author-url><authid>56502870100</authid><authname>Nakagawa K.</authname><surname>Nakagawa</surname><given-name>Kazuko</given-name><initials>K.</initials><afid>60021120</afid><afid>60021120</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56502870100</author-url><authid>56502870100</authid><authname>Nakagawa K.</authname><surname>Nakagawa</surname><given-name>Kazuko</given-name><initials>K.</initials><afid>60021120</afid><afid>60021120</afid></author><authkeywords>Aldehydes | Asthma | Chronic obstructive pulmonary disease | Genetic association study | Longitudinal study</authkeywords><intid>1035951489</intid><source-id>25240</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928911350"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928911350?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928911350&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928911350&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0304423815002162"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928911350</prism:url><dc:identifier>SCOPUS_ID:84928911350</dc:identifier><eid>2-s2.0-84928911350</eid><dc:title>In vitro antioxidant activities and phenolic content in crop residues of Tunisian globe artichoke</dc:title><dc:creator>Sihem D.</dc:creator><prism:publicationName>Scientia Horticulturae</prism:publicationName><prism:issn>03044238</prism:issn><prism:volume>190</prism:volume><prism:pageRange>128-136</prism:pageRange><prism:coverDate>2015-07-06</prism:coverDate><prism:coverDisplayDate>July 06, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.scienta.2015.04.014</prism:doi><pii>S0304423815002162</pii><dc:description>Â© 2015 Elsevier B.V. The phenolic content and in vitro antioxidant activity of the bracts, leaves and floral stems of two Tunisian globe artichoke cultivars ('Violet d'HyÃ©res' and 'Blanc d'Oran') were assessed; the tests used to assay antioxidant activity were based on ABTS [2,2-azino-bis-3-ethylbenzothiazoline-6-sulfonic acid] and DPPH [2,2-diphenyl-l-picrylhydrazyl]. In addition reducing power was measured and the phosphomolybdenum total antioxidant activity assay was included. The bracts of 'Violet d'HyÃ©res' possessed, on average, twice the quantity of phenolic compounds than those of 'Blanc d'Oran'. They also had a higher content of 3,5-O-dicaffeoylquinic acid. The bracts and floral stems contained high levels of total caffeoylquinic acid, whereas the leaves provided a potentially exploitable source of luteolin. Ethanolic extracts of both cultivars exhibited a high level of antioxidant activity. The ABTS EC&lt;inf&gt;50&lt;/inf&gt; value was high in extracts from the leaves of both cultivars, whereas the DPPH test showed no variation between the bracts, floral stems and leaves. The bracts were associated with strong reducing power and total antioxidant activity. Overall, the leaves were associated with more antioxidant activity than the bracts or the floral stems. The implication is that globe artichoke crop residues could provide a useful source of antioxidant compounds.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60055140</affiliation-url><afid>60055140</afid><affilname>Centre of Biotechnology of Sfax</affilname><name-variant>Centre de Biotechnologie de Sfax</name-variant><affiliation-city>Sfa</affiliation-city><affiliation-country>Tunisia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:106560299</affiliation-url><afid>106560299</afid><affilname>Faculty of Dentistry</affilname><name-variant>Faculty of Dentistry</name-variant><affiliation-city>Monastir</affiliation-city><affiliation-country>Tunisia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60010146</affiliation-url><afid>60010146</afid><affilname>Universita degli Studi di Catania</affilname><name-variant>UniversitÃ  di Catania</name-variant><affiliation-city>Catania</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115241115</affiliation-url><afid>115241115</afid><affilname>Dipartimento di Scienze Agrarie Forestali e Alimentari (DISAFA)</affilname><name-variant>Dipartimento di Scienze Agrarie Forestali e Alimentari (DISAFA)</name-variant><affiliation-city>Torino</affiliation-city><affiliation-country>Italy</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56623138300</author-url><authid>56623138300</authid><authname>Sihem D.</authname><surname>Sihem</surname><given-name>Dabbou</given-name><initials>D.</initials><afid>60055140</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56623154000</author-url><authid>56623154000</authid><authname>Samia D.</authname><surname>Samia</surname><given-name>Dabbou</given-name><initials>D.</initials><afid>60055140</afid><afid>106560299</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56623154000</author-url><authid>56623154000</authid><authname>Samia D.</authname><surname>Samia</surname><given-name>Dabbou</given-name><initials>D.</initials><afid>60055140</afid><afid>106560299</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56622875600</author-url><authid>56622875600</authid><authname>Gaetano P.</authname><surname>Gaetano</surname><given-name>Pandino</given-name><initials>P.</initials><afid>60010146</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56622899900</author-url><authid>56622899900</authid><authname>Sara L.</authname><surname>Sara</surname><given-name>Lombardo</given-name><initials>L.</initials><afid>60010146</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56622679700</author-url><authid>56622679700</authid><authname>Giovanni M.</authname><surname>Giovanni</surname><given-name>Mauromicale</given-name><initials>M.</initials><afid>60010146</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56623190200</author-url><authid>56623190200</authid><authname>Hassiba C.</authname><surname>Hassiba</surname><given-name>Chahdoura</given-name><initials>C.</initials><afid>60055140</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56623063000</author-url><authid>56623063000</authid><authname>Laura G.</authname><surname>Laura</surname><given-name>Gasco</given-name><initials>G.</initials><afid>115241115</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:56623182200</author-url><authid>56623182200</authid><authname>Ahmed Noureddine H.</authname><surname>Ahmed Noureddine</surname><given-name>Helal</given-name><initials>H.</initials><afid>60055140</afid></author><authkeywords>Antioxidant activity | Bracts | Floral stem | Globe artichoke | Leaves | Polyphenols</authkeywords><intid>1535861841</intid><source-id>26751</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927616720"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927616720?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927616720&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927616720&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915003180"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927616720</prism:url><dc:identifier>SCOPUS_ID:84927616720</dc:identifier><eid>2-s2.0-84927616720</eid><dc:title>Effect of nebivolol treatment during pregnancy on the genital circulation, fetal growth and postnatal development in the Wistar rat</dc:title><dc:creator>Altoama K.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>758</prism:volume><prism:pageRange>31-39</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.04.001</prism:doi><pii>S0014299915003180</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. The aim of study was to evaluate the effects of nebivolol, a cardioselective beta-1 adrenergic receptor blocker of the third generation with vasodilatory properties, vs. bisoprolol on the genital circulation, uterine vasculature, fetal growth and postnatal development in pregnant Wistar rats. Non invasive measurements of systolic and diastolic blood pressure (SBP and DBP) and heart rate (HR), and invasive measurement of genital blood flow (GBF) were taken in pregnant rats, by tail cuff and transonic probe methods respectively, after an oral treatment by gastric gavage with nebivolol (8 mg/kg/day) or bisoprolol (10 mg/kg/day) from day 11 to day 18 of pregnancy. Other morphometrical and histological measurements were performed on the ovarian and uterine arteries to evaluate the effect of nebivolol on the uterine vasculature. Furthermore, postnatal mortality and pup growth were recorded. The data demonstrated that nebivolol (compared with bisoprolol) induced a significant decrease in SBP, HR and GBF while DBP remained unchanged. Moreover, nebivolol increased the diameter and the length of ovarian and uterine arteries and the number of uterine artery segmental branches. The results also showed that the body weight gain of newborns in the nebivolol group was significantly lower vs. bisoprolol and vs. control with a higher mortality rate. The nebivolol action is not only limited to its favorable hemodynamic effects represented by a decrease in blood pressure, but it also produces adverse effects on fetal growth and postnatal development that may limit its therapeutic use in females during pregnancy.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110240602</affiliation-url><afid>110240602</afid><affilname>LUNAM UniversitÃ©</affilname><name-variant>LUNAM UniversitÃ©</name-variant><affiliation-city>Nantes</affiliation-city><affiliation-country>France</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:110240602</affiliation-url><afid>110240602</afid><affilname>LUNAM UniversitÃ©</affilname><name-variant>LUNAM UniversitÃ©</name-variant><affiliation-city>Nantes</affiliation-city><affiliation-country>France</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56593119400</author-url><authid>56593119400</authid><authname>Altoama K.</authname><surname>Altoama</surname><given-name>Kassem</given-name><initials>K.</initials><afid>110240602</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56593253500</author-url><authid>56593253500</authid><authname>Yassine Mallem M.</authname><surname>Yassine Mallem</surname><given-name>Mohamed</given-name><initials>M.</initials><afid>110240602</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:16837530600</author-url><authid>16837530600</authid><authname>Thorin C.</authname><surname>Thorin</surname><given-name>Chantal</given-name><initials>C.</initials><afid>110240602</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56592379800</author-url><authid>56592379800</authid><authname>Betti E.</authname><surname>Betti</surname><given-name>Eric</given-name><initials>E.</initials><afid>110240602</afid><afid>110240602</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56592379800</author-url><authid>56592379800</authid><authname>Betti E.</authname><surname>Betti</surname><given-name>Eric</given-name><initials>E.</initials><afid>110240602</afid><afid>110240602</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:6602339810</author-url><authid>6602339810</authid><authname>Desfontis J.</authname><surname>Desfontis</surname><given-name>Jean Claude</given-name><initials>J.C.</initials><afid>110240602</afid></author><authkeywords>Antihypertensive | Fetal growth | Genital circulation | Mortality | Nebivolol | Pregnancy</authkeywords><intid>35645633</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927931976"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927931976?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927931976&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927931976&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915003192"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927931976</prism:url><dc:identifier>SCOPUS_ID:84927931976</dc:identifier><eid>2-s2.0-84927931976</eid><dc:title>Direct and indirect cardiovascular actions of cathinone and MDMA in the anaesthetized rat</dc:title><dc:creator>Alsufyani H.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>758</prism:volume><prism:pageRange>142-146</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.079</prism:doi><pii>S0014299915003192</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. Abstract The stimulants cathinone (from Khat leaves) and methylenedioxymeth-amphetamine (MDMA) produce adrenoceptor mediated tachycardia and vasopressor actions that may be the result of direct receptor stimulation, actions on the noradrenaline transporter, and/or displacement of noradrenaline from nerve terminals. Effects of cathinone or MDMA were compared with those of the indirect sympathomimetic tyramine. Male Wistar rats were anaesthetized with pentobarbitone for blood pressure and heart rate recording. Some rats were sympathectomised by treatment with 6-hydroxydopamine. In the anaesthetised rat, cathinone, MDMA and tyramine (all 0.001-1 mg /kg) produced marked tachycardia, tyramine produced marked pressor responses and MDMA produced small pressor responses. The tachycardia to cathinone and MDMA was almost abolished by propranolol (1 mg/kg). Pretreatment with cocaine (1 mg/kg) did not significantly affect the tachycardia to cathinone or MDMA, but reduced the response to tyramine. However, in sympathectomised rats, the tachycardia to cathinone or MDMA was markedly attenuated, but the tachycardia to tyramine was only partially reduced. Blood pressure effects of tyramine and MDMA were also markedly attenuated by sympathectomy. The results demonstrate firstly that cocaine may not be the most suitable agent for assessing direct versus indirect agonism in cardiovascular studies. Secondly, the use of chemical sympathectomy achieved the desired goal of demonstrating that cardiac Î²-adrenoceptor mediated actions of cathinone and MDMA are probably largely indirect.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000050</affiliation-url><afid>60000050</afid><affilname>Royal College of Surgeons in Ireland</affilname><name-variant>Royal College of Surgeons</name-variant><affiliation-city>Dublin</affiliation-city><affiliation-country>Ireland</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56596717200</author-url><authid>56596717200</authid><authname>Alsufyani H.</authname><surname>Alsufyani</surname><given-name>Hadeel A.</given-name><initials>H.A.</initials><afid>60000050</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:7102949728</author-url><authid>7102949728</authid><authname>Docherty J.</authname><surname>Docherty</surname><given-name>James R.</given-name><initials>J.R.</initials><afid>60000050</afid></author><authkeywords>Cathinone | Indirect sympathomimetic | MDMA | Noradrenaline transporter | Sympathectomy</authkeywords><intid>35701358</intid><article-number>69883</article-number><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927622896"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927622896?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927622896&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927622896&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915002836"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927622896</prism:url><dc:identifier>SCOPUS_ID:84927622896</dc:identifier><eid>2-s2.0-84927622896</eid><dc:title>Evidence that the MEK/ERK but not the PI3K/Akt pathway is required for protection from myocardial ischemia-reperfusion injury by 3â²,4â²-dihydroxyflavonol</dc:title><dc:creator>Thomas C.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>758</prism:volume><prism:pageRange>53-59</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.054</prism:doi><pii>S0014299915002836</pii><dc:description>Â© 2015 Elsevier B.V. The novel pro-drug of 3â²4â²-dihydroxyflavonol, NP202, potently reduces myocardial infarct size resulting from ischemia-reperfusion (I/R) through mechanisms that remain to be fully defined. In this study, we investigated whether cardioprotection induced by NP202 depended on activation of the reperfusion injury survival kinase (RISK) pathways. We therefore examined the effects of PD98059 and LY294002, specific inhibitors of the MEK/ERK1/2 and PI3K/Akt pathways, respectively. In isolated cardiomyocytes, &lt;sup&gt;H2&lt;/sup&gt;&lt;sup&gt;O2&lt;/sup&gt;induced oxidative stress activated ERK1/2 and this was further enhanced by DiOHF, the active parent compound of NP202. Although oxidative stress did not stimulate Akt in cardiomyocytes, co-treatment with DiOHF substantially increased Akt phosphorylation. This suggests that DiOHF is a potent modulator of RISK pathways specifically in the context of stress stimulation. In anesthetised sheep, following 1 h ischemia and 3 h reperfusion, the contribution of the RISK pathways to NP202-mediated cardioprotection was determined by treating the animals with PD98059, LY294002 or vehicle prior to NP202 administration and reperfusion. Infarct size, as a percentage of the area-at-risk, was substantially reduced by NP202 (from 78Â±6 to 46Â±4%, P&lt;0.05). Inhibition of MEK/ERK1/2 abolished the cardioprotective effects of NP202 (infarct size 81Â±4%), whereas inhibition of PI3K/Akt had no effect (infarct size 53Â±4%). Our combined cellular and animal studies indicate that NP202 potently protects against myocardial I/R injury through complex mechanisms that involved augmentation of MEK/ERK1/2 signaling, but not PI3K/Akt signaling.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:114353065</affiliation-url><afid>114353065</afid><affilname>Florey Institute of Neuroscience and Mental Health</affilname><name-variant>The Florey Institute of Neuroscience and Mental Health</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103600</affiliation-url><afid>60103600</afid><affilname>Bio21 Molecular Science and Biotechnology Institute</affilname><name-variant>University of Melbourne</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011362</affiliation-url><afid>60011362</afid><affilname>Royal Melbourne Institute of Technology University</affilname><name-variant>RMIT University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006925</affiliation-url><afid>60006925</afid><affilname>La Trobe University</affilname><name-variant>La Trobe University</name-variant><affiliation-city>Melbourne</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7404413616</author-url><authid>7404413616</authid><authname>Thomas C.</authname><surname>Thomas</surname><given-name>Colleen J.</given-name><initials>C.J.</initials><afid>114353065</afid><afid>60006925</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7404413616</author-url><authid>7404413616</authid><authname>Thomas C.</authname><surname>Thomas</surname><given-name>Colleen J.</given-name><initials>C.J.</initials><afid>114353065</afid><afid>60006925</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55926459600</author-url><authid>55926459600</authid><authname>Lim N.</authname><surname>Lim</surname><given-name>Nicholas R.</given-name><initials>N.R.</initials><afid>60103600</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56593112400</author-url><authid>56593112400</authid><authname>Kedikaetswe A.</authname><surname>Kedikaetswe</surname><given-name>Alphious</given-name><initials>A.</initials><afid>114353065</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35811618800</author-url><authid>35811618800</authid><authname>Yeap Y.</authname><surname>Yeap</surname><given-name>Yvonne Y.</given-name><initials>Y.Y.</initials><afid>60103600</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7006255475</author-url><authid>7006255475</authid><authname>Woodman O.</authname><surname>Woodman</surname><given-name>Owen L.</given-name><initials>O.L.</initials><afid>60011362</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56591660600</author-url><authid>56591660600</authid><authname>Ng D.</authname><surname>Ng</surname><given-name>Dominic C H</given-name><initials>D.C.H.</initials><afid>60103600</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56591689100</author-url><authid>56591689100</authid><authname>May C.</authname><surname>May</surname><given-name>Clive N.</given-name><initials>C.N.</initials><afid>114353065</afid></author><authkeywords>Akt | ERK1/2 | Flavonol | LY294002 | Myocardial ischemia/reperfusion injury | Oxidative stress | PD98059 | Survival kinases</authkeywords><intid>1035641249</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927761344"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927761344?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927761344&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927761344&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915003179"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927761344</prism:url><dc:identifier>SCOPUS_ID:84927761344</dc:identifier><eid>2-s2.0-84927761344</eid><dc:title>Urocortin2 prolongs action potential duration and modulates potassium currents in guinea pig myocytes and HEK293 cells</dc:title><dc:creator>Yang L.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>758</prism:volume><prism:pageRange>97-106</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.078</prism:doi><pii>S0014299915003179</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. We previously reported that activation of corticotropin releasing factor receptor type 2 by urocortin2 up-regulates both L-type Ca&lt;sup&gt;2+&lt;/sup&gt; channels and intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; concentration in ventricular myocytes and plays an important role in cardiac contractility and arrhythmogenesis. This study goal was to further test the hypothesis that urocortin2 may modulate action potentials as well as rapidly and slowly activating delayed rectifier potassium currents. With whole cell patch-clamp techniques, action potentials and slowly activating delayed rectifier potassium currents were recorded in isolated guinea pig ventricular myocytes, respectively. And rapidly activating delayed rectifier potassium currents were tested in hERG-HEK293 cells. Urocortin2 produced a time- and concentration-dependent prolongation of action potential duration. The EC50 values of action potential duration and action potential duration at 90% of repolarization were 14.73 and 24.3 nM respectively. The prolongation of action potential duration of urocortin2 was almost completely or partly abolished by H-89 (protein kinase A inhibitor) or KB-R7943 (Na&lt;sup&gt;+&lt;/sup&gt;/Ca&lt;sup&gt;2+&lt;/sup&gt; exchange inhibitor) pretreatment respectively. And urocortin2 caused reduction of rapidly activating delayed rectifier potassium currents in hERG-HEK293 cells. In addition, urocortin2 slowed the rate of slowly activating delayed rectifier potassium channel activation, and rightward shifted the threshold of slowly activating delayed rectifier potassium currents to more positive potentials. Urocortin2 prolonged action potential duration via activation of protein kinase A and Na&lt;sup&gt;+&lt;/sup&gt;/ Ca&lt;sup&gt;2+&lt;/sup&gt; exchange in isolated guinea pig ventricular myocytes in a time- and concentration- dependent manner. In hERG-HEK293 cells, urocortin2 reduced rapidly activating delayed rectifier potassium current density which may contribute to action potential duration prolongation.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025084</affiliation-url><afid>60025084</afid><affilname>Shanghai Jiaotong University</affilname><name-variant>Shanghai Jiaotong University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009860</affiliation-url><afid>60009860</afid><affilname>Fudan University</affilname><name-variant>Fudan University</name-variant><affiliation-city>Shanghai</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">2</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55649314800</author-url><authid>55649314800</authid><authname>Yang L.</authname><surname>Yang</surname><given-name>Li Zhen</given-name><initials>L.Z.</initials><afid>60025084</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56593797900</author-url><authid>56593797900</authid><authname>Zhu Y.</authname><surname>Zhu</surname><given-name>Yi Chun</given-name><initials>Y.C.</initials><afid>60009860</afid></author><authkeywords>Action potential duration | hERG-HEK293 cells | Myocytes | Potassium currents | Urocortin2</authkeywords><intid>2035662322</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928112075"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928112075?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928112075&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928112075&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0303720715001719"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928112075</prism:url><dc:identifier>SCOPUS_ID:84928112075</dc:identifier><eid>2-s2.0-84928112075</eid><dc:title>C-Src/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction</dc:title><dc:creator>Chien P.</dc:creator><prism:publicationName>Molecular and Cellular Endocrinology</prism:publicationName><prism:issn>03037207</prism:issn><prism:eIssn>18728057</prism:eIssn><prism:volume>409</prism:volume><prism:pageRange>59-72</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.mce.2015.04.005</prism:doi><pii>S0303720715001719</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. Thrombin and COX-2 regulating cardiac hypertrophy are via various signaling cascades. Several transcriptional factors including CREB involve in COX-2 expression. However, the interplay among thrombin, CREB, and COX-2 in primary human neonatal ventricular cardiomyocytes remains unclear. In this study, thrombin-induced COX-2 promoter activity, mRNA and protein expression, and PGE&lt;inf&gt;2&lt;/inf&gt; synthesis were attenuated by pretreatment with the inhibitors of c-Src (PP1), Pyk2 (PF431396), EGFR (AG1478), PI3K/Akt (LY294002/SH-5), and p300 (GR343), or transfection with siRNAs of c-Src, Pyk2, EGFR, p110, Akt, CREB, and p300. Moreover, thrombin-stimulated phosphorylation of c-Src, Pyk2, EGFR, Akt, CREB and p300 was attenuated by their respective inhibitors. These results indicate that thrombin-induced COX-2 expression is mediated through PAR-1/c-Src/Pyk2/EGFR/PI3K/Akt linking to CREB and p300 cascades. Functionally, thrombin-induced hypertrophy and ANF/BNP release were, at least in part, mediated through a PAR-1/COX-2-dependent pathway. We uncover the importance of COX-2 regarding human cardiomyocyte hypertrophy that will provide a therapeutic intervention in cardiovascular diseases.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020351</affiliation-url><afid>60020351</afid><affilname>Chang Gung University</affilname><name-variant>Chang Gung University</name-variant><affiliation-city>Taoyuan</affiliation-city><affiliation-country>Taiwan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56592053700</author-url><authid>56592053700</authid><authname>Chien P.</authname><surname>Chien</surname><given-name>Peter Tzu Yu</given-name><initials>P.T.Y.</initials><afid>60020351</afid><afid>60020351</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56592053700</author-url><authid>56592053700</authid><authname>Chien P.</authname><surname>Chien</surname><given-name>Peter Tzu Yu</given-name><initials>P.T.Y.</initials><afid>60020351</afid><afid>60020351</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56153174200</author-url><authid>56153174200</authid><authname>Lin C.</authname><surname>Lin</surname><given-name>Chih Chung</given-name><initials>C.C.</initials><afid>60020351</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56480180200</author-url><authid>56480180200</authid><authname>Hsiao L.</authname><surname>Hsiao</surname><given-name>Li Der</given-name><initials>L.D.</initials><afid>60020351</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7407030244</author-url><authid>7407030244</authid><authname>Yang C.</authname><surname>Yang</surname><given-name>Chuen Mao</given-name><initials>C.M.</initials><afid>60020351</afid><afid>60020351</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7407030244</author-url><authid>7407030244</authid><authname>Yang C.</authname><surname>Yang</surname><given-name>Chuen Mao</given-name><initials>C.M.</initials><afid>60020351</afid><afid>60020351</afid></author><authkeywords>Cardiac hypertrophy | COX-2 | CREB | Primary human ventricular cardiomyocyte | Thrombin</authkeywords><intid>535733291</intid><source-id>26206</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928886388"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928886388?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928886388&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928886388&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279715001921"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928886388</prism:url><dc:identifier>SCOPUS_ID:84928886388</dc:identifier><eid>2-s2.0-84928886388</eid><dc:title>Trimetazidine protects cardiomyocytes against hypoxia-induced injury through ameliorates calcium homeostasis</dc:title><dc:creator>Wei J.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>236</prism:volume><prism:pageRange>47-56</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2015.04.022</prism:doi><pii>S0009279715001921</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. Intracellular calcium (Ca&lt;sup&gt;2+&lt;/sup&gt;&lt;inf&gt;i&lt;/inf&gt;) overload induced by chronic hypoxia alters Ca&lt;sup&gt;2+&lt;/sup&gt;&lt;inf&gt;i&lt;/inf&gt; homeostasis, which plays an important role on mediating myocardial injury. We tested the hypothesis that treatment with trimetazidine (TMZ) would improve Ca&lt;sup&gt;2+&lt;/sup&gt;&lt;inf&gt;i&lt;/inf&gt; handling in hypoxic myocardial injury. Cardiomyocytes isolated from neonatal Sprague-Dawley rats were exposed to chronic hypoxia (1% O&lt;inf&gt;2&lt;/inf&gt;, 5% CO&lt;inf&gt;2&lt;/inf&gt;, 37 Â°C). Intracellular calcium concentration ([Ca&lt;sup&gt;2+&lt;/sup&gt;]&lt;inf&gt;i&lt;/inf&gt;) was measured with Fura-2/AM. Perfusion of cardiomyocytes with a high concentration of caffeine (10 mM) was carried out to verify the function of the cardiac Na&lt;sup&gt;+&lt;/sup&gt;/Ca&lt;sup&gt;2+&lt;/sup&gt; exchanger (NCX) and the activity of sarco(endo)-plasmic reticulum Ca&lt;sup&gt;2+&lt;/sup&gt;-ATPase (SERCA2a). For TMZ-treated cardiomyocytes exposured in hypoxia, we observed a decrease in mRNA expression of proapoptotic Bax, caspase-3 activation and enhanced expression of anti-apoptotic Bcl-2. The cardiomyocyte hypertrophy were also alleviated in hypoxic cardiomyocyte treated with TMZ. Moreover, we found that TMZ treatment cardiomyocytes enhanced "metabolic shift" from lipid oxidation to glucose oxidation. Compared with hypoxic cardiomyocyte, the diastolic [Ca&lt;sup&gt;2+&lt;/sup&gt;]&lt;inf&gt;i&lt;/inf&gt; was decreased, the amplitude of Ca&lt;sup&gt;2+&lt;/sup&gt;&lt;inf&gt;i&lt;/inf&gt; oscillations and sarcoplasmic reticulum Ca&lt;sup&gt;2+&lt;/sup&gt; load were recovered, the activities of ryanodine receptor 2 (RyR2), NCX and SERCA2a were increased in cardiomyocytes treated with TMZ. TMZ attenuated abnormal changes of RyR2 and SERCA2a genes in hypoxic cardiomyocytes. In addition, cholinergic signaling are involved in hypoxic stress and the cardioprotective effects of TMZ. These results suggest that TMZ ameliorates Ca&lt;sup&gt;2+&lt;/sup&gt;&lt;inf&gt;i&lt;/inf&gt; homeostasis through switch of lipid to glucose metabolism, thereby producing the cardioprotective effect and reduction in hypoxic cardiomyocytes damage.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60018308</affiliation-url><afid>60018308</afid><affilname>Xi'an Jiaotong University</affilname><name-variant>Xi'an Jiaotong University</name-variant><affiliation-city>Xi'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55286555600</author-url><authid>55286555600</authid><authname>Wei J.</authname><surname>Wei</surname><given-name>Jinhong</given-name><initials>J.</initials><afid>60018308</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56327986100</author-url><authid>56327986100</authid><authname>Xu H.</authname><surname>Xu</surname><given-name>Hao</given-name><initials>H.</initials><afid>60018308</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56520703700</author-url><authid>56520703700</authid><authname>Shi L.</authname><surname>Shi</surname><given-name>Liang</given-name><initials>L.</initials><afid>60018308</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56411524000</author-url><authid>56411524000</authid><authname>Tong J.</authname><surname>Tong</surname><given-name>Jie</given-name><initials>J.</initials><afid>60018308</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:21935590500</author-url><authid>21935590500</authid><authname>Zhang J.</authname><surname>Zhang</surname><given-name>Jianbao</given-name><initials>J.</initials><afid>60018308</afid></author><authkeywords>Cardioprotection | Hypoxia | NCX | RyR2 | SERCA2a | Trimetazidine</authkeywords><intid>535862483</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928674163"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928674163?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928674163&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928674163&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0031018215002175"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928674163</prism:url><dc:identifier>SCOPUS_ID:84928674163</dc:identifier><eid>2-s2.0-84928674163</eid><dc:title>Compound-specific carbon isotope records of vegetation and hydrologic change in central Sulawesi, Indonesia, since 53,000 yr BP</dc:title><dc:creator>Wicaksono S.</dc:creator><prism:publicationName>Palaeogeography, Palaeoclimatology, Palaeoecology</prism:publicationName><prism:issn>00310182</prism:issn><prism:volume>430</prism:volume><prism:pageRange>47-56</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.palaeo.2015.04.016</prism:doi><pii>S0031018215002175</pii><dc:description>Â© 2015 Elsevier B.V. Lake Matano (2Â°29.1'S 121Â°20'E) in central Sulawesi, the deepest and one of the largest lakes in Indonesia, provides an excellent opportunity to reconstruct long-term hydrological and vegetation changes at the heart of the Maritime Continent within the tropical Western Pacific Warm Pool. We measured the carbon isotopic composition of terrestrial leaf waxes (Î´&lt;sup&gt;13&lt;/sup&gt;C&lt;inf&gt;wax&lt;/inf&gt;) in new sediment cores from Lake Matano to understand regional variations in vegetation and their interactions with local and high latitude climate forcings during the past 53 kyr. Variations in Î´&lt;sup&gt;13&lt;/sup&gt;C&lt;inf&gt;wax&lt;/inf&gt; record the expansion and contraction of C&lt;inf&gt;3&lt;/inf&gt; versus C&lt;inf&gt;4&lt;/inf&gt; vegetation as well as changes in plants' carbon and water use efficiency and, by inference, regional hydroclimate. During Marine Isotope Stages 1 and 3, more negative Î´&lt;sup&gt;13&lt;/sup&gt;C&lt;inf&gt;wax&lt;/inf&gt; values indicate that closed-canopy C&lt;inf&gt;3&lt;/inf&gt; rainforests predominated in Sulawesi, reflecting a wetter, less seasonal climate. In contrast, more positive Î´&lt;sup&gt;13&lt;/sup&gt;C&lt;inf&gt;wax&lt;/inf&gt; values record a terrestrial ecosystem with more abundant open canopy vegetation and possible expansion of C&lt;inf&gt;4&lt;/inf&gt; grasses between 29 and 14 ka BP, indicating that during Marine Isotope Stage 2, including the Last Glacial Maximum, the climate was more arid, likely with increased precipitation seasonality, in central Sulawesi. Comparison of our record with other paleovegetation and paleohydrological records from Sulawesi and nearby islands suggests coherent long-term hydrological changes in central Indonesia that appear to be sensitive to high latitude climate across glacial-interglacial boundaries. However, variations in the amplitude of the response of vegetation to these glacial-interglacial forcings highlight the importance of regional topographic control on climate and vegetation and suggest an important role for higher elevations in maintaining rainforest refugia during regionally arid time intervals when C&lt;inf&gt;4&lt;/inf&gt; savannas and grasslands expanded at lower elevations.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60011460</affiliation-url><afid>60011460</afid><affilname>Brown University</affilname><name-variant>Brown University</name-variant><affiliation-city>Providence</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60069382</affiliation-url><afid>60069382</afid><affilname>Institut Teknologi Bandung</affilname><name-variant>Institut Teknologi Bandung</name-variant><affiliation-city>Bandung</affiliation-city><affiliation-country>Indonesia</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">3</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56607050100</author-url><authid>56607050100</authid><authname>Wicaksono S.</authname><surname>Wicaksono</surname><given-name>Satrio A.</given-name><initials>S.A.</initials><afid>60011460</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55947319900</author-url><authid>55947319900</authid><authname>Russell J.</authname><surname>Russell</surname><given-name>James M.</given-name><initials>J.M.</initials><afid>60011460</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:6506055679</author-url><authid>6506055679</authid><authname>Bijaksana S.</authname><surname>Bijaksana</surname><given-name>Satria</given-name><initials>S.</initials><afid>60069382</afid></author><authkeywords>Biomarker | Carbon | Maritime Continent | Monsoon | Orbital-scale | Precipitation | Sulawesi | Vegetation</authkeywords><intid>1535824328</intid><source-id>13985</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928013702"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928013702?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928013702&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928013702&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S016643281500248X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928013702</prism:url><dc:identifier>SCOPUS_ID:84928013702</dc:identifier><eid>2-s2.0-84928013702</eid><dc:title>Hemispheric specialization in affective responses, cerebral dominance for language, and handedness Lateralization of emotion, language, and dexterity</dc:title><dc:creator>Costanzo E.</dc:creator><prism:publicationName>Behavioural Brain Research</prism:publicationName><prism:issn>01664328</prism:issn><prism:eIssn>18727549</prism:eIssn><prism:volume>288</prism:volume><prism:pageRange>11-19</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbr.2015.04.006</prism:doi><pii>S016643281500248X</pii><dc:description>Â© 2015 Elsevier B.V. Hemispheric specialization in affective responses has received little attention in the literature. This is a fundamental variable to understand circuit dynamics of networks subserving emotion. In this study we put to test a modified "valence" hypothesis of emotion processing, considering that sadness and happiness are processed by each hemisphere in relation to dominance for language and handedness. Mood induction and language activation during functional magnetic resonance imaging (fMRI) were used in 20 right-handed and 20 nonright-handed subjects, focusing on interconnected regions known to play critical roles in affective responses: subgenual cingulate cortex, amygdala, and anterior insular cortex. We observed a consistent relationship between lateralization of affective processing, motor dexterity, and language in individuals with clear right-handedness. Sadness induces a greater activation of right-hemisphere cortical structures in right-handed, left-dominant individuals, which is not evident in nonright-handed subjects who show no consistent hemispheric dominance for language. In anterior insula, right-handed individuals displayed reciprocal activation of either hemisphere depending upon mood valence, whereas amygdala activation was predominantly left-sided regardless of mood valence. Nonright-handed individuals exhibited less consistent brain lateralization of affective processing regardless of language and motor dexterity lateralization. In contrast with traditional views on emotion processing lateralization, hemispheric specialization in affective responses is not a unitary process but is specific to the brain structure being activated.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024120</affiliation-url><afid>60024120</afid><affilname>Fundacion Para La Lucha Contra Las Enfermedades Neurologicas de La Infancia</affilname><name-variant>FLENI</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60019907</affiliation-url><afid>60019907</afid><affilname>Universidad de Buenos Aires, Facultad de Medicina</affilname><name-variant>Facultad de Medicina</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:113886502</affiliation-url><afid>113886502</afid><affilname>Argentine National Council of Scientific and Technological Research (CONICET</affilname><name-variant>Argentine National Council of Scientific and Technological Research (CONICET</name-variant><affiliation-city/><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001563</affiliation-url><afid>60001563</afid><affilname>Universidad de Buenos Aires</affilname><name-variant>University of Buenos Aires</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60009065</affiliation-url><afid>60009065</afid><affilname>Hospital de Clinicas Jose de San Martin</affilname><name-variant>Universidad de Buenos Aires</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029251</affiliation-url><afid>60029251</afid><affilname>University of Miami</affilname><name-variant>University of Miami</name-variant><affiliation-city>Coral Gables</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60001563</affiliation-url><afid>60001563</afid><affilname>Universidad de Buenos Aires</affilname><name-variant>University of Buenos Aires</name-variant><affiliation-city>Buenos Aires</affiliation-city><affiliation-country>Argentina</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">31</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26021109400</author-url><authid>26021109400</authid><authname>Costanzo E.</authname><surname>Costanzo</surname><given-name>Elsa Yolanda</given-name><initials>E.Y.</initials><afid>60024120</afid><afid>60019907</afid><afid>60001563</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26021109400</author-url><authid>26021109400</authid><authname>Costanzo E.</authname><surname>Costanzo</surname><given-name>Elsa Yolanda</given-name><initials>E.Y.</initials><afid>60024120</afid><afid>60019907</afid><afid>60001563</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:26021109400</author-url><authid>26021109400</authid><authname>Costanzo E.</authname><surname>Costanzo</surname><given-name>Elsa Yolanda</given-name><initials>E.Y.</initials><afid>60024120</afid><afid>60019907</afid><afid>60001563</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24073967900</author-url><authid>24073967900</authid><authname>Villarreal M.</authname><surname>Villarreal</surname><given-name>Mirta</given-name><initials>M.</initials><afid>60024120</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24073967900</author-url><authid>24073967900</authid><authname>Villarreal M.</authname><surname>Villarreal</surname><given-name>Mirta</given-name><initials>M.</initials><afid>60024120</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:24073967900</author-url><authid>24073967900</authid><authname>Villarreal M.</authname><surname>Villarreal</surname><given-name>Mirta</given-name><initials>M.</initials><afid>60024120</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36472968400</author-url><authid>36472968400</authid><authname>Drucaroff L.</authname><surname>Drucaroff</surname><given-name>Lucas Javier</given-name><initials>L.J.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36472968400</author-url><authid>36472968400</authid><authname>Drucaroff L.</authname><surname>Drucaroff</surname><given-name>Lucas Javier</given-name><initials>L.J.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36472968400</author-url><authid>36472968400</authid><authname>Drucaroff L.</authname><surname>Drucaroff</surname><given-name>Lucas Javier</given-name><initials>L.J.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56597987200</author-url><authid>56597987200</authid><authname>Ortiz-VillafaÃ±e M.</authname><surname>Ortiz-VillafaÃ±e</surname><given-name>Manuel</given-name><initials>M.</initials><afid>60024120</afid><afid>60019907</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56597987200</author-url><authid>56597987200</authid><authname>Ortiz-VillafaÃ±e M.</authname><surname>Ortiz-VillafaÃ±e</surname><given-name>Manuel</given-name><initials>M.</initials><afid>60024120</afid><afid>60019907</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22233746200</author-url><authid>22233746200</authid><authname>Castro M.</authname><surname>Castro</surname><given-name>Mariana Nair</given-name><initials>M.N.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22233746200</author-url><authid>22233746200</authid><authname>Castro M.</authname><surname>Castro</surname><given-name>Mariana Nair</given-name><initials>M.N.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22233746200</author-url><authid>22233746200</authid><authname>Castro M.</authname><surname>Castro</surname><given-name>Mariana Nair</given-name><initials>M.N.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:22233746200</author-url><authid>22233746200</authid><authname>Castro M.</authname><surname>Castro</surname><given-name>Mariana Nair</given-name><initials>M.N.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55578858600</author-url><authid>55578858600</authid><authname>Goldschmidt M.</authname><surname>Goldschmidt</surname><given-name>Micaela</given-name><initials>M.</initials><afid>60024120</afid><afid>60019907</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55578858600</author-url><authid>55578858600</authid><authname>Goldschmidt M.</authname><surname>Goldschmidt</surname><given-name>Micaela</given-name><initials>M.</initials><afid>60024120</afid><afid>60019907</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56598020700</author-url><authid>56598020700</authid><authname>Wainsztein A.</authname><surname>Wainsztein</surname><given-name>Agustina Edith</given-name><initials>A.E.</initials><afid>60024120</afid><afid>60019907</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56598020700</author-url><authid>56598020700</authid><authname>Wainsztein A.</authname><surname>Wainsztein</surname><given-name>Agustina Edith</given-name><initials>A.E.</initials><afid>60024120</afid><afid>60019907</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603339061</author-url><authid>6603339061</authid><authname>LadrÃ³n-de-Guevara M.</authname><surname>LadrÃ³n-de-Guevara</surname><given-name>MarÃ­a Soledad</given-name><initials>M.S.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603339061</author-url><authid>6603339061</authid><authname>LadrÃ³n-de-Guevara M.</authname><surname>LadrÃ³n-de-Guevara</surname><given-name>MarÃ­a Soledad</given-name><initials>M.S.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:6603339061</author-url><authid>6603339061</authid><authname>LadrÃ³n-de-Guevara M.</authname><surname>LadrÃ³n-de-Guevara</surname><given-name>MarÃ­a Soledad</given-name><initials>M.S.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:56597531500</author-url><authid>56597531500</authid><authname>Romero C.</authname><surname>Romero</surname><given-name>Carlos</given-name><initials>C.</initials><afid>60024120</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56631510700</author-url><authid>56631510700</authid><authname>Brusco L.</authname><surname>Brusco</surname><given-name>Luis Ignacio</given-name><initials>L.I.</initials><afid>113886502</afid><afid>60009065</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:56631510700</author-url><authid>56631510700</authid><authname>Brusco L.</authname><surname>Brusco</surname><given-name>Luis Ignacio</given-name><initials>L.I.</initials><afid>113886502</afid><afid>60009065</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:8408084100</author-url><authid>8408084100</authid><authname>Camprodon J.</authname><surname>Camprodon</surname><given-name>Joan A.</given-name><initials>J.A.</initials><afid>60029929</afid></author><author seq="12"><author-url>http://api.elsevier.com/content/author/author_id:35355232200</author-url><authid>35355232200</authid><authname>Nemeroff C.</authname><surname>Nemeroff</surname><given-name>Charles</given-name><initials>C.</initials><afid>60029251</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6602305643</author-url><authid>6602305643</authid><authname>Guinjoan S.</authname><surname>Guinjoan</surname><given-name>Salvador MartÃ­n</given-name><initials>S.M.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6602305643</author-url><authid>6602305643</authid><authname>Guinjoan S.</authname><surname>Guinjoan</surname><given-name>Salvador MartÃ­n</given-name><initials>S.M.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6602305643</author-url><authid>6602305643</authid><authname>Guinjoan S.</authname><surname>Guinjoan</surname><given-name>Salvador MartÃ­n</given-name><initials>S.M.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><author seq="13"><author-url>http://api.elsevier.com/content/author/author_id:6602305643</author-url><authid>6602305643</authid><authname>Guinjoan S.</authname><surname>Guinjoan</surname><given-name>Salvador MartÃ­n</given-name><initials>S.M.</initials><afid>60024120</afid><afid>60019907</afid><afid>113886502</afid><afid>60001563</afid></author><authkeywords>Amygdala | Anterior insula | Emotion | FMRI | Lateralization | Subgenual cingulate</authkeywords><intid>35716097</intid><source-id>14285</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930089383"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930089383?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930089383&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930089383&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0303720715001124"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930089383</prism:url><dc:identifier>SCOPUS_ID:84930089383</dc:identifier><eid>2-s2.0-84930089383</eid><dc:title>Caloric restriction and the adipokine leptin alter the SDF-1 signaling axis in bone marrow and in bone marrow derived mesenchymal stem cells</dc:title><dc:creator>Periyasamy-Thandavan S.</dc:creator><prism:publicationName>Molecular and Cellular Endocrinology</prism:publicationName><prism:issn>03037207</prism:issn><prism:eIssn>18728057</prism:eIssn><prism:volume>410</prism:volume><prism:pageRange>64-72</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.mce.2015.03.001</prism:doi><pii>S0303720715001124</pii><dc:description>Â© 2015. Growing evidence suggests that the chemokine stromal cell-derived factor-1 (SDF-1) is essential in regulating bone marrow (BM) derived mesenchymal stromal/stem cell (BMSC) survival, and differentiation to either a pro-osteogenic or pro-adipogenic fate. This study investigates the effects of caloric restriction (CR) and leptin on the SDF-1/CXCR4 axis in bone and BM tissues in the context of age-associated bone loss. For in vivo studies, we collected bone, BM cells and BM interstitial fluid from 12 and 20 month-old C57Bl6 mice fed ad-libitum (AL), and 20-month-old mice on long-term CR with, or without, intraperitoneal injection of leptin for 10 days (10 mg/kg). To mimic conditions of CR in vitro, 18 month murine BMSCs were treated with (1) control (Ctrl): normal proliferation medium, (2) nutrient restriction (NR): low glucose, low serum medium, or (3) NR + leptin: NR medium + 100 ng/ml leptin for 6-48 h. In BMSCs both protein and mRNA expression of SDF-1 and CXCR4 were increased by CR and CR + leptin. In contrast, the alternate SDF-1 receptor CXCR7 was decreased, suggesting a nutrient signaling mediated change in SDF-1 axis signaling in BMSCs. However, in bone SDF-1, CXCR4 and 7 gene expression increase with age and this is reversed with CR, while addition of leptin returns this to the "aged" level. Histologically bone formation was lower in the calorically restricted mice and BM adipogenesis increased, both effects were reversed with the 10 day leptin treatment. This suggests that in bone CR and leptin alter the nutrient signaling pathways in different ways to affect the local action of the osteogenic cytokine SDF-1. Studies focusing on the molecular interaction between nutrient signaling by CR, leptin and SDF-1 axis may help to address age-related musculoskeletal changes.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115115607</affiliation-url><afid>115115607</afid><affilname>Georgia Regents University</affilname><name-variant>Georgia Regents University</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000305</affiliation-url><afid>60000305</afid><affilname>Case Western Reserve University</affilname><name-variant>Case Western Reserve University</name-variant><affiliation-city>Cleveland</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115115607</affiliation-url><afid>115115607</afid><affilname>Georgia Regents University</affilname><name-variant>Georgia Regents University</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115115607</affiliation-url><afid>115115607</afid><affilname>Georgia Regents University</affilname><name-variant>Georgia Regents University</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115115607</affiliation-url><afid>115115607</afid><affilname>Georgia Regents University</affilname><name-variant>Georgia Regents University</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115115607</affiliation-url><afid>115115607</afid><affilname>Georgia Regents University</affilname><name-variant>Georgia Regents University</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60014232</affiliation-url><afid>60014232</afid><affilname>VA Medical Center</affilname><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">19</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:10539215500</author-url><authid>10539215500</authid><authname>Periyasamy-Thandavan S.</authname><surname>Periyasamy-Thandavan</surname><given-name>Sudharsan</given-name><initials>S.</initials><afid>115115607</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:25421890300</author-url><authid>25421890300</authid><authname>Herberg S.</authname><surname>Herberg</surname><given-name>Samuel</given-name><initials>S.</initials><afid>60000305</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:25626099400</author-url><authid>25626099400</authid><authname>Arounleut P.</authname><surname>Arounleut</surname><given-name>Phonepasong</given-name><initials>P.</initials><afid>115115607</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:8711176600</author-url><authid>8711176600</authid><authname>Upadhyay S.</authname><surname>Upadhyay</surname><given-name>Sunil</given-name><initials>S.</initials><afid>115115607</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56572517800</author-url><authid>56572517800</authid><authname>Dukes A.</authname><surname>Dukes</surname><given-name>Amy</given-name><initials>A.</initials><afid>115115607</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56571862300</author-url><authid>56571862300</authid><authname>Davis C.</authname><surname>Davis</surname><given-name>Colleen</given-name><initials>C.</initials><afid>115115607</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:8866401000</author-url><authid>8866401000</authid><authname>Johnson M.</authname><surname>Johnson</surname><given-name>Maribeth</given-name><initials>M.</initials><afid>115115607</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:25926533100</author-url><authid>25926533100</authid><authname>McGee-Lawrence M.</authname><surname>McGee-Lawrence</surname><given-name>Meghan</given-name><initials>M.</initials><afid>115115607</afid><afid>115115607</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:25926533100</author-url><authid>25926533100</authid><authname>McGee-Lawrence M.</authname><surname>McGee-Lawrence</surname><given-name>Meghan</given-name><initials>M.</initials><afid>115115607</afid><afid>115115607</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006335397</author-url><authid>7006335397</authid><authname>Hamrick M.</authname><surname>Hamrick</surname><given-name>Mark W.</given-name><initials>M.W.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006335397</author-url><authid>7006335397</authid><authname>Hamrick M.</authname><surname>Hamrick</surname><given-name>Mark W.</given-name><initials>M.W.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid></author><author seq="9"><author-url>http://api.elsevier.com/content/author/author_id:7006335397</author-url><authid>7006335397</authid><authname>Hamrick M.</authname><surname>Hamrick</surname><given-name>Mark W.</given-name><initials>M.W.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005768389</author-url><authid>7005768389</authid><authname>Isales C.</authname><surname>Isales</surname><given-name>Carlos M.</given-name><initials>C.M.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005768389</author-url><authid>7005768389</authid><authname>Isales C.</authname><surname>Isales</surname><given-name>Carlos M.</given-name><initials>C.M.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid></author><author seq="10"><author-url>http://api.elsevier.com/content/author/author_id:7005768389</author-url><authid>7005768389</authid><authname>Isales C.</authname><surname>Isales</surname><given-name>Carlos M.</given-name><initials>C.M.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7202970264</author-url><authid>7202970264</authid><authname>Hill W.</authname><surname>Hill</surname><given-name>William D.</given-name><initials>W.D.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid><afid>60014232</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7202970264</author-url><authid>7202970264</authid><authname>Hill W.</authname><surname>Hill</surname><given-name>William D.</given-name><initials>W.D.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid><afid>60014232</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7202970264</author-url><authid>7202970264</authid><authname>Hill W.</authname><surname>Hill</surname><given-name>William D.</given-name><initials>W.D.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid><afid>60014232</afid></author><author seq="11"><author-url>http://api.elsevier.com/content/author/author_id:7202970264</author-url><authid>7202970264</authid><authname>Hill W.</authname><surname>Hill</surname><given-name>William D.</given-name><initials>W.D.</initials><afid>115115607</afid><afid>115115607</afid><afid>115115607</afid><afid>60014232</afid></author><authkeywords>Aging | Bone formation | CXCR4 | CXCR7 | Nutrient signaling | Osteoporosis</authkeywords><intid>536064052</intid><source-id>26206</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84924978856"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84924978856?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84924978856&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84924978856&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315001554"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84924978856</prism:url><dc:identifier>SCOPUS_ID:84924978856</dc:identifier><eid>2-s2.0-84924978856</eid><dc:title>Dual chronoamperometric detection of enzymatic biomarkers using magnetic beads and a low-cost flow cell</dc:title><dc:creator>Moral-Vico J.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>69</prism:volume><prism:pageRange>328-336</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.02.042</prism:doi><pii>S0956566315001554</pii><dc:description>Â© 2015 Elsevier B.V. In this work we report on the production of a low cost microfluidic device for the multiplexed electrochemical detection of magneto bioassays. As a proof of concept, the device has been used to detect myeloperoxidase (MPO), a cardiovascular biomarker. With this purpose, two bioassays have been optimized in parallel onto magnetic beads (MBs) for the simultaneous detection of MPO endogenous peroxidase activity and quantification of total MPO. Since the two bioassays produced signals of different magnitude for each concentration of MPO tested, two detection strategies have been compared, which entailed registering steady state currents (Iss) under substrate flow, and measuring the peak currents (Ip) produced in a stopped flow approach. As it will be shown, appropriate tuning of the detection and flow conditions can provide extremely sensitive detection, but also allow simultaneous detection of assays or parameters that would produce signals of different orders of magnitude when measured by a single detection strategy. In order to demonstrate the feasibility of the detection strategy reported, a dual MPO mass and activity assay has been finally applied to the study of 10 real plasma samples, allowing patient classification according to the risk of suffering a cardiovascular event.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60103765</affiliation-url><afid>60103765</afid><affilname>CSIC - Instituto de Microelectronica de Barcelona (IMB-CNM)</affilname><name-variant>IMB-CNM (CSIC)</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:115064677</affiliation-url><afid>115064677</afid><affilname>Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol. Badalona</affilname><name-variant>Institut d'Investigacio en Ciencies de la Salut Germans Trias i Pujol. Badalona</name-variant><affiliation-city/><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:</affiliation-url><afid/><affilname>MATGAS A. I. E. Campus UAB</affilname><affiliation-city>Bellaterra</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60028462</affiliation-url><afid>60028462</afid><affilname>Hospital Universitari Germans Trias i Pujol</affilname><name-variant>Hospital Germans Trias i Pujol</name-variant><affiliation-city>Badalona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023020</affiliation-url><afid>60023020</afid><affilname>Universidad Autonoma de Barcelona</affilname><name-variant>Universitat Autonoma de Barcelona</name-variant><affiliation-city>Barcelona</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60085101</affiliation-url><afid>60085101</afid><affilname>CIBER Bioingenieria, Biomateriales y Nanomedicina</affilname><name-variant>Biomateriales y Nanomedicina (CIBER-BBN)</name-variant><affiliation-city>Zaragoza</affiliation-city><affiliation-country>Spain</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">11</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55053469800</author-url><authid>55053469800</authid><authname>Moral-Vico J.</authname><surname>Moral-Vico</surname><given-name>Javier</given-name><initials>J.</initials><afid>60103765</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:36460593200</author-url><authid>36460593200</authid><authname>Barallat J.</authname><surname>Barallat</surname><given-name>Jaume</given-name><initials>J.</initials><afid>115064677</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:23392019400</author-url><authid>23392019400</authid><authname>Abad L.</authname><surname>Abad</surname><given-name>Llibertat</given-name><initials>L.</initials><afid>60103765</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:25651981700</author-url><authid>25651981700</authid><authname>OlivÃ©-Monllau R.</authname><surname>OlivÃ©-Monllau</surname><given-name>Rosa</given-name><initials>R.</initials><afid>60103765</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37005737300</author-url><authid>37005737300</authid><authname>MuÃ±oz-Pascual F.</authname><surname>MuÃ±oz-Pascual</surname><given-name>Francesc Xavier</given-name><initials>F.X.</initials><afid>60103765</afid><afid/></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:37005737300</author-url><authid>37005737300</authid><authname>MuÃ±oz-Pascual F.</authname><surname>MuÃ±oz-Pascual</surname><given-name>Francesc Xavier</given-name><initials>F.X.</initials><afid>60103765</afid><afid/></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:6603403672</author-url><authid>6603403672</authid><authname>GalÃ¡n Ortega A.</authname><surname>GalÃ¡n Ortega</surname><given-name>Amparo</given-name><initials>A.</initials><afid>60028462</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56539523900</author-url><authid>56539523900</authid><authname>del Campo F.</authname><surname>del Campo</surname><given-name>F. Javier</given-name><initials>F.J.</initials><afid>60103765</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8846924600</author-url><authid>8846924600</authid><authname>Baldrich E.</authname><surname>Baldrich</surname><given-name>Eva</given-name><initials>E.</initials><afid>60103765</afid><afid>60023020</afid><afid>60085101</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8846924600</author-url><authid>8846924600</authid><authname>Baldrich E.</authname><surname>Baldrich</surname><given-name>Eva</given-name><initials>E.</initials><afid>60103765</afid><afid>60023020</afid><afid>60085101</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:8846924600</author-url><authid>8846924600</authid><authname>Baldrich E.</authname><surname>Baldrich</surname><given-name>Eva</given-name><initials>E.</initials><afid>60103765</afid><afid>60023020</afid><afid>60085101</afid></author><authkeywords>Cardiovascular disease | Electrochemical detection | Enzyme biomarker | Low-Cost flow cell | Magneto-Immunosensor | Myeloperoxidase (MPO)</authkeywords><intid>35230932</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929359674"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929359674?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929359674&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929359674&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0009279715001891"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929359674</prism:url><dc:identifier>SCOPUS_ID:84929359674</dc:identifier><eid>2-s2.0-84929359674</eid><dc:title>The peroxidase activity of ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; cooperates with lipid peroxidation: The participation of hydroperoxide and hydroxyl radicals in the damage to proteins and DNA</dc:title><dc:creator>Miura T.</dc:creator><prism:publicationName>Chemico-Biological Interactions</prism:publicationName><prism:issn>00092797</prism:issn><prism:eIssn>18727786</prism:eIssn><prism:volume>236</prism:volume><prism:pageRange>67-73</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.cbi.2015.04.019</prism:doi><pii>S0009279715001891</pii><dc:description>Â©2015 Published by Elsevier Ireland Ltd. To investigate the mechanisms of cardiotoxicity induced by adriamycin (ADM), the enzymatic activities of ADM-Fe&lt;sup&gt;3+&lt;/sup&gt;, including the peroxidase and lipoxygenase (LOX) activity, and participation of active oxygen species in the damage to biological components were examined. ADM-Fe&lt;sup&gt;3+&lt;/sup&gt;, but not ADM, steadily oxidized tetramethyl-p-phenylenediamine in the presence of peroxides, indicating that ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; acts as a peroxidase. However, the activity of ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; as peroxidase was very low compared with that of heme peroxidase, but was similar to that of LOX, which has a known peroxidase activity. Conversely, the activity of ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; as a LOX was also very low compared with that of LOX itself. However, the lipid hydroperoxides (LOOH) produced by ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; were the substrate for ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; as a peroxidase. These findings indicate that lipid peroxidation cooperates with the peroxidase activity of ADM-Fe&lt;sup&gt;3+&lt;/sup&gt;. Hydroxyl radicals (HO) were generated when ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; was incubated with H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;, but not with LOOH. Alcohol dehydrogenase was inactivated by LOOH. Conversely, DNA was mainly damaged by ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; with H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;. A small amount of DNA remained at the starting point on agarose gels during incubation with ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; with LOOH and ADM-Fe&lt;sup&gt;3+&lt;/sup&gt; with H&lt;inf&gt;2&lt;/inf&gt;O&lt;inf&gt;2&lt;/inf&gt;. It seems that HO and compound I-like species participate in the strand breaks and the aggregation of DNA, respectively.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016997</affiliation-url><afid>60016997</afid><affilname>Hokkaido Pharmaceutical University</affilname><name-variant>Hokkaido College of Pharmacy</name-variant><affiliation-city>Otaru</affiliation-city><affiliation-country>Japan</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:7402844813</author-url><authid>7402844813</authid><authname>Miura T.</authname><surname>Miura</surname><given-name>Toshiaki</given-name><initials>T.</initials><afid>60016997</afid></author><authkeywords>Adriamycin-Fe3+ | Compound I | Hydroxyl radical | Lipid peroxidation | Lipoxygenase | Peroxidase</authkeywords><intid>1535946022</intid><source-id>24652</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84929311973"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84929311973?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84929311973&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84929311973&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0165027015001612"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84929311973</prism:url><dc:identifier>SCOPUS_ID:84929311973</dc:identifier><eid>2-s2.0-84929311973</eid><dc:title>Critical differences between two classical surgical approaches for middle cerebral artery occlusion-induced stroke in mice</dc:title><dc:creator>Smith H.</dc:creator><prism:publicationName>Journal of Neuroscience Methods</prism:publicationName><prism:issn>01650270</prism:issn><prism:eIssn>1872678X</prism:eIssn><prism:volume>249</prism:volume><prism:pageRange>99-105</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jneumeth.2015.04.008</prism:doi><pii>S0165027015001612</pii><dc:description>Â© 2015 Elsevier B.V. Stroke is the third leading cause of death and the leading cause of long-term disability in North America. On average, someone in the US has a stroke every 45. s, and worldwide, stroke claims 15 million lives each year. Therefore, reliable stroke models are vital to the production of effective new therapies for the treatment of this devastating cerebral vascular accident. New method: Middle cerebral artery occlusion (MCAo) is considered to be the most clinically relevant surgical model of ischemic stroke, in which a variety of methods may be employed to block the MCA (the most common being through insertion of a monofilament). In this study, we have compared two different approaches that are currently used arbitrarily in various laboratories worldwide: one involving insertion of a monofilament via the common carotid artery (Koizumi et al.) and one via the external carotid artery (Longa et al.). Results and comparisons with existing methods: We assessed various parameters, including: mortality rates, neurological scores, inflammation levels, cellular trafficking (using intravital microscopy) and infarct volumes in mice after using each of the two approaches. We found that the Longa method produced a greater, and robust, inflammatory response, versus the Koizumi method. Conclusions: In conclusion, we suggest that the Longa method is superior for the study of both short and long-term outcomes of ischemic stroke. These results have considerable implications on stroke model selection for researchers.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029426</affiliation-url><afid>60029426</afid><affilname>LSU Health Sciences Center - New Orleans</affilname><name-variant>Louisiana State University Health Sciences Center</name-variant><affiliation-city>New Orleans</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54920788100</author-url><authid>54920788100</authid><authname>Smith H.</authname><surname>Smith</surname><given-name>Helen K.</given-name><initials>H.K.</initials><afid>60029426</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:35453397100</author-url><authid>35453397100</authid><authname>Russell J.</authname><surname>Russell</surname><given-name>Janice M.</given-name><initials>J.M.</initials><afid>60029426</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:7201565504</author-url><authid>7201565504</authid><authname>Granger D.</authname><surname>Granger</surname><given-name>D. Neil</given-name><initials>D.N.</initials><afid>60029426</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7801414361</author-url><authid>7801414361</authid><authname>Gavins F.</authname><surname>Gavins</surname><given-name>Felicity N E</given-name><initials>F.N.E.</initials><afid>60029426</afid></author><authkeywords>Acute stroke | Animal models | CCA | ECA | ICA | Inflammation | MCA/MCAo | Microcirculation | Physiology</authkeywords><intid>1535945228</intid><source-id>16765</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927546996"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927546996?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927546996&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927546996&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0303720715001641"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927546996</prism:url><dc:identifier>SCOPUS_ID:84927546996</dc:identifier><eid>2-s2.0-84927546996</eid><dc:title>Hemeoxygenase-1 maintains bone mass via attenuating a redox imbalance in osteoclast</dc:title><dc:creator>Ke K.</dc:creator><prism:publicationName>Molecular and Cellular Endocrinology</prism:publicationName><prism:issn>03037207</prism:issn><prism:eIssn>18728057</prism:eIssn><prism:volume>409</prism:volume><prism:pageRange>11-20</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.mce.2015.03.022</prism:doi><pii>S0303720715001641</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. Heme oxygenase-1 (HO-1) has long been considered to be an endogenous antioxidant. However, the role of HO-1 is highly controversial in developing metabolic diseases. We hypothesized that HO-1 plays a role in maintaining bone mass by alleviating a redox imbalance. We investigated its role in bone remodeling. The absence of HO-1 in mice led to decreased bone mass with elevated activity and number of OCs, as well as higher serum levels of reactive oxygen species (ROS). HO-1, which is constitutively expressed at a high level in osteoclast (OC) precursors, was down-regulated during OC differentiation. HO-1 deficiency in bone marrow macrophages (BMM) in vitro resulted in increased numbers and activity of OCs due to enhanced receptor activator of nuclear factor-ÎºB ligand (RANKL) signaling. This was associated with increased activation of nuclear factor-ÎºB and of nuclear factor of activated T-cells, cytoplasmic 1 along with elevated levels of intracellular calcium and ROS. Decreased bone mass in the absence of HO-1 appears to be mainly due to increased osteoclastogenesis and bone resorption resulting from elevated RANKL signaling in OCs. Our data highlight the potential role of HO-1 in maintaining bone mass by negatively regulating OCs.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032624</affiliation-url><afid>60032624</afid><affilname>Ulsan University</affilname><name-variant>University of Ulsan</name-variant><affiliation-city>Ulsan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032624</affiliation-url><afid>60032624</afid><affilname>Ulsan University</affilname><name-variant>University of Ulsan</name-variant><affiliation-city>Ulsan</affiliation-city><affiliation-country>South Korea</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:54389325300</author-url><authid>54389325300</authid><authname>Ke K.</authname><surname>Ke</surname><given-name>Ke</given-name><initials>K.</initials><afid>60032624</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56589975000</author-url><authid>56589975000</authid><authname>Safder M.</authname><surname>Safder</surname><given-name>M. A.</given-name><initials>M.A.</initials><afid>60032624</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:36954578600</author-url><authid>36954578600</authid><authname>Sul O.</authname><surname>Sul</surname><given-name>Ok Joo</given-name><initials>O.J.</initials><afid>60032624</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:23103028600</author-url><authid>23103028600</authid><authname>Kim W.</authname><surname>Kim</surname><given-name>Woon Ki</given-name><initials>W.K.</initials><afid>60032624</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:7201515134</author-url><authid>7201515134</authid><authname>Suh J.</authname><surname>Suh</surname><given-name>Jae Hee</given-name><initials>J.H.</initials><afid>60032624</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55114313900</author-url><authid>55114313900</authid><authname>Joe Y.</authname><surname>Joe</surname><given-name>Yeonsoo</given-name><initials>Y.</initials><afid>60032624</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:56585154300</author-url><authid>56585154300</authid><authname>Chung H.</authname><surname>Chung</surname><given-name>Hun Taeg</given-name><initials>H.T.</initials><afid>60032624</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:24521871300</author-url><authid>24521871300</authid><authname>Choi H.</authname><surname>Choi</surname><given-name>Hye Seon</given-name><initials>H.S.</initials><afid>60032624</afid></author><authkeywords>Heme oxygenase-1 | Osteoclast | Reactive oxygen species | Receptor activator of nuclear factor-ÎºB ligand signaling</authkeywords><intid>1535633727</intid><source-id>26206</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84925337666"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84925337666?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84925337666&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84925337666&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1386142515003327"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84925337666</prism:url><dc:identifier>SCOPUS_ID:84925337666</dc:identifier><eid>2-s2.0-84925337666</eid><dc:title>Energy transfer and luminescence properties of Sr[1-3( x + y )/2]Al2B2O7:xEu3+, yBi3+ phosphor</dc:title><dc:creator>Cao R.</dc:creator><prism:publicationName>Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy</prism:publicationName><prism:issn>13861425</prism:issn><prism:volume>146</prism:volume><prism:pageRange>38-42</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.saa.2015.03.036</prism:doi><pii>S1386142515003327</pii><dc:description>Â© 2015 Elsevier B.V. All rights reserved. PL spectra of Sr0.97Al2B2O7:0.03Eu3+ and Sr0.96Al2B2O7:0.03Eu3+, 0.01Bi3+ phosphors sintered at 1000 C (Î»ex = 394 nm), their CIE chromaticity coordinates, and picture under 254 nm UV lamp. (Graph Presented). Sr[1-3( x + y )/2]Al2B2O7:xEu3+, yBi3+ (x = 0-5 mol% and y = 0-5 mol%) phosphors are synthesized by a solid-state reaction method in air, and their crystal structure, fluorescence lifetime, and luminescence properties are investigated. The optimal composition is determined to be (Sr0.94Eu0.03Bi0.01)Al2B2O7. The PLE band peaks within the range 200-550 nm are due to O2- â Eu3+ charge transfer band, 7F0 â 5H3, 5D4, 5L7, 5L6, 5D3, 5D2, and 5D1 transitions, respectively. The strongest PL band peak under excitation 394 nm light is at â¼615 nm owing to 5D0 â 7F2 transition of Eu3+ ion. The PL intensity of Eu3+, Bi3+ co-doped SrAl2B2O7 phosphor is 1.3 times that of Eu3+ doped SrAl2B2O7 phosphor due to the energy transfer between Eu3+ and Bi3+ ions, which is explained by the energy level diagrams of Bi3+ and Eu3+ ions. The CIE chromaticity coordinates of Sr0.955Al2B2O7:0.03Eu3+ and Sr0.94Al2B2O7:0.03Eu3+, 0.01Bi3+ phosphors under excitation 394 nm light are (x = 0.6292, y = 0.3702) and (x = 0.6284, y = 0.3711), respectively. These phosphors will be used as reddish orange emitting phosphor candidate for white LED with â¼394 nm near ultraviolet LED chip.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073559</affiliation-url><afid>60073559</afid><affilname>Jinggangshan University</affilname><name-variant>Jinggangshan University</name-variant><affiliation-city>Ji'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60073559</affiliation-url><afid>60073559</afid><affilname>Jinggangshan University</affilname><name-variant>Jinggangshan University</name-variant><affiliation-city>Ji'an</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60092863</affiliation-url><afid>60092863</afid><affilname>Xiamen University of Technology</affilname><name-variant>Xiamen University of Technology</name-variant><affiliation-city>Xiamen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">6</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:9245408200</author-url><authid>9245408200</authid><authname>Cao R.</authname><surname>Cao</surname><given-name>Renping</given-name><initials>R.</initials><afid>60073559</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56482721500</author-url><authid>56482721500</authid><authname>Liang T.</authname><surname>Liang</surname><given-name>Tao</given-name><initials>T.</initials><afid>60073559</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56564357800</author-url><authid>56564357800</authid><authname>Li W.</authname><surname>Li</surname><given-name>Wensheng</given-name><initials>W.</initials><afid>60073559</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:12244221100</author-url><authid>12244221100</authid><authname>Cao C.</authname><surname>Cao</surname><given-name>Chunyan</given-name><initials>C.</initials><afid>60092863</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56564609200</author-url><authid>56564609200</authid><authname>Wen Y.</authname><surname>Wen</surname><given-name>Yufeng</given-name><initials>Y.</initials><afid>60073559</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:8724728500</author-url><authid>8724728500</authid><authname>Hu Q.</authname><surname>Hu</surname><given-name>Qianglin</given-name><initials>Q.</initials><afid>60073559</afid></author><authkeywords>Optical materials Energy transfer Phosphor Luminescence</authkeywords><intid>2035274905</intid><source-id>24530</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930085927"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930085927?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930085927&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930085927&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0303720715001471"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930085927</prism:url><dc:identifier>SCOPUS_ID:84930085927</dc:identifier><eid>2-s2.0-84930085927</eid><dc:title>Childhood obesity, bone development, and cardiometabolic risk factors</dc:title><dc:creator>Pollock N.</dc:creator><prism:publicationName>Molecular and Cellular Endocrinology</prism:publicationName><prism:issn>03037207</prism:issn><prism:eIssn>18728057</prism:eIssn><prism:volume>410</prism:volume><prism:pageRange>52-63</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.mce.2015.03.016</prism:doi><pii>S0303720715001471</pii><dc:description>Â© 2015. Osteoporosis and obesity are both major public health concerns. It has long been considered that these are distinct disorders rarely found in the same individual; however, emerging evidence supports an important interaction between adipose tissue and the skeleton. Whereas overweight per se may augment bone strength, animal studies suggest that the metabolic impairment that accompanies obesity is detrimental to bone. Obesity during childhood, a critical time for bone development, likely has profound and lasting effects on bone strength and fracture risk. This notion has received little attention in children and results are mixed, with studies reporting that bone strength development is enhanced or impaired by obesity. Whether obesity is a risk factor for osteoporosis or childhood bone health, in general, remains an important clinical question. Here, we will focus on clarifying the controversial relationships between childhood obesity and bone strength development, and provide insights into potential mechanisms that may regulate the effect of excess adiposity on bone.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60024399</affiliation-url><afid>60024399</afid><affilname>Medical College of Georgia</affilname><name-variant>Medical College of Georgia</name-variant><affiliation-city>Augusta</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">1</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56606350900</author-url><authid>56606350900</authid><authname>Pollock N.</authname><surname>Pollock</surname><given-name>Norman K.</given-name><initials>N.K.</initials><afid>60024399</afid></author><authkeywords>Bone | Children | Fat | Inflammation | Insulin resistance | Obesity</authkeywords><intid>1786064140</intid><source-id>26206</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928683498"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928683498?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928683498&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928683498&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S016502701500151X"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928683498</prism:url><dc:identifier>SCOPUS_ID:84928683498</dc:identifier><eid>2-s2.0-84928683498</eid><dc:title>An improved technique for cerebrospinal fluid collection of cisterna magna in Rhesus monkeys</dc:title><dc:creator>Li X.</dc:creator><prism:publicationName>Journal of Neuroscience Methods</prism:publicationName><prism:issn>01650270</prism:issn><prism:eIssn>1872678X</prism:eIssn><prism:volume>249</prism:volume><prism:pageRange>59-65</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.jneumeth.2015.04.004</prism:doi><pii>S016502701500151X</pii><dc:description>Â© 2015 Elsevier B.V. Background: Currently-used cerebellomedullary cistern puncture method for collecting cerebrospinal fluid (CSF) from monkeys is simple, inexpensive, and practical, but with high risk for brainstem injury and CSF blood contamination. An improved technique was thus developed and characterized. Method: Magnetic resonance imaging was used to identify the space and position of the cisterna magna in monkeys. Accordingly, a newly defined procedure for needle punctuation was tested in comparison with the traditional method. Blood contamination in CSF samples and brainstem injury were determined to define the superior of the improved method over the transitional method. Results: The cisterna magna in monkeys was found to be a "â¿" shape. The needle was punctured into the cisterna magna aiming at the wider superior gap avoided brainstem injury. The improved method showed that the rate of blood contamination in the CSF samples was reduced from 66.7% to 16.7%, the higher rate of blood contamination was associated with higher risk for brainstem injury.Comparison with existing methods: In traditional method, the needle is punctured aiming at the inferior gap with high density of blood vessels. In improved method, the needle is punctured aiming at the superior gap, pointing to the nose root while advancing the needle and avoiding injury to blood vessels. Conclusions: This improved technique not only avoids blood contamination of CSF, but also prevents brainstem injury during the process of CSF collection. It is recommended for adaptation for CSF collection in monkeys.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60016521</affiliation-url><afid>60016521</afid><affilname>Sichuan University</affilname><name-variant>Sichuan University</name-variant><affiliation-city>Chengdu</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60020633</affiliation-url><afid>60020633</afid><affilname>University of Louisville</affilname><name-variant>University of Louisville</name-variant><affiliation-city>Louisville</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56609756200</author-url><authid>56609756200</authid><authname>Li X.</authname><surname>Li</surname><given-name>Xianglong</given-name><initials>X.</initials><afid>60016521</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:41661339800</author-url><authid>41661339800</authid><authname>Han P.</authname><surname>Han</surname><given-name>Pengfei</given-name><initials>P.</initials><afid>60016521</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56609477700</author-url><authid>56609477700</authid><authname>Guo Y.</authname><surname>Guo</surname><given-name>Yingjia</given-name><initials>Y.</initials><afid>60016521</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:56609493200</author-url><authid>56609493200</authid><authname>Sun H.</authname><surname>Sun</surname><given-name>Huaiqiang</given-name><initials>H.</initials><afid>60016521</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55821473500</author-url><authid>55821473500</authid><authname>Xiao Y.</authname><surname>Xiao</surname><given-name>Ying</given-name><initials>Y.</initials><afid>60016521</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7402784605</author-url><authid>7402784605</authid><authname>Kang Y.</authname><surname>Kang</surname><given-name>Y. James</given-name><initials>Y.J.</initials><afid>60016521</afid><afid>60020633</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7402784605</author-url><authid>7402784605</authid><authname>Kang Y.</authname><surname>Kang</surname><given-name>Y. James</given-name><initials>Y.J.</initials><afid>60016521</afid><afid>60020633</afid></author><authkeywords>Cerebrospinal fluid | Cisterna magna | MRI | Rhesus monkey | Sampling procedure</authkeywords><intid>1035819109</intid><source-id>16765</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928888984"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928888984?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928888984&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928888984&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S1053811915003304"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928888984</prism:url><dc:identifier>SCOPUS_ID:84928888984</dc:identifier><eid>2-s2.0-84928888984</eid><dc:title>Vascular risk factors, cerebrovascular reactivity, and the default-mode brain network</dc:title><dc:creator>Haight T.</dc:creator><prism:publicationName>NeuroImage</prism:publicationName><prism:issn>10538119</prism:issn><prism:eIssn>10959572</prism:eIssn><prism:volume>115</prism:volume><prism:pageRange>7-16</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.neuroimage.2015.04.039</prism:doi><pii>S1053811915003304</pii><dc:description>Â© 2015 Elsevier Inc. Cumulating evidence from epidemiologic studies implicates cardiovascular health and cerebrovascular function in several brain diseases in late life. We examined vascular risk factors with respect to a cerebrovascular measure of brain functioning in subjects in mid-life, which could represent a marker of brain changes in later life. Breath-hold functional MRI (fMRI) was performed in 541 women and men (mean age 50.4. years) from the Coronary Artery Risk Development in Young Adults (CARDIA) Brain MRI sub-study. Cerebrovascular reactivity (CVR) was quantified as percentage change in blood-oxygen level dependent (BOLD) signal in activated voxels, which was mapped to a common brain template and log-transformed. Mean CVR was calculated for anatomic regions underlying the default-mode network (DMN) - a network implicated in AD and other brain disorders - in addition to areas considered to be relatively spared in the disease (e.g. occipital lobe), which were utilized as reference regions. Mean CVR was significantly reduced in the posterior cingulate/precuneus (Î². =. -. 0.063, 95% CI: -. 0.106, -. 0.020), anterior cingulate (Î². =. -. 0.055, 95% CI: -. 0.101, -. 0.010), and medial frontal lobe (Î². =. -. 0.050, 95% CI: -. 0.092, -. 0.008) relative to mean CVR in the occipital lobe, after adjustment for age, sex, race, education, and smoking status, in subjects with pre-hypertension/hypertension compared to normotensive subjects. By contrast, mean CVR was lower, but not significantly, in the inferior parietal lobe (Î². =. -. 0.024, 95% CI: -. 0.062, 0.014) and the hippocampus (Î². =. -. 0.006, 95% CI: -. 0.062, 0.050) relative to mean CVR in the occipital lobe. Similar results were observed in subjects with diabetes and dyslipidemia compared to those without these conditions, though the differences were non-significant. Reduced CVR may represent diminished vascular functionality for the DMN for individuals with prehypertension/hypertension in mid-life, and may serve as a preclinical marker for brain dysfunction in later life.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60017252</affiliation-url><afid>60017252</afid><affilname>National Institute on Aging</affilname><name-variant>National Institute on Aging</name-variant><affiliation-city>Bethesda</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60006297</affiliation-url><afid>60006297</afid><affilname>University of Pennsylvania</affilname><name-variant>University of Pennsylvania</name-variant><affiliation-city>Philadelphia</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029445</affiliation-url><afid>60029445</afid><affilname>University of Minnesota Twin Cities</affilname><name-variant>University of Minnesota</name-variant><affiliation-city>Minneapolis</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025038</affiliation-url><afid>60025038</afid><affilname>UC Berkeley</affilname><name-variant>University of California</name-variant><affiliation-city>Berkeley</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029230</affiliation-url><afid>60029230</afid><affilname>University of Alabama School of Medicine</affilname><name-variant>University of Alabama at Birmingham</name-variant><affiliation-city/><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56622847000</author-url><authid>56622847000</authid><authname>Haight T.</authname><surname>Haight</surname><given-name>Thaddeus J.</given-name><initials>T.J.</initials><afid>60017252</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56463578700</author-url><authid>56463578700</authid><authname>Bryan R.</authname><surname>Bryan</surname><given-name>R. Nick</given-name><initials>R.N.</initials><afid>60006297</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:8556756900</author-url><authid>8556756900</authid><authname>Erus G.</authname><surname>Erus</surname><given-name>Guray</given-name><initials>G.</initials><afid>60006297</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7005310126</author-url><authid>7005310126</authid><authname>Davatzikos C.</authname><surname>Davatzikos</surname><given-name>Christos</given-name><initials>C.</initials><afid>60006297</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:24495657500</author-url><authid>24495657500</authid><authname>Jacobs D.</authname><surname>Jacobs</surname><given-name>David R.</given-name><initials>D.R.</initials><afid>60029445</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:56133990700</author-url><authid>56133990700</authid><authname>D'Esposito M.</authname><surname>D'Esposito</surname><given-name>Mark</given-name><initials>M.</initials><afid>60025038</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:35372126200</author-url><authid>35372126200</authid><authname>Lewis C.</authname><surname>Lewis</surname><given-name>Cora E.</given-name><initials>C.E.</initials><afid>60029230</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006392362</author-url><authid>7006392362</authid><authname>Launer L.</authname><surname>Launer</surname><given-name>Lenore J.</given-name><initials>L.J.</initials><afid>60017252</afid></author><authkeywords>Alzheimer's disease | Neurophysiology | Vascular risk factors</authkeywords><intid>2035857419</intid><source-id>17495</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928169954"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928169954?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928169954&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928169954&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0166432815002454"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928169954</prism:url><dc:identifier>SCOPUS_ID:84928169954</dc:identifier><eid>2-s2.0-84928169954</eid><dc:title>Characterizing brain iron deposition in subcortical ischemic vascular dementia using susceptibility-weighted imaging: An in vivo MR study</dc:title><dc:creator>Liu C.</dc:creator><prism:publicationName>Behavioural Brain Research</prism:publicationName><prism:issn>01664328</prism:issn><prism:eIssn>18727549</prism:eIssn><prism:volume>288</prism:volume><prism:pageRange>33-38</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bbr.2015.04.003</prism:doi><pii>S0166432815002454</pii><dc:description>Â© 2015 Elsevier B.V. The aim of this study was to investigate the brain iron accumulation in subcortical ischemic vascular dementia (SIVD) and its correlation with the severity of cognitive impairment. Thirty five patients with SIVD and 35 healthy controls underwent high-resolution susceptibility-weighted imaging. The phase shift value of the bilateral hippocampus (HP), caudate nucleus (CN), globus pallidus (GP), putamen (PU), thalamus (TH), red nucleus (RN), substantia nigra (SN), anterior cingulate cortex (ACC), posterior cingulate (PCC), parietal cortex (PC) and frontal white matter (FWM) were examined and correlated with neuropsychological scores for SIVD patients. They exhibited significant increased phase shift values in the bilateral HP, CN, PU, right GP and left SN (. P&lt;. 0.05). Close correlations were found between the phase shift value of the left HP, right CN and neuropsychological scores. Our results suggest that brain iron deposition may be a biomarker of SIVD and play an important role in the pathophysiological mechanism.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029929</affiliation-url><afid>60029929</afid><affilname>Massachusetts General Hospital</affilname><name-variant>Massachusetts General Hospital</name-variant><affiliation-city>Boston</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60023797</affiliation-url><afid>60023797</afid><affilname>Third Military Medical University</affilname><name-variant>Third Military Medical University</name-variant><affiliation-city>Chongqing</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60030616</affiliation-url><afid>60030616</afid><affilname>Montreal Neurological Institute and Hospital</affilname><name-variant>Montreal Neurological Institute</name-variant><affiliation-city>Montreal</affiliation-city><affiliation-country>Canada</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">9</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56133042800</author-url><authid>56133042800</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Chen</given-name><initials>C.</initials><afid>60023797</afid><afid>60029929</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56133042800</author-url><authid>56133042800</authid><authname>Liu C.</authname><surname>Liu</surname><given-name>Chen</given-name><initials>C.</initials><afid>60023797</afid><afid>60029929</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:16022288600</author-url><authid>16022288600</authid><authname>Li C.</authname><surname>Li</surname><given-name>Chuanming</given-name><initials>C.</initials><afid>60023797</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56020774400</author-url><authid>56020774400</authid><authname>Yang J.</authname><surname>Yang</surname><given-name>Jun</given-name><initials>J.</initials><afid>60023797</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:7101655625</author-url><authid>7101655625</authid><authname>Gui L.</authname><surname>Gui</surname><given-name>Li</given-name><initials>L.</initials><afid>60023797</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56599378700</author-url><authid>56599378700</authid><authname>Zhao L.</authname><surname>Zhao</surname><given-name>Lu</given-name><initials>L.</initials><afid>60030616</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:7404362358</author-url><authid>7404362358</authid><authname>Evans A.</authname><surname>Evans</surname><given-name>Alan C.</given-name><initials>A.C.</initials><afid>60030616</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:55511927000</author-url><authid>55511927000</authid><authname>Yin X.</authname><surname>Yin</surname><given-name>Xuntao</given-name><initials>X.</initials><afid>60023797</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:55878875200</author-url><authid>55878875200</authid><authname>Wang J.</authname><surname>Wang</surname><given-name>Jian</given-name><initials>J.</initials><afid>60023797</afid></author><authkeywords>Cognitive impairment | Iron deposition | Phase changes | SIVD | SWI | Vascular dementia</authkeywords><intid>1535732897</intid><source-id>14285</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84930086760"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84930086760?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84930086760&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84930086760&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0303720715001513"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84930086760</prism:url><dc:identifier>SCOPUS_ID:84930086760</dc:identifier><eid>2-s2.0-84930086760</eid><dc:title>Vitamin D, muscle and bone: Integrating effects in development, aging and injury</dc:title><dc:creator>Girgis C.</dc:creator><prism:publicationName>Molecular and Cellular Endocrinology</prism:publicationName><prism:issn>03037207</prism:issn><prism:eIssn>18728057</prism:eIssn><prism:volume>410</prism:volume><prism:pageRange>3-10</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.mce.2015.03.020</prism:doi><pii>S0303720715001513</pii><dc:description>Â© 2015 Elsevier Ireland Ltd. Beyond the established effects of muscle loading on bone, a complex network of hormones and growth factors integrates these adjacent tissues. One such hormone, vitamin D, exerts broad-ranging effects in muscle and bone calcium handling, differentiation and development. Vitamin D also modulates muscle and bone-derived hormones, potentially facilitating cross-talk between these tissues. In the clinical setting, vitamin D deficiency or mutations of the vitamin D receptor result in generalized atrophy of muscle and bone, suggesting coordinated effects of vitamin D at these sites. In this review, we discuss emerging evidence that vitamin D exerts specific effects throughout the life of the musculoskeletal system - in development, aging and injury. From this holistic viewpoint, we offer new insights into an old debate: whether vitamin D's effects in the musculoskeletal system are direct via local VDR signals or indirect via its systemic effects in calcium and phosphate homeostasis.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60003992</affiliation-url><afid>60003992</afid><affilname>Westmead Millennium Institute</affilname><name-variant>Westmead Millennium Institute</name-variant><affiliation-city>Parramatta</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60025709</affiliation-url><afid>60025709</afid><affilname>University of Sydney</affilname><name-variant>University of Sydney</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60002773</affiliation-url><afid>60002773</afid><affilname>Garvan Institute of Medical Research</affilname><name-variant>Garvan Institute of Medical Research</name-variant><affiliation-city>Sydney</affiliation-city><affiliation-country>Australia</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60032445</affiliation-url><afid>60032445</afid><affilname>Salk Institute for Biological Studies</affilname><name-variant>Salk Institute for Biological Studies</name-variant><affiliation-city>San Diego</affiliation-city><affiliation-country>United States</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>re</subtype><subtypeDescription>Review</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35790989100</author-url><authid>35790989100</authid><authname>Girgis C.</authname><surname>Girgis</surname><given-name>Christian M.</given-name><initials>C.M.</initials><afid>60003992</afid><afid>60025709</afid><afid>60002773</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35790989100</author-url><authid>35790989100</authid><authname>Girgis C.</authname><surname>Girgis</surname><given-name>Christian M.</given-name><initials>C.M.</initials><afid>60003992</afid><afid>60025709</afid><afid>60002773</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:35790989100</author-url><authid>35790989100</authid><authname>Girgis C.</authname><surname>Girgis</surname><given-name>Christian M.</given-name><initials>C.M.</initials><afid>60003992</afid><afid>60025709</afid><afid>60002773</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56565108700</author-url><authid>56565108700</authid><authname>Baldock P.</authname><surname>Baldock</surname><given-name>Paul A.</given-name><initials>P.A.</initials><afid>60002773</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56583805800</author-url><authid>56583805800</authid><authname>Downes M.</authname><surname>Downes</surname><given-name>Michael</given-name><initials>M.</initials><afid>60032445</afid></author><authkeywords>Bone | Muscle | Osteoporosis | Sarcopenia | Vitamin D | Vitamin D receptor</authkeywords><intid>536064272</intid><source-id>26206</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84928153566"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84928153566?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84928153566&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84928153566&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0306261915004390"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84928153566</prism:url><dc:identifier>SCOPUS_ID:84928153566</dc:identifier><eid>2-s2.0-84928153566</eid><dc:title>Development of structural-functional integrated concrete with macro-encapsulated PCM for thermal energy storage</dc:title><dc:creator>Memon S.</dc:creator><prism:publicationName>Applied Energy</prism:publicationName><prism:issn>03062619</prism:issn><prism:volume>150</prism:volume><prism:pageRange>245-257</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.apenergy.2015.03.137</prism:doi><pii>S0306261915004390</pii><dc:description>Â© 2015 Elsevier Ltd. In this research, we prepared macro-encapsulated paraffin-lightweight aggregate (LWA) for the development of structural-functional integrated normal weight aggregate concrete (NWAC). The macro-encapsulated paraffin-LWA was prepared by incorporation of paraffin into porous LWAs through vacuum impregnation. The sealing performance of the epoxy was evaluated by thermal cycling test while the thermal conductivity of macro encapsulated Paraffin-LWAs was improved by incorporating different percentages of graphite powder into epoxy. The chemical compatibility, thermal properties, thermal stability and reliability of macro-encapsulated paraffin-LWA was also determined. Finally, the compressive strength and thermal performance of concrete containing macro-encapsulated paraffin-LWA was evaluated. Test results showed that the maximum percentage of paraffin absorbed by LWA was 70%. The thermal conductivity of the macro-encapsulated paraffin-LWA with 15% graphite powder was 162% higher than that of epoxy. Moreover, the developed macro-encapsulated paraffin-LWA was found to be chemically compatible, thermally stable and reliable (did not show any sign of degradation below 150. Â°C and sustained 1000 cycles of melting and freezing) and it has high latent heat storage capacity (102.5. J/g). The compressive strength of NWAC with macro-encapsulated PCM-LWA at 28. days ranged from 33.29 to 53.11. MPa, therefore presenting an opportunity for structural applications. The indoor thermal performance test revealed that NWAC with macro-encapsulated paraffin-LWA can function in reducing the energy consumption by decreasing the indoor temperature and shifting the loads away from the peak periods. Thus, we demonstrated and produced concrete with structural and thermostatic properties.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60000937</affiliation-url><afid>60000937</afid><affilname>Shenzhen University</affilname><name-variant>Shenzhen University</name-variant><affiliation-city>Qingshuihe, Shenzhen</affiliation-city><affiliation-country>China</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60089631</affiliation-url><afid>60089631</afid><affilname>COMSATS Institute of Information Technology</affilname><name-variant>COMSATS Institute of Information Technology</name-variant><affiliation-city>Islamabad</affiliation-city><affiliation-country>Pakistan</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60013983</affiliation-url><afid>60013983</afid><affilname>City University of Hong Kong</affilname><name-variant>City University of Hong Kong</name-variant><affiliation-city>Hong Kong</affiliation-city><affiliation-country>China</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">5</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23989112800</author-url><authid>23989112800</authid><authname>Memon S.</authname><surname>Memon</surname><given-name>Shazim Ali</given-name><initials>S.A.</initials><afid>60000937</afid><afid>60089631</afid></author><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:23989112800</author-url><authid>23989112800</authid><authname>Memon S.</authname><surname>Memon</surname><given-name>Shazim Ali</given-name><initials>S.A.</initials><afid>60000937</afid><afid>60089631</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55948578000</author-url><authid>55948578000</authid><authname>Cui H.</authname><surname>Cui</surname><given-name>Hongzhi</given-name><initials>H.</initials><afid>60000937</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55650160500</author-url><authid>55650160500</authid><authname>Lo T.</authname><surname>Lo</surname><given-name>Tommy Y.</given-name><initials>T.Y.</initials><afid>60013983</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24290131700</author-url><authid>24290131700</authid><authname>Li Q.</authname><surname>Li</surname><given-name>Qiusheng</given-name><initials>Q.</initials><afid>60013983</afid></author><authkeywords>Lightweight aggregate | Macro encapsulation | Phase change material | Structural-functional integrated concrete | Thermal performance</authkeywords><intid>35733766</intid><source-id>28801</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84927534751"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84927534751?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84927534751&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84927534751&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0014299915002861"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84927534751</prism:url><dc:identifier>SCOPUS_ID:84927534751</dc:identifier><eid>2-s2.0-84927534751</eid><dc:title>Increased Rho-kinase-mediated prostate contractions associated with impairment of Î²-adrenergic-cAMP-signaling pathway by chronic nitric oxide deficiency</dc:title><dc:creator>Calmasini F.</dc:creator><prism:publicationName>European Journal of Pharmacology</prism:publicationName><prism:issn>00142999</prism:issn><prism:eIssn>18790712</prism:eIssn><prism:volume>758</prism:volume><prism:pageRange>24-30</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>5 July 2015</prism:coverDisplayDate><prism:doi>10.1016/j.ejphar.2015.03.057</prism:doi><pii>S0014299915002861</pii><dc:description>Â© 2015 Elsevier B.V. Impairment of nitric oxide (NO) - cyclic GMP signaling pathway is likely to contribute to human begnin prostate hyperplasia (BPH). In the present study we have used a model of chronic NO synthesis inhibition to evaluate the functional alterations of prostate smooth muscle (PSM) machinery, and involvement of Rho-kinase pathway. Wistar rats were treated with the NO inhibitor N&lt;sup&gt;Ï&lt;/sup&gt;-nitro-l-arginine methyl ester (L-NAME, 20 mg/kg/day; 4 weeks), after which contractile responses to phenylephrine (Î±&lt;inf&gt;1&lt;/inf&gt;-adrenoceptor agonist; 1 nM to 100 Î¼M), carbachol (muscarinic agonist; 1 nM to 1 mM) and Î±,Î²-methylene ATP (P2X receptor agonist; 1-10 Î¼M), as well as to electrical-field stimulation (EFS; 1-32 Hz) were evaluated. PSM relaxations to isoproterenol (non-selective Î²-adrenoceptor agonist, 0.1 nM to 10 Î¼M) and sodium nitroprusside (NO donor, 1 nM to 10 mM) were also evaluated. The ratio prostate weight/body weight was 22% greater (P&lt;0.05) in L-NAME compared with control group. The PSM contractions to phenylephrine, carbachol and Î±,Î²-methylene ATP were higher in L-NAME (E&lt;inf&gt;max&lt;/inf&gt;: 3.85Â±0.25, 3.52Â±0.35 and 2.03Â±0.2 mN, respectively) compared with control group (E&lt;inf&gt;max&lt;/inf&gt;: 3.08Â±0.17, 2.37Â±0.18 and 1.57Â±0.18 mN, respectively). The PSM contractions induced by EFS were also significantly greater in L-NAME group. Prior incubation with the Rho-kinase inhibitor Y27632 (1 Î¼M) fully reversed the enhanced contractions to phenylephrine and carbachol. Isoproterenol-induced PSM relaxations were 34% lower in L-NAME group, which was associated with reduced levels of cAMP in prostate tissue. The relaxations to sodium nitroprusside remained unaltered in L-NAME group. In summary, chronic NO deficiency leads to increased Rho-kinase-mediated PSM contractile responses accompanied by impairment of Î²-adrenergic-cAMP-signaling pathway.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60029570</affiliation-url><afid>60029570</afid><affilname>Universidade Estadual de Campinas</affilname><name-variant>State University of Campinas</name-variant><affiliation-city>Campinas</affiliation-city><affiliation-country>Brazil</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">8</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55920012800</author-url><authid>55920012800</authid><authname>Calmasini F.</authname><surname>Calmasini</surname><given-name>Fabiano Beraldi</given-name><initials>F.B.</initials><afid>60029570</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:54682077400</author-url><authid>54682077400</authid><authname>Leiria L.</authname><surname>Leiria</surname><given-name>Luiz OsÃ³rio Silveira</given-name><initials>L.O.S.</initials><afid>60029570</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:56589448400</author-url><authid>56589448400</authid><authname>Alves M.</authname><surname>Alves</surname><given-name>Marcos JosÃ©</given-name><initials>M.J.</initials><afid>60029570</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:24073185400</author-url><authid>24073185400</authid><authname>BÃ¡u F.</authname><surname>BÃ¡u</surname><given-name>Fernando Ricardo</given-name><initials>F.R.</initials><afid>60029570</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:55965106300</author-url><authid>55965106300</authid><authname>Alexandre E.</authname><surname>Alexandre</surname><given-name>Eduardo Costa</given-name><initials>E.C.</initials><afid>60029570</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:43161311500</author-url><authid>43161311500</authid><authname>Silva F.</authname><surname>Silva</surname><given-name>FÃ¡bio Henrique</given-name><initials>F.H.</initials><afid>60029570</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:24073240300</author-url><authid>24073240300</authid><authname>MÃ³nica F.</authname><surname>MÃ³nica</surname><given-name>FabÃ­ola Zakia</given-name><initials>F.Z.</initials><afid>60029570</afid></author><author seq="8"><author-url>http://api.elsevier.com/content/author/author_id:7006466498</author-url><authid>7006466498</authid><authname>Antunes E.</authname><surname>Antunes</surname><given-name>Edson</given-name><initials>E.</initials><afid>60029570</afid></author><authkeywords>Beta-adrenergic pathway | L-NAME | Nitric oxide | Prostate | Rho-kinase</authkeywords><intid>2035629516</intid><source-id>21333</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923620105"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923620105?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923620105&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923620105&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315001293"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923620105</prism:url><dc:identifier>SCOPUS_ID:84923620105</dc:identifier><eid>2-s2.0-84923620105</eid><dc:title>Highly sensitive cell imaging Off-On fluorescent probe for mitochondria and ATP</dc:title><dc:creator>Srivastava P.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>69</prism:volume><prism:pageRange>179-185</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.02.028</prism:doi><pii>S0956566315001293</pii><dc:description>Â© 2015 Elsevier B.V. A smart Off-On molecular scaffold/fluorescent probe 1 has been designed and synthesized. The probe has shown considerable photostability, cell permeability, organelle specificity and selectivity for ATP. The multicolor live cell imaging experiments in HeLa cells showed high selectivity of probe 1 for mitochondria with fluorescence turn-on response. As a proof of concept and promising prospects for application in biological sciences probe 1 has been utilized to detect ATP sensitively in a partial aqueous medium and intracellularly in HeLa cells. The favorable interaction between triphosphate unit of ATP and piperazine N atoms of probe 1 is attributed to synergistic effects of H-bonding and electrostatic interactions that encouraged the CH-Ï and ÏâÏ stacking between anthracene and purine rings. Consequently, the observed enhanced turn-on emission and a naked-eye sensitive blue-green color in the medium is attributable to arrest in photoinduced electron transfer (PET) process.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008721</affiliation-url><afid>60008721</afid><affilname>Banaras Hindu University</affilname><name-variant>Banaras Hindu University</name-variant><affiliation-city>Varanasi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:112614236</affiliation-url><afid>112614236</afid><affilname>Indian Institute of Toxicology and Research (IITR)</affilname><name-variant>Indian Institute of Toxicological Research (IITR)</name-variant><affiliation-city>Lucknow</affiliation-city><affiliation-country>India</affiliation-country></affiliation><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60008721</affiliation-url><afid>60008721</afid><affilname>Banaras Hindu University</affilname><name-variant>Banaras Hindu University</name-variant><affiliation-city>Varanasi</affiliation-city><affiliation-country>India</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">7</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:55696363900</author-url><authid>55696363900</authid><authname>Srivastava P.</authname><surname>Srivastava</surname><given-name>Priyanka</given-name><initials>P.</initials><afid>60008721</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:55337400000</author-url><authid>55337400000</authid><authname>Razi S.</authname><surname>Razi</surname><given-name>Syed S.</given-name><initials>S.S.</initials><afid>60008721</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55578807679</author-url><authid>55578807679</authid><authname>Ali R.</authname><surname>Ali</surname><given-name>Rashid</given-name><initials>R.</initials><afid>60008721</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:55938444400</author-url><authid>55938444400</authid><authname>Srivastav S.</authname><surname>Srivastav</surname><given-name>Saurabh</given-name><initials>S.</initials><afid>60008721</afid></author><author seq="5"><author-url>http://api.elsevier.com/content/author/author_id:56351978700</author-url><authid>56351978700</authid><authname>Patnaik S.</authname><surname>Patnaik</surname><given-name>Satyakam</given-name><initials>S.</initials><afid>112614236</afid></author><author seq="6"><author-url>http://api.elsevier.com/content/author/author_id:55639734900</author-url><authid>55639734900</authid><authname>Srikrishna S.</authname><surname>Srikrishna</surname><given-name>Saripella</given-name><initials>S.</initials><afid>60008721</afid></author><author seq="7"><author-url>http://api.elsevier.com/content/author/author_id:7402454257</author-url><authid>7402454257</authid><authname>Misra A.</authname><surname>Misra</surname><given-name>Arvind</given-name><initials>A.</initials><afid>60008721</afid></author><authkeywords>ATP | Biosensor | Fluorescence | Live cell imaging | Mitochondria | PET</authkeywords><intid>35003374</intid><source-id>15437</source-id></entry><entry><link ref="self" href="http://api.elsevier.com/content/abstract/scopus_id:84923262281"/><link ref="author-affiliation" href="http://api.elsevier.com/content/abstract/scopus_id:84923262281?field=author,affiliation"/><link ref="scopus" href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84923262281&amp;origin=inward"/><link ref="scopus-citedby" href="http://www.scopus.com/inward/citedby.url?partnerID=HzOxMe3b&amp;scp=84923262281&amp;origin=inward"/><link ref="full-text" href="http://api.elsevier.com/content/article/eid:1-s2.0-S0956566315001104"/><prism:url>http://api.elsevier.com/content/abstract/scopus_id:84923262281</prism:url><dc:identifier>SCOPUS_ID:84923262281</dc:identifier><eid>2-s2.0-84923262281</eid><dc:title>Trapping cells in paper for white blood cell count</dc:title><dc:creator>Zhang Y.</dc:creator><prism:publicationName>Biosensors and Bioelectronics</prism:publicationName><prism:issn>09565663</prism:issn><prism:eIssn>18734235</prism:eIssn><prism:volume>69</prism:volume><prism:pageRange>121-127</prism:pageRange><prism:coverDate>2015-07-05</prism:coverDate><prism:coverDisplayDate>July 05, 2015</prism:coverDisplayDate><prism:doi>10.1016/j.bios.2015.02.019</prism:doi><pii>S0956566315001104</pii><dc:description>Â© 2015 Elsevier B.V. White blood cell count is an important indicator of each individual's health condition. An abnormal white blood cell count usually results from an infection, cancer, or other conditions that trigger systemic inflammation responses. White blood cell count also provides predictive information on the incidence of cardiovascular diseases and Type 2 diabetes. Therefore, monitoring white blood cell count on a regular basis can potentially help individuals to take preventive measures and improve healthcare outcomes. Currently, white blood cell count is primarily conducted in centralized laboratories, and it requires specialized equipment and dedicated personnel to perform the test and interpret the results. So far there has been no rapid test that allows white blood cell count in low-resource settings. In this study, we have demonstrated a vertical flow platform that quantifies white blood cells by trapping them in the paper. White blood cells were tagged with gold nanoparticles, and flowed through the paper via a small orifice. The white blood cell count was determined by measuring the colorimetric intensity of gold nanoparticles on the surface of white blood cells that were trapped in the paper mesh. Using this platform, we were able to quantify white blood cells in 15. Î¼L of blood, and visually differentiate the abnormal count of white blood cells from the normal count. The proposed platform enabled rapid white blood cell count in low resource settings with a small sample volume requirement. Its low-cost, instrument-free operations would be attractive for point-of-care applications.</dc:description><citedby-count>0</citedby-count><affiliation><affiliation-url>http://api.elsevier.com/content/affiliation/affiliation_id:60026499</affiliation-url><afid>60026499</afid><affilname>Institute of Bioengineering and Nanotechnology, A-Star, Singapore</affilname><name-variant>Institute of Bioengineering and Nanotechnology</name-variant><affiliation-city>Singapore City</affiliation-city><affiliation-country>Singapore</affiliation-country></affiliation><prism:aggregationType>Journal</prism:aggregationType><subtype>ar</subtype><subtypeDescription>Article</subtypeDescription><author-count limit="100">4</author-count><author seq="1"><author-url>http://api.elsevier.com/content/author/author_id:56524684900</author-url><authid>56524684900</authid><authname>Zhang Y.</authname><surname>Zhang</surname><given-name>Yi</given-name><initials>Y.</initials><afid>60026499</afid></author><author seq="2"><author-url>http://api.elsevier.com/content/author/author_id:56523801000</author-url><authid>56523801000</authid><authname>Bai J.</authname><surname>Bai</surname><given-name>Jianhao</given-name><initials>J.</initials><afid>60026499</afid></author><author seq="3"><author-url>http://api.elsevier.com/content/author/author_id:55962147100</author-url><authid>55962147100</authid><authname>Wu H.</authname><surname>Wu</surname><given-name>Hong</given-name><initials>H.</initials><afid>60026499</afid></author><author seq="4"><author-url>http://api.elsevier.com/content/author/author_id:35235846500</author-url><authid>35235846500</authid><authname>Ying J.</authname><surname>Ying</surname><given-name>Jackie Y.</given-name><initials>J.Y.</initials><afid>60026499</afid></author><authkeywords>Flow-through | Gold nanoparticle | Immunoassay | Paper microfluidics | Vertical flow | White blood cell count</authkeywords><intid>1034935643</intid><source-id>15437</source-id></entry></search-results>
